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Background: Multiple sclerosis (MS) is the most common cause of disability in young 
people and yet there are no interventions available which reliably alter disease 
progression. This is despite several decades of research using the most common animal 
model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). There 
is now emerging evidence across the neurosciences to suggest that limited internal 
validity (measures to reduce bias) and external validity (e.g. using a clinically relevant 
animal model) may influence the translational success.  
 
Aim and objectives: To provide an unbiased summary of the scope of the literature on 
candidate drugs for MS tested in EAE to identify potential reasons for the failures to 
translate efficacy to clinical trials. My objectives were, across all of the identified 
publications, to: (1) describe the reporting of measures to reduce bias and to assess 
their impact on measures of drug efficacy; (2) assess the relationship between 
treatment related effects measured using different outcome measures; (3) assess the 
prevalence and impact of any publication bias; (4) compare findings from the above 
with another disease with limited translational success (Parkinson’s disease; PD).  
 
Methods: I used systematic searches of three online databases to identify relevant 
publications. Estimates of efficacy were extracted for neurobehavioural scores, 
inflammation, demyelination and axon loss. For PD experiments, we searched for 
dopamine agonists tested in animal models of PD with outcome assessed as change in 
neurobehavioural scores. I calculated normalised mean difference or standardised 
mean difference effect sizes and combined these in a meta-analysis using a random 
effects model. I used stratified meta-analysis or meta-regression to assess the extent to 
which different study design characteristics explained differences in reported 
efficacies. These characteristics included: measures to reduce bias (random allocation 
to group and blinded assessment of outcome), the animal species, sex, time of drug 
administration, route of drug administration and the number of animals per group. 
Publication bias was assessed using funnel plotting, Egger regression and “trim and 
fill”.  
 
Results: I identified 1464 publications reporting drugs tested in EAE. Reported study 
quality was poor: 11% reported random allocation to group, 17% reported blinded 
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assessment of neurobehavioural outcomes, 28% reported blinded assessment of 
histological outcomes, and <1% reported a sample size calculation. Estimates of 
efficacy measured as the reduction in inflammation were substantially higher in un-
blinded studies (47.1% reduction (95% CI 41.8-52.4)) versus blinded studies (33.1% 
(25.8-40.4). Moreover, the same finding was identified for 121 publications on 
dopamine agonists tested in experimental PD models where efficacy was measured as 
change in neurobehavioural outcomes. For EAE studies we were unable to include data 
from 631 publications describing original research. Usually this was because the 
publication did not include basic details such as the number of animals in each group 
(115 publications), the observed variance (592) or suitable control data (49). For each 
category of outcome I found evidence of a substantial publication bias. Interventions 
were most commonly administered on or before the induction of EAE with shorter 
times to treatment associated with higher estimates of efficacy for the reduction in 
mean severity scores (a neurobehavioural outcome). Treatment related effects were 
found to vary across different outcome measures with the largest effect being for the 
reduction in axon loss. Where neurobehavioural scores and axon loss were measured 
in the same cohort of animals, the concordance between efficacies in these increased 
with later times to treatment. 
 
Conclusions: In this, the largest systematic review and meta-analysis of animal studies 
in any domain, I have found that a large number of publications present incomplete 
data. In addition, measures to reduce bias are seldom reported, the lack of which is 
associated with overstatements of efficacy for both a measure of drug efficacy in EAE 
and experimental PD studies. Translational success may have also been affected by the 
majority of studies administering drugs on or before EAE induction which is of limited 
relevance in the clinical setting where patients do not present at that stage of disease. 
Moreover, my analysis of the relationship between outcome measures provides 
empirical evidence from systematically identified studies to suggest that targeting axon 
loss as later time points is most strongly associated with improvements in 
neurobehavioural scores. Therefore drugs which are successfully able to target axon 
loss at these time points may offer substantial hope for clinical success. Overall, 
improvements in the conduct and reporting of preclinical studies are likely to improve 
their utility, and the prospects for translational success. While my findings relate 
predominately to the animal modelling of MS and PD it is likely that they also hold for 
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 “After what precedes, need I detain you long over the question of 
treatment? The time has not yet come when such a subject can be 
seriously considered. I can only tell you of some experiments which 
have been tried the results of which have, unfortunately, not been 
very encouraging” (Jean-Martin Charcot on the treatment of 
multiple sclerosis, 19th century). 
 
Multiple sclerosis (MS) affects over 2.5 million individuals worldwide and is the leading 
cause of disability in young and middle aged adults in the developed world. Of concern 
is that for such a devastating and life altering disease there are just a few clinically 
available interventions, none of which are able to reliably alter disease progression. 
With this in mind it could be argued – with perhaps a little less pessimism – that 
Charcot's statement could well be mistaken for a description of treatments written in 
the 21st century.  
 
Descriptions of MS possibly date back as far as the fourteenth century but it was only 
described and named in the terms we understand it today by French neurologist Jean-
Martin Charcot in 1868 (Murray, 2009). Described then as “sclerose en plaques” based 
on Charcot’s observations of post-mortem brains from patients with paraplegia, he 
noted disseminated scars or “plaques” (lesions) of the nerve sheaths (before the official 
discovery of myelin by Rudolf Virchow) in the central nervous system (CNS). From the 
earliest descriptions it took another three centuries to gain a more accurate 
perspective of the disease pathophysiology; for example an early hypothesis was that 
suppression of sweat was to blame (Putman, 1938) and the earliest treatments were 
most likely ineffective and/or potentially toxic, including for example bleeding, arsenic 
or chloroform (Murray, 2009). 
 
Currently the life expectancy of an MS patient is 5-10 years less than a non-affected 
individual (Compston and Coles, 2008). Despite this however, 50% of patients are 
unable to perform household or employment tasks after 10 years, and 50% are 
nonambulatory after 25 years (Trapp and Nave, 2008). As many as 50% also suffer 
depression, have a lower quality of life, and have an increased risk of both suicidal 
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ideation and suicide compared to the general population (Feinstein, 2002, Feinstein, 
2011, Feinstein, 1997, Wynia et al., 2008).  
 
The list of potential symptoms suffered by MS patients is extensive. They manifest as a 
result of inflammation and compromised axons, predominately in the white matter of 
the CNS which results in partial to complete loss of signal conduction in the affected 
axons. The location and extent of this pathology determines the range and severity of 
clinical symptoms which include, but are not limited to, muscle weakness, stiffness,  
painful spasms, loss of vision, loss of balance and/or limb coordination, cognitive 
disruption (dementia, attention deficits), fatigue, chronic pain, bladder and/or bowel 
dysfunction, erectile dysfunction, speech disruption and temperature sensitivity, 
(Compston and Coles, 2002).  
 
1.1. Problem statement 
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used animal 
model of MS. A vast number of treatments are considered to have shown promise in 
EAE; however, few have successfully translated from bench to bedside (Sriram and 
Steiner, 2005). As I will describe in this introductory chapter, there have been 
numerous failed clinical trials, and the long term efficacy of all clinically available 
interventions has been questioned. 
 
The problem I aim to address in this PhD thesis is whether we can explain some of this 
limited clinical success through a robust analysis of the supporting preclinical literature 
using systematic review and meta-analysis. 
 
1.2. Multiple Sclerosis 
1.2.1. The clinical course and diagnosis of MS 
There are four clear patterns (courses) in the presentation of clinical symptoms of MS 
over the lifetime of the disease (Figure 1.1) (Lublin and Reingold, 1996, Compston and 
Coles, 2008).  Relapsing remitting MS (RRMS) is the most common course, affecting 
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approximately 80% of patients, and is characterised by periods of remission between 
relapses, the duration of which can vary considerably between individuals. Many years 
of RRMS may pass, but in time approximately 65% of patients begin to steadily decline 
with no further periods of remission in a disease course known as secondary 
progressive MS (SPMS). Primary progressive MS (PPMS) is less common, affecting 
approximately 10% of MS patients, and is characterised by a steady decline from onset 
of symptoms until death. Finally, progressive relapsing MS (PRMS) affects 
approximately 5% of patients and is characterised by a progressive disease course 
from the onset with periods of increased symptoms which then improve.  
 
 
Figure 1.1. The four typical presentations of clinical disease severity in MS.   
 
MS is a disease which typically strikes in young people. The median age of onset for 
RRMS patients is in the late twenties, although primary progressive MS typically begins 
a decade later. Different clinical courses are also associated with different sex ratios; 
RRMS patients are roughly twice as likely to be female as male but this ratio declines 
with progressive forms of the disease (Confavreux and Vukusic, 2006).  
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The clinical diagnosis of MS is not always straight forward. A combination of clinical 
and paraclinical parameters may be used to try and differentiate MS from a number of 
diseases which manifest with similar signs and symptoms, including for example 
autoimmune (e.g. Srjögen syndrome), psychiatric (e.g. somatisation disorder) or 
vascular diseases (e.g. spinal vascular malformation) (Rolak and Fleming, 2007). As 
such, diagnosis depends on the demonstration of lesion dissemination in space (i.e. 
within the CNS) and time (i.e. monophasic or multiphasic disease course) as well as the 
exclusion of other diseases. The task of a neurologist is to assess both the risk of 
presenting with further episodes (a diagnostic criterion for MS), and to predict the 
prognosis, thus determining how aggressive any treatment strategy should be (Miller et 
al., 2005, Thrower, 2007). 
 
Diagnostic criteria for MS were introduced in the 1960’s to aid clinicians and 
standardise the diagnosis (Schumacker et al., 1965). In the early 1980’s the Poser 
criteria described four diagnostic categories: clinically definite MS; laboratory 
supported definite MS; clinically probably MS; and laboratory supported probable MS 
(Poser et al., 1983). The more recent McDonald criteria1 were introduced to try to cut 
down on the number of misdiagnoses and are now the gold-standard diagnostic tool for 
patients who present with a typical clinically isolated syndrome (CIS), an acute or sub-
acute episode of neurological disturbance which 85% of MS patients first present with 
(McDonald et al., 2001, Polman et al., 2011, Miller et al., 2005, Miller et al., 2012). The 
McDonald criteria also take into account the more recent advances in diagnostic tools 
(e.g. magnetic resonance imaging; MRI) and simplified the diagnosis into three 
categories: MS; possible MS; and not MS.  
 
Patients can be diagnosed on clinical presentation alone, but paraclinical tests are 
recommended to aid diagnosis when there are strong suspicions of MS but the 
McDonald criteria are not completely met. MRI has become an important paraclinical 
diagnostic tool with 95% of patients showing some white matter abnormalities 
                                                          
1The first edition of the McDonald criteria were published in 2001 and aided in earlier diagnoses 
with a high degree of sensitivity and specificity. The criteria were updated in 2005 and 2011. 
The latter edition is a  simplified version which preserves diagnostic sensitivity and specificity 
and helps to differentiate between MS of neuromyelitis optica (NMO) and NMO spectrum 
disorders. The criteria are relevant to patients who present with a typical CIS or symptoms 
suggestive of CNS inflammatory demyelinating disease.  
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(Compston and Coles, 2008). Moreover, MRI is a strong predictor for the conversion of 
CIS to clinically definite MS which can be crucial for early diagnosis and treatment 
(Barkhof et al., 1997, O'Riordan et al., 1998). There are no known specific blood 
biomarkers which can confirm the diagnosis of MS, but the presence of oligoclonal 
bands or elevated immunoglobulin G (IgG) in the cerebrospinal fluid (CSF) are strongly 
linked with MS (though not specific) and can thus also be used to aid diagnosis (Link 
and Huang, 2006, Tintore et al., 2008). A reduction in evoked potentials, suggestive of 
axon damage, is indicative of MS and is a feature in even the earliest stages of disease 
pathology (Trapp et al., 1998).  
 
1.2.2. Aetiology: nature versus nurture 
The aetiology of MS is not known. It is almost universally accepted that there is an 
interplay between genetic and environmental factors, although the extent of their 
individual roles is still a major source of debate (Hutchinson, 2011).  
 
Whilst it might be more straightforward to try and treat a disease after we have 
established its cause, this is unfortunately not a luxury that has been afforded to the MS 
drug research community. In the following two sections I will briefly describe some of 
the theories on the aetiology of MS in order to further place into context the complex 
nature of MS. 
  
1.2.2.1. Environment factors 
A number of non-inheritable factors have been proposed to explain the aetiology of MS 
with some of the strongest clues coming from epidemiological studies (for review see: 
Ascherio and Munger, 2007a, Ascherio and Munger, 2007b, Ramagopalan et al., 2010). 
Geographically we know that MS is relatively rare in Asia and Africa but common in the 
US, Europe, New Zealand and parts of Australia (Milo and Kahana, 2010, Rosati, 2001), 
and it is rarer in the tropics and subtropics of all continents (Ascherio and Munger, 
2007a). Up until recently MS was also found to be more prevalent with higher latitudes 
(Simpson et al., 2011) both above and below the equator (Compston and Coles, 2008), 
but this is a trend which may be disappearing due to the increased prevalence in lower 
latitude regions (Alonso and Hernan, 2008). The relative lack of MS in warmer climates 
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led to the hypothesis that the risk of MS increased with vitamin D deficiency from a lack 
of sunlight (Goldberg, 1974, Ascherio et al., 2010). Specifically it is thought that vitamin 
D may interact with, and alter the expression of a gene with known association to MS 
susceptibly (HLA-DRB1; see section 1.2.2.2) (Ramagopalan et al., 2009). As an 
intervention, vitamin D has been shown to be effective as an adjunct to another disease 
modifying therapy (Soilu-Hanninen et al., 2012). However, evidence of efficacy from 
vitamin D supplementation (as an individual therapy) in large, high quality clinical 
trials has yet to be established, with inconclusive results from smaller studies 
(Kampman et al., 2012, Mosayebi et al., 2011).   
  
Epidemiological differences have also led to the hypothesis that MS is caused by a wide-
spread pathogenic infection which confers protection against MS if the individual is 
infected in early childhood, but causes MS if it is contracted at a later age (Hernan et al., 
2001, Alvord et al., 1987, Ascherio and Munger, 2010). This idea was termed the 
hygiene hypothesis because areas with greater hygiene are more strongly linked to a 
higher prevalence and incidence of MS. In support of the hygiene hypothesis there is a 
plethora of evidence linking MS to contraction of the Epstein Barr Virus (EBV) (Levin et 
al., 2010, Ascherio and Munch, 2000, Sumaya et al., 1980), which the majority of people 
in developing countries are infected with in the earliest years of life. In fact over 90% of 
the worldwide population become infected (Cohen, 2000), and it is therefore thought 
that later age of infection is a risk factor for EBV causing MS. Advocates for the role of 
infection in MS aetiology also suggest links to a rarer pathogen that is more common in 
regions of high MS prevalence (Kurtzke, 1993), or infection with pathogens such as the 
Human Herpes Virus 6 (HHV6s) or chlamydia pneumonia (Sriram and Steiner, 2006, 
Fainardi et al., 2008, Bagos et al., 2006, Swanborg et al., 2003).  
 
Although it cannot explain the latitude difference in the epidemiology of MS, cigarette 
smoke has also been hypothesised to increase the risk of disease (Hedstrom et al., 
2011, Sundstrom et al., 2008, Handel et al., 2011). Moreover, there is evidence both 
supporting and refuting the idea that cigarette smoke is associated with an increased 
risk of transition from relapsing-remitting MS to secondary progressive MS (Hernan et 
al., 2005, Koch et al., 2007), and it offers a novel, albeit incomplete, hypothesis for the 
skewed sex ratio in MS prevalence (Palacios et al., 2011).  
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1.2.2.2. Genetic factors 
Early indications for the role of genetic susceptibility in MS came from observations of 
greater prevalence in relatives (Robinson, 1929). The familial risk of MS is as much as 
300 times greater in monozygotic twins and 20-40 times greater in a biological first 
degree relative (Ebers et al., 1995). However, these observations alone are insufficient 
to determine the extent to which environmental sharing plays a role.  
 
In the early 1970’s the association between the human leucocyte antigen (HLA) region 
of the major histocompatibility complex (MHC) to diseases with a known genetic 
susceptibility was discovered.  In fact the first associated diseases were with coeliac 
disease (Falchuk et al., 1972) and psoriasis (Russell et al., 1972), and since then almost 
all autoimmune diseases have been associated with loci of this region (Svejgaard, 
2008). MS is most strongly associated with allelic variation in the HLA class II region, 
although the class I region has also been recently implicated (for a recent review see 
Gourraud et al., 2012). Carrying the HLA DRB1*1501 haplotype has been suggested to 
increase the risk of developing MS by an odds ratio of 3.08 (Sawcer et al., 2011) which 
provides the strongest genetic link to MS susceptibility identified so far.  
 
The major breakthrough in genetic epidemiology came when it became affordable to 
screen thousands of single nucleotide polymorphisms (SNPs), leading to the 
development of genome wide association studies (GWAS). This approach was used to 
identify the first non-HLA region genes associated with MS.   These were the interleukin 
7 receptor alpha (IL7Rα) and IL2Rα (Hafler et al., 2007), and since then over 50 
associated loci have been identified in this manner (Gourraud et al., 2012). However, it 
has also been suggested that GWAS are prone to bias such as being underpowered 
(Elbers et al., 2009, Pluzhnikov et al., 2010, Zhong and Prentice, 2008, Ioannidis, 2008).  
Attempts have been made to address these concerns in future studies but nonetheless 
results should be interpreted with some caution (Pearson and Manolio, 2008, Laurie et 




1.2.2.3. Interplay between environment and genetic factors  
Migration studies have afforded invaluable insights into the potential roles of genes and 
environment in MS aetiology. As already mentioned, there are regions of high and low 
MS prevalence and incidence. Interestingly, if an individual moves from a high risk area 
to a low risk area, the risk decreases; however, moving in the opposite direction, from 
low risk to high risk does not result in an increased risk of MS. Moreover this protection 
from MS is unfortunately not conferred to that individual’s child, as their risk is equal to 
the overall risk for that area (Ascherio and Munger, 2007a). Both the hygiene 
hypothesis and genetic factors go some way to explain the lack of change in risk from 
low to high risk areas; however both fall short in explaining how individuals migrating 
from a high to low risk area have a decreased risk. If infection at a young age confers 
protection, moving to a “less hygienic” area should increase the risk of MS if the 
migration occurred after infancy; and likewise, if genetics are the sole cause of MS, 
migration should not affect the risk. 
 
It is clear that MS cannot be explained in full by any individual risk factor. What is 
known is that genetics play a role in predisposing some individuals to MS and some 
environmental factor(s) can trigger the onset of MS. What is not known is which 
environmental factors, alone or combination, are vital, associated or merely 
coincidental; and how allelic variation contributes to disease aetiology.  
 
1.2.3. Pathology and Disease Mechanisms 
MS is driven by a complex relationship between inflammation and neurodegeneration 
in the CNS. More recent advances in imaging techniques have allowed us to probe 
deeper into the CNS. In turn this has led to novel insights such as the extent of atrophy 
in the grey matter, when before MS was widely regarded as a disease of the white 
matter (Dalton et al., 2004). Despite these advances however, the underpinnings of MS 
remain an enigma. Importantly, there are both subtle and stark differences in the 
pathophysiology and pathology within and between patient populations with a 
particular clinical course. Current research is no doubt aided by a greater – albeit not 
complete – knowledge of some of these differences, which include for example, 
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different lesion pathology (described below) and patients either being interferon-beta 
(IFN-β) responders or non-responders (Killestein and Polman, 2011). 
 
1.2.3.1. Pathology 
The pathological hallmark of MS is the presence of demyelinating, inflammatory lesions 
occurring both within the white and grey matter of the CNS. Axon loss is considered the 
cause of permanent disability (Trapp et al., 1999) and occurs within the setting of acute 
demyelinating lesions or chronic demyelination (Ferguson et al., 1997). Myelinated 
axons conduct fast and efficient electrical impulses via sodium channels at the nodes of 
Ranvier (saltatory conduction). As myelin is lost, sodium channels are redistributed, 
but this process is not sufficient and conduction velocity reduces. Moreover, chronic 
demyelination renders axons vulnerable to immune cell attack and/or 
neurodegeneration. Axons become transected and eventually fully degenerated, leading 
to complete loss of impulse conduction, and the subsequent neurological deficits. 
Symptomatology therefore depends on the location of lesions within the CNS.  
 
1.2.3.2. Mechanisms of damage 
In the past it was considered that the CNS was immunologically inert and separated 
from the immune cells of the periphery by the tightly controlled blood brain barrier 
(BBB) in a state called “immune privilege”. We now know that the immune cells of the 
periphery actively engage with the CNS and can cross the BBB but that their action 
within the CNS is tightly controlled by the microenvironment and resident regulatory 
cells of the CNS. In MS there is a breakdown of the BBB which may allow immune cells 
to freely enter the CNS either as, or becoming, auto-reactive cells to self-myelin 
antigens, and may result in dilution of the aforementioned immunosuppressive 
environment (Galea et al., 2007). The precise trigger and order of events is unknown, 
however autoimmune responses may occur through mechanisms such as molecular 
mimicry, bystander activation and/or epitope spreading (Fujinami et al., 2006), or as a 
result of neurodegenerative processes (Zipp and Aktas, 2006, Trapp and Nave, 2008).  
The immune cells which invade the CNS are thought to include Th17 cells which 
produce IL17 cytokines, and/or Th1 cells which produce IFN-gamma. Perhaps due to 
disruption of the regulatory processes in specific areas of the brain, which would 
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usually prevent autoimmune responses, these cells are able to unleash their repertoire 
of pro-inflammatory reactions in localised areas in the CNS (lesions). 
 
Lesions are characterised by distinct areas of acute inflammation. Four distinct lesion 
patterns have been described based on macrophage and T cell involvement with or 
without antibody or compliment deposition, how well the lesion edge is defined and 
the extent of oligodendrocyte death  (Lucchinetti et al., 2000).  
 
One of the major areas of debate surrounding MS pathophysiology is the relationship 
between inflammatory and neurodegenerative processes in the CNS. It seems clear that 
inflammation plays an important role in the pathogenesis of the disease; however it 
remains unclear whether inflammatory processes are the primary factor in subsequent 
demyelination and axon loss, or whether inflammation is secondary to 
neurodegenerative processes (for two comprehensive reviews see Trapp and Nave, 
2008, Peterson and Fujinami, 2007). To add to this complex “chicken and egg” scenario, 
we do not know to what extent these processes interact beyond the primary cause 
including the extent to which inflammatory cells play a detrimental and protective role 
in axon survival (Peterson and Fujinami, 2007).  
 
1.2.3.3. Mechanisms of repair 
The spatial pattern of destruction in the CNS and the physical symptoms of MS are 
defined by the interplay between mechanisms of damage and repair (Stadelmann and 
Bruck, 2008). Anti-inflammatory processes, including the removal of myelin debris and 
recruitment of M2 macrophages and regulatory T-cells (Treg), lead to the acute 
inflammatory phase fading. In terms of actual repair, one such mechanism is 
remyelination by the recruitment of mature oligodendrocytes in the white matter of the 
CNS. This generates new myelin sheaths for exposed, demyelinated axons (Franklin and 
ffrench-Constant, 2008, Franklin and Kotter, 2008).  Remyelination efficiency appears 
to differ amongst individuals and is therefore difficult to quantify collectively, however 
estimates suggest that in 20% of patients their lesions will remyelinate extensively, and 
that it also occurs in progressive forms of the disease (Patrikios et al., 2006). 
Remyelinated lesions are called shadow plaques – so called because although the new 
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myelin sheaths restore sufficient conduction velocity to potentially allow the patient to 
function normally, they are both shorter and thinner than the lost myelin that they 
replace. Thus in RRMS the temporal pattern of remission corresponds to the anti-
inflammatory processes initially, and then remyelination and the subsequent resolution 
of saltatory conduction.  Over time remyelination becomes less efficient and eventually 
fails, ultimately leading to the prolonged exposure of axons to an inflammatory 
environment. Furthermore the longer axons are exposed, the greater the risk of attack 
by immune cells, or degeneration, which ultimately leads to the increasing permanent 
disability.  
 
1.2.3.4. Pathophysiology of the clinical disease course 
Complex pathophysiology translates to a heterogeneous disease course. The most 
obvious indication of this is the differences in clinical presentation between RRMS and 
progressive forms of the disease. A fundamental pathological hallmark which defines 
the differences between these subtypes is the accumulation of neurodegeneration, and 
beyond a certain threshold the patient transitions to a progressive disease course 
(Figure 1.2). Likewise, in PPMS, neurodegenerative processes are prominent from the 
start of the disease and have been likened to SPMS with an amputated relapsing 






Figure 1.2. A typical clinical course of MS showing the transition from the preclinical to a 
progressive phase over time. From left to right the lower panels represent: the pathology of a 
normal axon; the degeneration of myelin and the axon during the relapsing-remitting phase of 
disease; and the axon loss that occurs during the progressive phases of disease including SPMS 
and PPMS. The arrows beneath the clinical course represent MRI positive activity, and the large 




1.2.4. Treatment strategies 
1.2.4.1. Current treatment strategies 
Since the first descriptions of MS, the arsenal of treatment strategies has reflected the 
evolution of theories on its pathogenesis and pathophysiology. In the earliest era of MS 
therapeutics these included vomiting (to treat a suspected blood toxin), quinine or 
arsenic therapies and a range of equally forbidding therapies in between (Murray, 
2009). All of the currently approved interventions which could reasonably fall under 
the category of “disease modifying therapy” (DMT), rather than symptom management, 
reflect the discovery of the role of inflammation and autoimmunity in MS. The first of 
these was IFN-β-1b (Betaseron®) which was approved in 1993. This was followed by 
the approval of IFN-β-1a (Avonex®) in 1996, glatiramer acetate (GA; Copaxone®) in 
1997 and a second formulation of IFN-β-1b (Rebif®) in 1998. The next decade saw the 
approval of mitoxantrone (Novantrone®) in 2000 which was the first intervention for 
SPMS (this is not licensed for use in MS in the UK but is widely used).  A monoclonal 
antibody to integrin 4, natalizumab (Tysabi®) was approved in 2004 but removed in 
2005 following safety concerns and subsequently re-introduced in 2006 under strict 
guidance on its use. Finally, in 2010 the first oral intervention for RRMS, fingolimod 
(Gilenya®), was FDA approved2.  
 
1.2.4.2. Evidence of efficacy 
The clinical success of the aforementioned DMTs has been variable. GA was introduced 
to the drug market amidst a great deal of expectation and hype. Chemically, GA is a 
random copolymer of myelin basic protein (MBP) and was therefore initially used in 
the laboratory to try and induce EAE by eliciting an autoimmune response (reflecting 
the theory of MS being autoimmune mediated). Surprisingly, treatment of animals with 
GA rendered them resistant to further attempts to induce disease via the typical 
method (fragments of, or whole MBP; see section 1.3.1); possibly by mechanisms such 
as immune tolerance (Racke et al., 2010). However, a systematic review of its use in 
randomised control trials (RCTs) suggests that it is only marginally effective in 
reducing relapse rate in RRMS patients, and has no discernible effect in progressive 
                                                          
2
Approved for use in the European Union in 2011 although use is dependent on specific licensing 




forms of the disease (La Mantia et al., 2010). On the other hand, the interferons and 
natalizumab have shown significant benefit in reducing annualised relapse rate in 
RRMS patients (Nikfar et al., 2010, Oliver et al., 2011, Hutchinson et al., 2009, Rudick et 
al., 2006). However, natalizumab as a monotherapy has also been found to have no 
impact on the progression of disease as measured by a change in the expanded 
disability status scale (EDSS) (O'Connor et al., 2004) although it is currently being 
trialled in SPMS (Biogen Idec., 2012). A systematic review of mitoxantrone found 
evidence of moderate efficacy in reducing progression of relapsing and progressive 
forms of the disease (Boneschi et al., 2005). However the use of mitoxantrone has been 
limited to secondary progressive MS and worsening RRMS due to the potential for 
serious adverse side effects (see next section). The newest addition to the clinically 
approved interventions, and the first oral intervention, fingolimod has also shown 
promise in short term RRMS studies (Kappos et al., 2006, Kappos et al., 2010, 
Devonshire et al., 2012).  
 
A challenge for clinicians is weighing up the benefits versus the risk of adverse events 
for the DMTs, which are extensive and include for example flu like symptoms and 
injection site reactions. However, the most serious adverse effects are linked to the 
three interventions which could also be considered the most powerful disease 
modifiers, mitoxantrone, natalizumab and fingolimod. The first evidence for the serious 
implications of applying a strong immunomodulator in MS came from a phase III 
clinical trial on combination treatment with natalizumab and IFN-β-1a (Kleinschmidt-
DeMasters and Tyler, 2005). Three patients developed progressive multifocal 
eukoencephalopathy (PML), a rare and often fatal neurological disease (Rudick et al., 
2006, Kleinschmidt-DeMasters and Tyler, 2005). PML is caused by the JC virus which is 
commonly harboured by humans, but while this is successfully kept in-check by the 
immune system in most individuals, treatment with natalizumab (most often as a 
monotherapy) allows this to manifest in the CNS. Approximately 1 in 500 patients on 
this treatment develop PML. Those with the highest risk are JC positive, have 
previously taken immunosuppressants and have had prolonged treatment with 




1.2.4.3. The therapeutic gap 
All of the clinically available DMTs, bar mitoxantrone, are aimed primarily at treating 
RRMS, although mitoxantrone was also used for this patient group.  However, even in 
these patients neurodegeneration may continue whilst the disease is clinically silent. It 
was not until the end of the last century that we learnt the importance of axon loss in 
disease progression and crucially it is this pathological hallmark that no intervention 
has been shown to reliably target in long term, high quality clinical trials. Whereas 
RRMS patients therefore have a handful of DMTs available to them, there is no 
treatment available for patients with progressive forms of the disease. If we take the 
estimate that 65% of patients with RRMS will transition to SPMS, and that 10% begin 
with PPMS, roughly 75% of all MS patients currently have, or will have very few 
treatment options. If in fact MS is a primary neurodegenerative disease (or has an 
element of this) it is perhaps no wonder that the plethora of immunomodulatory drugs 
have little benefit beyond the short term relief of acute inflammation in RRMS.  
 
1.2.4.4. Is there a failure to translate efficacy? 
With every relative success in the clinic, there has been a host of failures; either due to 
a lack of efficacy or serious adverse effects (for review see: Meuth et al., 2010, 
Ulzheimer et al., 2010, Ziemssen, 2008, Chan and Gold, 2007). The key question is why 
these failed to show efficacy after promising preclinical tests, and whether these 
adverse effects might have been predicted.  
 
Clinical trials should be conducted based on reliable evidence from animal studies, or 
from other clinical trials which are themselves based on reliable evidence from animal 
studies (Figure 1.3). Reliable animal studies are those which are of low risk of bias, are 
pragmatically designed to reflect what is achievable in the human disease, use a sample 
size large enough to obtain statistical significance, and have a replicable study design. 
Literature on drug efficacy tested in preclinical models of focal-ischaemia, glioma, 
intracerebral haemorrhage and Alzheimer’s disease have shown that this is not always 




There are three broad explanations for the failure to translate efficacy from animals to 
humans: (1) efficacy was understated in clinical trials (falsely negative); (2) efficacy 
was overstated in the animals model (falsely positive); or (3) the animal model did not 
replicate robustly the human disease. Beyond the biological differences between 
animals and humans (point 3), or even between EAE and MS, a number of tools have 
emerged which have afforded us novel insights into the reasons for the lack of clinical 
trial success. Namely these are systematic review and meta-analysis which are 
described in detail in section 1.4.1. 
 
 
Figure 1.3. The relationship between clinical trials and animal experiments. Clinical trials 
should be based on reliable evidence from animal experiments; observations from clinical trials 
can likewise be used to inform the design of further animal studies; and clinical trials can be 
based on other high quality clinical trials of other diseases where they have shown sufficient 
evidence of safety and efficacy; and animal studies can be used to inform further animal studies. 
 
1.3. Animal models of MS 
To our knowledge, MS is a uniquely human condition. Being such a complex disease, it 
is of little surprise that there is a repertoire of animal models available which are 
designed to mimic the different hypotheses on its aetiology and pathophysiology, and 
which can be used to test potential therapeutics. Animal models of any human disease 
are important tools in translational research. Models of MS are also particularly critical 
for assessing the pathology and pathophysiology at various stages of the disease as we 
currently have no way of predicting who will develop MS (and even if we did, obvious 
ethical reasons preclude conducting a biopsy on them). Moreover, on the rare occasions 
that biopsies have been done on patients with established MS, they typically represent 
a chronic, burnt-out phase of the disease, although actively demyelinating lesions have 




There are four broad ways to model MS which are toxin, virus, transgenic or 
autoimmune based and each of these have advantages and disadvantages for studying 
different aspects of MS (Table 1.1). The latter, commonly known as experimental 
autoimmune encephalomyelitis (EAE), is the most commonly used model of MS and 
also the main focus of this thesis. However, as I will describe below it is also the most 
widely debated over its utility as a model to identify suitable drugs for clinical use. 
 
Model Description 
Viral Viral models include Theiler’s murine encephalomyelitis virus (TMEV) 
and murine hepatitis virus (MHV).  
These are useful models of autoimmunity triggered by a virus which 
reflects the corresponding hypothesis in humans.  
Toxin Toxin models commonly include lysolecithin (an activator of 
phospholipase A2) or cuprizone (a copper chelator). Not a model of MS 
as a whole, but rather a model of focal demyelination and remyelination.  
Transgenic Spontaneous development of EAE-like pathology. Typically generated on 
the C57BL/6 background and so the disease course is characteristic of 
this strain (monophasic with poor recovery).  
Autoimmune EAE is the most common animal model of MS. See section 1.3.1 for 
details. 
Table 1.1. Describing the broad animal models of MS. (For a comprehensive overview, 
see Lavi and Constantinescu, 2005) 
 
1.3.1. Experimental autoimmune encephalomyelitis  
 
“The most disappointing aspect of EAE as a potential model for MS 
is its almost total inability to point toward a meaningful therapy or 




Over the past decade the usefulness of EAE has been criticised, no doubt because of the 
frustrating lack of successful clinically available DMTs which have emerged from its 
use. The question therefore is whether these criticisms are valid. In this section I will 
provide a brief history of EAE and its pathophysiology, and summarise some of the 
currently held views on its utility in translational research.  
 
EAE was born out of the accidental discovery in the 1920s that the myelin antigens in 
rabies vaccinations could sometime cause “paralytic accidents” in humans (Stuart and 
Krikorian, 1928) which was later attributed to the fact that repeated injection of brain 
tissue might have caused an allergic reaction. Thomas Rivers was the first to formally 
generate the EAE model, which was initially created in monkeys (Rivers et al., 1933). 
Over the next decade some fine tuning was required – mostly with the co-use of 
Freunds adjuvant that enabled a reduction in the number of injections of myelin 
antigen from up to 85 over a year to a single injection (Kabat et al., 1947, Van Epps, 
2005). EAE has thus had over 8 decades worth of model-refinement and research into 
pathophysiology and pathology – both of the model itself and the human disease, and 
as a tool in translational drug research.  
 
EAE cannot accurately be described as one model, but rather represents a spectrum of 
MS-like diseases because each individual species and strain reacts differently, and not 
always subtly, to the immunogenic agents used to induce disease (Gold et al., 2006). 
Typically there are two methods to induce EAE. Active EAE is induced by injection of 
whole CNS antigens or their fragments (including myelin basic protein (MBP), 
proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG)) mixed with 
adjuvant (Freunds complete adjuvant; CFA) into the periphery. In the induction phase 
of active EAE, peripheral antigen-specific T-cells become activated and proliferate in 
the lymph nodes. In the subsequent effector phase, the autoreactive T-cells migrate to 
the CNS where they encounter their specific myelin antigen, causing autoimmune 
damage and clinical signs. The second method, passive EAE, models the effector phase 
in isolation from the induction phase. Autoreactive T-cells, typically taken from the 
peripheral lymph nodes, of EAE donors are adoptively transferred to naive recipients. 
Passive EAE is useful for being largely reproducible as it bypasses the often-variable 
and strain specific induction phase. However, the actual rate of successful induction for 
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both active and passive EAE is dependent on a number of factors such as any infections 
in the animal house, the dosing regime, the background strain and the researchers 
ability to successfully administer the immunogens.  
 
Within individual strains and the specific method used to induce disease, the course of 
EAE is largely predictable in animals that are successfully induced (Gold et al., 2006). 
The symptomatic correlate to the effector phase is called the prodromal phase, during 
which time the animal continues to appear normal. This is typically followed by weight 
loss and ascending paralysis starting at the tail tip, and EAE is commonly assessed on 
an ordinal scale (e.g. from 0=healthy to 5 or 6=death) which resembles the 10 point 
EDSS in human clinical trials. In some EAE models the animals may rapidly progress to 
a paralytic state (acute EAE), or they may spontaneously recover from clinical signs, or 
develop chronic paralysis (chronic EAE), or they may develop a relapsing remitting 
disease course (Wekerle, 2008).  
 
In human MS, the role of B cells, T cells, innate and adaptive immunity and processes of 
neurodegeneration, amongst others, are becoming better defined (for a useful review 
see Mix et al., 2010). EAE is generally considered to be mediated by CD4+ Th1 cells 
(Damsker 2010), however roles for other immune cells, particularly Th17 have been 
extensively researched and debated (Koenders 2010). Adding to the complexity of EAE 
is the need to understand how and why different species and strains react uniquely to 
each induction method. Moreover, none of the models successfully recapitulate the full 
complexity of the human disease, but each one has similarities and differences in terms 
of pathophysiology, pathology and clinical course (Gold et al., 2006).  
 
The value of EAE has been questioned. It has been used specifically in the development 
of four clinically available interventions: glatiramer acetate, mitoxantrone, natalizumab 
and more recently fingolimod. However, these relative success stories are balanced 
somewhat by the large volume of failed clinical trials after reported success in EAE 
(Chan and Gold, 2007). There is no shortage of opinion on why EAE has not always 
been successful in identifying clinically useful interventions. Proposed reasons for the 
discrepancies include: genetics (species differences, peculiarities of inbred animal 
strains), pathogenics (individual variability between MS patients) and kinetics 
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(different ontogeny and biorhythms, temporal differences of immune reactivity and 
response to therapy) (Mix et al., 2010); difficulties in choosing the correct dosing 
regimen which meets the fine balance between efficacy and safety (Steinman and 
Zamvil, 2006); differences in the immune system of human and murine animals and the 
inadequacies in modelling such a complex disease using one animal model (Wekerle, 
2008). Finally it has been said that:  
“the reasons for this failure are not only, as shown here, that MS and 
EAE differ quite substantially, but also that even from the larger, 
more comprehensive picture, most of the evidence suggests that the 
EAE models do not reflect the pathology of a progressive disorder 
as MS. Moreover, the various EAE models are dissimilar in their 
pathology and immunology to such an extent that it is unclear why 
one EAE model will be better served than another” (Sriram and 
Steiner, 2005).  
 
Interestingly, questions have also been asked about experimental design and 
interpretation including whether the choice of model for the human condition contains 
the answers, and whether there are inadequacies in the execution of studies or the 
treatment and interpretation of data (Bolton, 2007). Research on the biological 
underpinnings of this complex translational issue is not complete, but is nonetheless 
extensive (Denic et al., 2011, Mix et al., 2010). However it is interesting that the 
adequacy of EAE trial design has until recently received less attention. 
 
1.4. Systematic review and meta-analysis 
As we are faced with ever increasing literature on interventions for diseases in the life 
sciences, so too is there an increasing need to be able to critically appraise the 
literature and weigh competing evidence. Systematic review is a tool to identify and 
summarise all of the available research on a specific research question to allow the 
wider research community to make informed decisions from the best available 
evidence. Meta-analysis is often applied to data identified in a systematic review; it is 





1.4.1. Systematic reviews 
Reviews are necessary to summarise the available information on any given topic. For 
some topics, the volume of available information can be gargantuan. To date, Pubmed 
holds over 21.5 million records (data accessed on May 20th 2012) dating from 1809 to 
2012. Moreover, in 2012 alone, 690 of these have “multiple sclerosis” in the title. Thus 
keeping up to date on a field of research can be an almost impossible task without 
reviews of the relevant literature.  
Traditionally reviews are narrative, where the author can choose which literature to 
include and how to summarise the information. Narrative reviews can be particularly 
prone to bias because the author may choose only the literature which supports 
his/her own views. Moreover, even authors with no vested interest in the conclusions 
of a review can be subject to bias (Antman et al., 1992). Consequently systematic 
reviews are becoming increasingly popular. The most recent published audit in 2007 
suggested that there is an estimated annual publication rate of 25,000 systematic 
reviews (Moher et al., 2007). In a more recent study, a random sample of 1000 
publications taken from Pubmed, 1% were systematic reviews (Baginskaitė, 2012).  
 
A systematic review involves applying scientific, reproducible and transparent 
methodology to the selection, critical appraisal and synthesise of all the available 
primary research which is relevant to a specific research question (Cook et al., 1997, 
Greenhalgh, 1997). Systematic reviews are not immune to bias, but their purpose is to 
try and minimise it. The methods should be included with the review, allowing the 
reader to cast judgement on the efforts made to avoid bias. To aid in this task, 
systematic reviews have been subject to the same scrutiny as many other areas of 
research, namely in the form of field-specific reporting guidelines (the PRISMA 
statement, Moher et al., 2009; discussed in more detail in Chapter 4). Additionally 
systematic reviews are most often treated as pieces of original research (Meerpohl et 
al., 2012) and therefore should include criticisms and their limitations in the discussion 





A systematic review without the statistical aggregation of data is often called a 
qualitative systematic review; and with the statistical aggregation of data it is called a 
quantitative systematic review or more commonly, a meta-analysis. Meta-analyses in 
the life sciences are commonly used to try and identify consistencies amongst 
treatment effects (source of homogeneity), as well as sources of variation between 
treatment effects (heterogeneity). Fundamental to the practice of conventional meta-
analysis however is identifying the information which will be most beneficial to 
clinicians, for which meta-analysis has played a role in changing clinical practice (Lau et 
al., 1992).  
Systematic reviews and meta-analyses of clinical data typically involve selecting the 
best available evidence – that is data from all randomised controlled trials (RCTs). The 
endpoints for analysis can be, for example, those which are deemed clinically relevant 
to the patient subpopulation for which evidence of efficacy is being sought. Pooling 
these data together gives a global estimate of efficacy, which in itself is only meaningful 
if an assessment is made to estimate whether there is substantial heterogeneity 
(Thompson, 1994). However, when an assessment of heterogeneity is conducted, and 
potential sources of it are identified, meta-analyses can give invaluable insights  into, 
for example: whether the treatment works under any condition in the patient 
subpopulation of interest (e.g. SPMS rather than RRMS); whether different study design 
paradigms increase the chances of positive findings (e.g. intravenous injection rather 
than oral administration); or whether there is a dose response (e.g. is a “high” dose 
significantly more beneficial than a “low” dose); and whether a particular drug is 
beneficial at for example improving one outcome measure with no effect on another.  
 
Meta-analysis is not considered a novel practice. The first is cited as having been 
conducted by Karl Pearson in 1904 (O'Rourke, 2007). However, meta-analysis has only 
become widely recognised within the last few decades. In part, this wider recognition 
must be attributed to the inspiring work of Iain Chalmers who set up and established 
the Cochrane collaboration 3  (www.cochrane.org). In 2004 alone this worldwide 
                                                          
3 Named after Archie Cochrane, a British physician and epidemiologist. His influential book 
“Effectiveness and Efficiency: Random Reflections on Health Services” described the importance of 
evidence from RCTs and the lack of reliable evidence on which many common healthcare 
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collaboration published over 100 systematic reviews (Moher et al., 2007) representing 
nearly half of the total number published.  
 
Secondary analyses of clinical trial datasets have allowed the identification of 
methodological shortcomings in clinical trials. Because similar approaches to 
understanding shortcomings in in vivo experiments were plausible, the Collaborrative 
Approach to Meta-Analysis and Review of Animal Data from Experimental Studies4 
(CAMARADES; www.camarades.info) was set up to conduct systematic reviews and 
meta-analyses of preclinical research. This was to see if these experiments hold any of 
the clues to translational failures and/or the conditions under which translation is most 
likely to occur sucessfully. These approaches have led to a clinical trial of hypothermia 
in patients with focal ischaemia, based on the best available evidence of efficacy from 
animal models (van der Worp et al., 2007, van der Worp et al., 2010b, Macleod et al., 
2010).  
 
To date CAMARADES have conducted reviews on experimental models of stroke, 
glioma, Alzheimer’s disease, Huntington’s disease, and bone cancer induced pain. The 
original focus for the collaboration was the translational failures in focal ischaemia, for 
which there are only four available treatments for patients: rehabilitation, 
hemicraniotomy or pharmacologic treatment with either aspirin or thrombolytic 
plasminogen activator (tPA) (Khaja and Grotta, 2007). Interestingly, a systematic 
review of the interventions tested in animals and/or humans identified that of 1026 
interventions tested in either animals and/or humans, 17 had only been tested in 
humans (O'Collins et al., 2006). Moreover, for 51% of the 114 drugs tested in humans, 
the first report of its clinical use was published before the first report of its use in a 
focal ischemia model of stroke. This suggests that animal data are not always used to 
inform the design of clinical trials.   
 
                                                                                                                                                                    
interventions were based. His work and vision is seen as pioneering in the development of 
evidence based healthcare practices. 
4 The “S” in the acronym CAMARADES originally represented “stroke” until 2007 when work 
begun on Parkinson’s disease and multiple sclerosis. It was subsequently changed to represent 
“studies” and since then the group has conducted reviews on an increasing number of disease 
models.   
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The importance of adequate internal validity of a study, that is measures to reduce bias 
such as random allocation to group and blinded assessment of outcome, are well 
documented in the clinical literature (Gluud, 2006). This has led to the development of 
reporting guidelines (CONSORT statement, Begg et al., 1996) which have had at least 
some positive impact on the quality of clinical trials (Hopewell et al., 2010). However 
these factors have been shown to be true of the experimental literature also. 
Consistently it has been found that publications which do not report these measures to 
reduce bias tend to over-estimate efficacy (van der Worp and Macleod, 2011). Such 
information has in turn led to the development of reporting guidelines for the 
preclinical literature (ARRIVE guidelines, Kilkenny et al., 2011), and the establishment 
of organisations to oversee the proper conduct of animal research including the 
National Centre for the Replacement, Refinement and Reduction of Animals in Research 
(NC3Rs; www.nc3rs.org.uk).  
 
1.5. Aim and objectives  
As I have described in the preceding sections, MS is a devastating disease, and perhaps 
understandably because of its complex nature, one which is difficult to treat. Systematic 
review and meta-analysis have emerged as useful tools in both the clinical and 
preclinical literature to understand translational failures and so I have adopted these 
methods to try and provide further insights into the translational failure from EAE 
studies to clinical trials.  
 
The aim of this PhD was to provide an unbiased summary of the scope of the literature 
on candidate drugs for MS tested in EAE to identify potential reasons for the failures to 
translate efficacy to clinical trials. Specifically my objectives were, across all of the 
identified literature, to: (1) describe the reporting of measures to reduce bias and to 
assess their impact on measures of drug efficacy (Chapter 3); (2) assess the prevalence 
and impact of any publication bias (Chapter 3); (3) compare findings from the above 
with another disease with limited translational success (Parkinson’s disease, PD; 
Chapter 4); (4) assess all of the literature in one volume of a leading journal to assess 
the study quality and reporting across a broader field of research (Chapter 5);  and (5) 
assess the relationship between treatment related effects measured using different 




In addition I set out to describe the differences between common methodologies used 
in meta-analysis using data from my analyses (Chapter 7) and to describe my 
experience of trying to use systematic review and meta-analysis of the preclinical EAE 
literature alongside evidence from clinical trials to identify putative drugs to take 
forward to a clinical trial of SPMS (Chapter 8).  
 
1.6. Hypotheses 
My hypothesis is that systematic review and meta-analysis will identify areas for 
further improvement in the use of EAE as a therapeutic tool in MS research. In 
particular, I hypothesise that the EAE literature is prone to the same biases and limits 
to efficacy - associated with compromised internal and external validity - as identified 









By convention I predominately use the pronoun “we” throughout this thesis. Specific 
contributions from others are detailed in each results chapter.   
 
As part of this PhD I refined the methodological approach to the estimation of 
normalised mean difference (NMD) effect sizes (section 2.2.2i) to be more appropriate 
for data reported from animal experiments and so I have provided a detailed 
description of these calculations. For the purpose of continuity the same detail is given 
to the calculations for standardised mean differences (SMD) effect sizes (section 2.2.2ii). 
Less detail is given to other approaches where the methodology is well established and 
applied unchanged to animal data. 
 
2.1. Systematic Review 
The aim of a systematic review is to summarise all of the relevant literature on a 
particular topic of interest. Systematic reviews should therefore have transparent, 
reproducible methodology and every effort should be made to reduce selection bias.  
 
2.1.1. Electronic search 
A thorough search strategy was formulated to identify relevant publications for each 
research question, details of which are given in the relevant results chapter of this 
thesis. Up to three online databases were searched:  Embase, ISI Web of Knowledge and 
Pubmed. Results were downloaded onto Reference Manager (Version 11) and duplicate 
entries (from multiple online databases) were deleted.   
 
References were screened by two reviewers against pre-specified inclusion and 
exclusion criteria (described in each results chapter), with the exception of the updated 
EAE literature review which was screened by one reviewer. We reviewed titles and/or 
abstracts or the full PDF if further investigation was required. Electronic PDFs were 
obtained for publications which met the inclusion criteria. Where articles could not be 
obtained electronically or as hard-copies via The University of Edinburgh, they were 
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obtained via inter-library loan. There were no language or date restrictions on any 
search.  
 
2.1.2. Data Extraction 
All data were extracted onto the CAMARADES data-manager, a centralised Microsoft 
Access database (2003 version). The CAMARADES data-manager was originally 
developed to collate data on animal models of stroke. As part of this PhD, I modified 
and enhanced the data-manager to support the collation of data from publications 
describing other animal models including EAE. 
 
Where relevant outcomes were expressed graphically, we measured data using digital 
ruler software (Universal Desktop Ruler).  
 
2.1.3. Methodological Quality 
Each publication reporting animal experiments was assessed against a pre-specified 
study quality checklist, amended from (Sena et al., 2007a). The quality checklist for 
animal studies included: (1) being published in a peer reviewed journal; and the 
reporting of: (2) random allocation to group; (3) blinded assessment of outcome; (4) a 
sample size calculation; (5) compliance with animal welfare regulations; and (6) a 
statement of a potential conflict of interest. 
 
We separately noted whether blinded assessment of outcome was for 
neurobehavioural and/or histological outcome. Each checklist item was awarded one 
point except where publications reported either one or both of the blinded assessment 
of neurobehavioural and histological score where one point was awarded in total. 
 





Meta-analysis involves the calculation of an effect size for each comparison which are 
subsequently aggregated into one global estimate or into two or more subgroups, 
hereafter referred to as strata (Section 2.3.2, Figure 2.1).  
 
Throughout this thesis, the following terminology is used when referring to meta-
analysis: raw data are the mean and variance reported in a publication; a comparison 
refers to the raw data when extracted from a control and treatment group for an 
outcome measure in the format suitable for, and contributing to, the meta-analysis; an 
outcome measure refers to the test used to determine effect size such as 
neurobehavioural score, axon loss, inflammation or demyelination; an effect size, for the 
purposes of this thesis, refers to the magnitude of the difference between the outcome 
in the control and treatment group; and a global estimate is the aggregated, weighted 
average calculated in a meta-analysis. 
 
For the purposes of this thesis the term effect size is only used to represent the 
magnitude of the difference between a treatment and control group. To avoid 
repetition of this term, I use the term efficacy in the context of the global estimate and 
this does not have any relation to the use of this term in pharmacology. 
 
The following steps outline the methods we used to conduct a meta-analysis and 
explore sources of heterogeneity (section 2.3). Table 2.1 outlines the notation used in 




Notation Corresponds to 
 ̅  Mean in the control group 
 ̅   Mean in the treatment group 
 ̅     Mean in the sham group 
   Number of animals in the control group 
    Number of animals in the treatment group 
  
  True number of control animals 
  Total number of animals (Equation 2.2) 
    Reported or calculated standard deviation in the control group 
     Reported  or calculated standard deviation in the treatment group 
    Reported standard error in the control group 
     Reported standard error in the treatment group 
   Pooled standard deviation for Hedge’s G 
          A multiplication factor (see Table 2.2). 




Figure 2.1. A flow diagram, starting from top left, to show the methods we used to calculate and 
aggregate effect sizes and explore sources of heterogeneity.  
 
2.2.1. Calculating the total number of animals used. 
The number of animals per group contributes to the measure of precision of the global 
estimate of efficacy in a meta-analysis. Since a control group can serve more than one 
treatment group, the number of animals in the control groups was adjusted to avoid 
giving undue weight to that study in the meta-analysis (Equation 2.1). Thus for each 
32 
 
outcome extracted and included in the meta-analysis, a value for the number of 
treatment groups served by that control group was also extracted.  
 
Equation 2.1.   
     
  
                                      
 
 
Where   
  refers to the true number of control animals.  
 
The total number of animals (N) for the comparison is calculated as shown in Equation 
2.2. 
 
2.2.2. Effect size calculation 
There are three broad methods to calculate effect sizes on continuous data: raw 
difference in means, normalised mean difference (NMD) and standardised mean 
difference (SMD). For the data described in this thesis it was only appropriate to use 
NMDs or SMDs (see Chapter 7). For a comprehensive overview of other calculation 
methods which are outside the scope of this thesis both Egger et al (2001) and 
Borenstein et al (2009) provide excellent resources.  
 
i. Normalised mean difference 
Where data exist on a ratio scale (that is, where the score that would be achieved by a 
normal, untreated, unlesioned “sham” animal is known or can be inferred), we can 
express the absolute difference in means as a proportion. We calculate the absolute 
difference between outcomes for each of the control and treatment groups and 
outcome in sham animals (Equation 2.3); and we express the effect size as the 




difference between these two values expressed as a proportion of the larger of the 
two5 (Equation 2.4 to Equation 2.5).  
 
If | ̅   ̅    |   | ̅    ̅    |, we use the formula; 
 
Or if | ̅    ̅    |  | ̅   ̅    |, we use the formula;  
 
For individual comparisons where the variance was reported as a standard error (SE), 
these were converted to standard deviations (SD; Equation 2.6).  
 
The raw standard deviations were also normalised to the same denominator used in 
the effect size calculation (Equation 2.4-Equation 2.5). 
 
                                                          
5
 This calculation is based on previously described methods for the meta-analysis of animal 
experiments (MACLEOD, M. R., BRISCOE, C. L. & SANDERCOCK, P. A. G. 2005a. Systematic review 
and meta-analysis of the efficacy of tPA in experimental stroke. Journal of the Neurological 
Sciences, 238, S73-S73. As part of this PhD I modified this calculation to account for the 
substantial variation in metrics used to measure the raw data. The previous method did not 
adequately take into account situations in which the treatment and/or control group performed 
“better” than the sham group. Additionally, for very precise studies, the effect size tended 
towards infinity. This new calculation generates effect sizes which lie between -100% to +100%, 
unless either one or both groups perform better than the sham group in which case the effect 
size can be higher or lower.  
Equation 2.3.  | ̅   ̅    | and | ̅   ̅    | 
Equation 2.4.            
( ̅   ̅    )  ( ̅    ̅    )
( ̅   ̅    )
           
Equation 2.5.            
( ̅    ̅    )  ( ̅   ̅    )
( ̅    ̅    )
           
Equation 2.6.        √   
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Thus if | ̅   ̅    |   | ̅    ̅    |, we use the formulae; 
 
Or if | ̅    ̅    |  | ̅   ̅    |, we use the formulae;  
 
Finally, the standard error for the effect size,     is; 
Equation 2.9.      √
    
 
  
     
     
 




Importantly, in the calculation of this NMD effect size, the value for sham does not 
provide the direction of the effect (i.e. where a higher score represents a better or 
worse outcome) and so the effect size needs to be adjusted according to the rules 
shown in Table 2.2. Specifically, the effect size was multiplied by -1 when either: the 
control group had a better outcome than the treatment group and where a higher score 
represented a better outcome; or the treatment group had a better outcome than the 
control group and where a higher score represented a worse outcome. 
 
Table 2.2. The correction factor used to normalise the direction of the effect size.  
Equation 2.7.             
   
 ̅   ̅    
 and             
    
 ̅   ̅    
 
Equation 2.8.             
   
 ̅    ̅    
 and             
    
 ̅    ̅    
 
Better outcome in? Higher mean score represents? Multiply effect size by? 
Control group Better outcome -1 
Treatment group Better outcome 1 
Control group Worse outcome -1 
Treatment group Worse outcome 1 
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Finally, for an NMD to be calculated, the value for sham either had to be reported or 
able to be inferred. The baseline value can sometimes be inferred using rational 
scientific reasoning. For example, for neurobehavioural scores measured on a 0-5 scale 
where 0 represents a healthy animal and 5 represents death, it can be assumed that a 
sham animal will be graded as 0. This approach was also applied to: any scoring system 
where the animal was graded on an ordinal scale with 0 representing a healthy animal; 
for axon loss and demyelination it was assumed that a healthy animal would have no 
axon loss or demyelination. For inflammatory markers, where these were not 
measured on an ordinal scale, they were excluded unless a value for a sham animal was 
reported.   
 
ii. Standardised mean difference 
If outcomes are measured on different scales without a value for sham being either 
reported or able to be inferred, it is not appropriate to calculate NMDs as the baseline 
to normalise the raw data to is unknown. Instead we can divide the difference in means 
by a measure of the standard deviation to convert all of the outcome measures onto a 
standardised scale with units measured in standard deviations. There are three 
primary methods to calculate a standardised mean difference (Egger et al., 2001): 
Cohen’s D whereby the difference in means is divided by the pooled standard deviation 
of the two groups; Hedge’s G which is based on Cohen’s D but includes a correction 
factor for small sample size bias (cited as being less than ten (Hedges and Olkin, 1985)), 
and Glass’s Delta, whereby the difference in means is divided by the standard deviation 
of the control group only. To account for potentially small sample sizes used in animal 
experiments, in this thesis I have only reported effect sizes calculated using Hedge’s G.  
 
The standardised effect size was calculated using the formula for Hedge’s G, shown in 






Equation 2.10.     
 ̅   ̅  
  
   (  
 
    
)            
Where    
  is the pooled variance, calculated as shown in Equation 2.11, and N is the 
total number of animals, calculated as described in section 2.2.1. The direction factor is 
as described in Table 2.2. 
 
Equation 2.11.    √
(      )   
  (     )    
 
   
 
 
Where the variance of both groups was reported as SEM, they were converted to SDs 
using the formula in Equation 2.6. The standard error of the effect size was calculated 
as shown in Equation 2.12.  
Equation 2.12.     √
 
       
  
   
 
 (      )
 
 
2.2.3. Weighting of effect sizes 
Effect sizes in a meta-analysis are weighted before aggregation. Without weighting, the 
global estimate would be a simple average. In this thesis the effect sizes were weighted 
by the inverse of the squared standard error of the effect size, as shown in Equation 
2.13, to give a weighted effect size (        ) as shown in Equation 2.14. 
Equation 2.13. 
   
 
    
  
 
Equation 2.14.            
 
   
  
Where     is calculated in Equation 2.7 (NMD) or Equation 2.10 (SMD) and     is 
calculated as shown in Equation 2.9 (NMD) or Equation 2.12 (SMD). 
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2.2.4. Aggregating effect sizes (meta-analysis) 
Individual effect sizes can be aggregated using either a fixed-effects or random-effects 
model (Borenstein, 2009). The fixed effects model is used when the underlying (true) 
effect size (sometimes referred to as the treatment effect in other texts) is assumed to 
be the same, or fixed, across all of the comparisons in the meta-analysis. The true effect 
size is what we would expect to observe if our sample size were infinitely large so that 
we have no random sampling error. In practice the true effect size of a study depends 
on the population sample and so we can expect some variation at least. However, if a 
meta-analysis is conducted on for example propranolol in an aged population with the 
same severity of hypertension (our inclusion criteria), we could reasonably assume 
that the true effect size is similar enough between studies to conduct a fixed effects 
meta-analysis. With this assumption the observed effect sizes vary due to random 
sampling error alone.  
 
The random effects model is used when we assume that the underlying effect size is 
different amongst samples in the meta-analysis. A random effects meta-analysis 
therefore takes into account both the within-study (sampling error) and between-study 
(differences in the true effect size) variance. If we assume that the effect sizes lie on a 
normal distribution, the centre would represent the average effect, which in the case of 
the fixed effects model is the true treatment effect and the width would represent the 
differences in true effect sizes. This difference is the heterogeneity between studies and 
is represented by tau-squared (τ2; Figure 2.2). 
 
In this thesis I combined data from a number of different study design paradigms and 
thus my pre-specified criteria was to use the more conservative random effects model 






Figure 2.2. The distribution of effect sizes in a fixed effects and random effects model. (A) The 
true treatment effect (circles) is either the same amongst all of the comparisons in the meta-
analysis or it is different, and the overall estimate (vertical dotted line) will be based on the 
observed effect sizes (squares) which differ from the true treatment effect due to sampling error 
within the study. (B) The effect sizes in a meta-analysis are typically assumed to be follow a 
normal distribution, with the centre representing the global estimate of efficacy (vertical dotted 
line) and the width representing the between study heterogeneity, tau-squared. The table in (C) 
shows the interpretation of overall effect sizes and heterogeneity.  
 
The random effects meta-analysis was conducted as follows: 
 
i. Nesting of similar outcomes using a fixed effects estimate 
Nesting is a term used to describe the pooling of effect sizes from similar outcomes 
when they are measured in the same cohort of animals. For example, if the outcome of 
interest is inflammation, we can make the assumption that the treatment related effects 
will be sufficiently similar across for example the reduction in both T cells and 
macrophages and so we nest their effect sizes. Without this assumption, it would be 
necessary to choose only one of these outcomes for further analysis as animals should 
not be represented more than once in the same meta-analysis. 
 
The methods to combine these estimates of effect size in the fixed effects model are 
outlined below, using      to represent the fixed-effect effect size for each nested 
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comparison (Equation 2.15). For the outcomes which we grouped,      for each nested 
comparison is the sum of the individual weighted effect sizes divided by the sum of the 
weight  which was calculated as shown in Equation 2.13. 
 
Equation 2.15.       
∑      
 
   
∑    
 
   
 
Where   is calculated using Equation 2.13 and      is calculated using Equation 
2.14.  
 
The standard error was calculated as shown in Equation 2.16. 
 
Equation 2.16. 
     
 
√
∑   
 
   
            
 
Where              is the number of observations from the same cohort of animals 
contributing to the nested estimate of effect size.  
 
 
ii. Calculate a fixed effects estimate 
The nested estimate of effect size,      was taken forward to this stage of the analysis. 
In this model a fixed effects estimate is calculated for the entire population (global) or 
for each sub-group (strata). Equation 2.13 to Equation 2.16 are essentially repeated 
using      in the new measure of weight (Equation 2.17) by which the nested effect size 
     is multiplied to give a new estimate of effect size (Equation 2.18) with its standard 
error (Equation 2.19). 
 
Equation 2.17.  
  
 





Equation 2.18.         
∑      
  
   




        
 
√∑       
 
 
iii. Calculate    
As mentioned previously, for each outcome measure in a meta-analysis, there is a 
measure of between-study variation, reflecting the difference between the true 
treatment effect and the observed treatment effect; and the within-study variation, 
reflecting the difference between the observed treatment effects across different 
studies. 
 
Tau-squared (  ) is the amount of between-study variation in the true effect sizes. If    
is large compared to the within study variance, the global effect will tend towards a 
simple average. In the calculation of the fixed-effects effect size, the effect size for each 
outcome measure was weighted by the precision of the estimate, based on the within-
study variance. In the random effects model, the fixed effects estimate of effect size is 
again weighted by the precision of the effect size estimate, but this time it takes into 
account both the within-study variance (SE of the fixed effects estimate) and the 
between-study variance (  ).  
 
The true effect size for an intervention is unknown and so    cannot be calculated 
directly. However, it can be estimated using the method of moments (Dersimonian and 





Equation 2.20.    
    
 
 
Where    is the estimate of between-study variance, Q is Cochrans Q (Equation 2.21; 
the sum of the squared differences in effect sizes between studies and the pooled effect 
size); df is the degrees of freedom (Equation 2.22 and C is a measure used to convert 
the heterogeneity value into an average rather than a sum of squared deviations, and 
to put the value back into its original units (Equation 2.23).  
 
 
Equation 2.22.        
Where k is the number of comparisons 
 
Equation 2.23.   ∑   
 
   
 
∑   
 




   
  
 
iv. Calculate a random effects estimate 
To calculate the random-effects estimate of effect size, the nested effect size (ESϴi) is 
first weighted using the measure of within- and between-study variance, as shown in 
Equation 2.24 and Equation 2.25. Note that if    is less than zero, the random effects 
estimate will be the same as the fixed effects estimate.  
Equation 2.21.   ∑  (            )
 
 
   
 
Where         was calculated as shown in Equation 2.18. 
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Equation 2.24.     
  
 
(    
     ) 
 
 
Equation 2.25.         
            
  
 
The final estimate of effect size is calculated as shown in Equation 2.26, with its 
standard error shown in Equation 2.27 and 95% confidence intervals (95% CI) shown 
in Equation 2.28 
Equation 2.26. 
 
          
 
∑        
 
 
   
 
 
∑    
 
 
   
 
 
Equation 2.27.             
1  
√∑    
 
 
   
  
 
Equation 2.28.                                   
 
2.3. Heterogeneity 
Heterogeneity between studies can be assessed to see if specific factors in the study 
design can explain variability in effect sizes. To assess the potential sources of 
heterogeneity, the amount of heterogeneity has to first be calculated (see next section) 
for which we used two methods: Cochrans Q (hereafter referred to as Q; (Cochran, 
1954)) and I2 (Higgins et al., 2003). To assess whether specific covariates could explain 
excess heterogeneity (where present) we used two methods: stratified meta-analysis, 
often referred to elsewhere as sub-group analysis (Borenstein, 2009), and meta-
regression (Thompson and Higgins, 2002).  
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2.3.1. Estimating the amount of heterogeneity 
Q is an estimate of the between study heterogeneity which is sensitive to the ratio of 
the observed variation to the within-study error, rather than their absolute values  
Equation 2.21). In other words, Q is not affected by the units of the effect size. Q is 
calculated from the effect sizes in the fixed effect model. If all of the true effect sizes are 
assumed to be the same, and that any variation is due to sampling error, the expected 
value of Q is simply the degrees of freedom (Equation 2.22). Assuming also that all 
comparisons have the same true effect size (the null hypothesis), the values of Q follow 
a chi-squared distribution with [k (comparisons) minus one] degrees of freedom. 
Therefore the difference between Q and the expected variation can be tested using the 
chi-squared test of significance; a significant result indicative of there being differences 
between the true effect sizes. Importantly, a non-significant value does not indicate that 
there is one true effect size. Instead, low power within studies (small sample size for 
the comparisons) and low power between studies (a small number of comparisons 
contributing to the meta-analysis) may yield a non-significant result.  
 
Q is useful for testing the significance of the difference between true effect sizes, both in 
a global estimate, and in sub-group analysis (described in section 2.3.2i). However, Q is 
not an intuitive value and it is sensitive to the number of comparisons. I2 is a descriptive 
value, developed to address this issue (Higgins et al., 2003) (Equation 2.29). It reflects 
the proportion of total variance between studies that is due to true differences in effect 
sizes as opposed to chance. I2 lies between 0% (all variation is due to chance) and 
100% (all variation reflects real differences between the true effect sizes between 
studies) and does not depend on the number of comparisons in the meta-analysis. 
 
Equation 2.29.    
    
 






2.3.2. Exploring sources of heterogeneity 
i. Stratified Analysis 
The previous equations demonstrate how to calculate an overall global estimate of 
efficacy. However, when comparisons from such a wide range of study design 
paradigms are included in the same meta-analysis, the global estimate of effect size 
should be interpreted with caution, and be presented along with an analysis of 
heterogeneity.  
 
The rationale behind a stratified meta-analysis is to assess whether the strata can 
account for a significant proportion of global heterogeneity. Therefore the random-
effects effect size and Q are computed as shown in equations Equation 2.20 to Equation 
2.28 for each stratum. For example, if the subgroup under investigation is the route of 
drug delivery, an effect size and Q is calculated for each individual stratum (e.g. 
intravenous, intraperitoneal, oral, etc…). It follows that if effect sizes within strata 
follow distributions around a true estimate which are different from each other, the 
overall amount of heterogeneity between studies will reduce because the sum of 
heterogeneity within the components of the strata is reduced (Figure 2.3). 
 
Thus for each subgroup under investigation, we calculated whether it explained a 
significant proportion of the between study heterogeneity using Equation 2.30 in 
Microsoft Excel:  
 
Equation 2.30.          (           (       ))   ) 
Where         is the amount of heterogeneity for the global estimate of effect size,  
        is the amount of heterogeneity within individual components of the strata, and 





Figure 2.3. The amount of calculated heterogeneity between studies when taking all of the 
effect sizes together (A), or when splitting the effect sizes into two components of the stratum 
under investigation, whose effect size distributions centre around different global effect sizes 
(B); and the method used to calculate the amount of heterogeneity that has been explained by 
stratification (C).  
 
ii. Meta-regression 
Meta-regression takes into account both the between- and within-study variance to 
assess the relationship between moderator variables (independent variables; IV), such 
as study design characteristics and the estimates of effect size (dependent variable; 
DV); (Thompson and Higgins, 2002). The method used in this thesis was the least 
squares method which is represented by the function metareg in Stata (Version 10; 
Equation 2.31).  
 
Equation 2.31.                  (              ) 
Where DV is the effect size, IV is the moderator variable, wsse(              ) is the 
measure of within-study standard error which in this case is the standard error for the 




Where the independent variable was measured on a continuous scale (for example time 
to treatment), they were entered directly into the regression analysis. Where the 
independent variable was a binary or categorical outcome (for example blinded 
assessment of outcome, route of drug delivery), we converted these to dummy 
variables using the tabulate function in Stata. For k dummy variables within the strata, 
k-1 were entered into the regression analysis; the dropped variable being referred to as 
the reference variable. This avoids perfect collinearity in the model because the effect 
of the reference variable can be inferred, and is the variable which the others are 
compared to.  
 
2.3.3. Choosing between methods 
In this thesis, we preferentially chose to calculate NMDs where appropriate because the 
unit of the effect size is intuitive (percentage difference in means), compared to SMDs 
(standard deviations). Therefore NMDs were calculated if sufficient data for sham was 
presented; and SMDs were calculated if data for sham was not presented for the vast 
majority of outcomes. The decision to use either method was made after the data were 
extracted when it was known which category the majority of data fell into.  
 
For the assessment of heterogeneity we preferentially choose meta-regression as it is 
the more conservative approach. At the time of analysis of the data from experimental 
PD studies (described in Chapter 4) meta-regression was not widely available and so 
we used stratified meta-analysis. Further exploration of the differences between these 
methods is described in Chapter 7.   
 
2.4. Statistics 
When we assessed heterogeneity we adjusted all p-values using Bonferonni correction 
to take into account multiple comparisons. Specific P values for each analysis are 





2.5. Publication Bias 
We assessed for publication bias using three methods: (1) funnel plotting (Light and 
Pillemer, 1984); (2) Egger regression (Egger et al., 1997); (3) and “trim and fill” (Duval 
and Tweedie, 2000). All three methods were conducted on pre-nested effect sizes. We 
conducted funnel plotting and Egger regression in Sigmaplot (version 11) using the 
inbuilt regression function for the latter. We conducted trim and fill analyses in Stata 
(version 10) and plotted the data in Sigmaplot.  
 
2.5.1. Funnel plotting 
Funnel plotting is a visual approach to the assessment of small study bias. Plotting each 
effect size against the inverse of its standard error (precision) should result in a 
symmetrical, normally distributed, funnel plot centred on the global effect size. 
Imprecise studies will represent the base of the “funnel” with more precise studies 
scattered up to the top of the funnel. If publication bias is present, a right-skewed 
funnel shape may be observed which is indicative of a preponderance of positive, 
imprecise comparisons (Figure 2.4). It should be noted that funnel plot asymmetry is 
not only associated with publication bias, but rather it may highlight other small-study 
effects. That is, where the result from a small study is inherently different of that from a 
larger study. These differences may be due to poorer methodological quality in smaller 
studies (and therefore may report overinflated estimates), citation bias, language bias 
or true heterogeneity (Egger et al., 1997) 
 
2.5.2. Egger regression 
Egger regression was conducted by plotting the effect size for each comparison divided 
by its standard error (x axis) against its precision. An abundance of imprecise, positive 
studies is indicated by a regression line crossing the origin above zero on the y axis.  
 
Where effect sizes were calculated as NMDs, the precision was the inverse of the 
variance (Equation 2.12).  Where SMDs were calculated, we noticed the unusual effect 
whereby there was substantial curved symmetry in the regression plot. This is due to 
the standardised effect size being constrained to a certain set of values by its sample 
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size (see Chapter 7 for details). For this reason we used a measure of pooled standard 
deviation (Equation 2.32) in the formula for precision:  
Equation 2.32. 
              
     
   (  (
 
    
)
 
Where       is the standard error of the difference in means, calculated as shown in 
Equation 2.33.  
 
Equation 2.33.       √




    
 
   
 
 
2.5.3. Trim and fill  
Trim and fill is a non-parametric approach which makes assumptions based on 
asymmetry, and also uses a “trim and fill” iterative approach to impute missing studies.  
This analysis was conducted in Stata version 10 using the metatrim command Equation 
2.34). The observed and “filled” (missing) values were plotted in Sigmaplot.  
 
Equation 2.34.                         i 
Where SEi is the standard error of the calculated nested NMD (Equation 2.9) or SMD 







Figure 2.4. The distribution of observed effect sizes in a meta-analysis when plotted against 
precision (1/SE) if publication bias does not exist (A) or if it does exist (B). In (B) the dashed 
vertical red (right) and grey (left) lines represent the global estimates of effect size in the 








3. The prevalence and impact of study quality, publication 
bias and incomplete reporting in experimental autoimmune 
encephalomyelitis 
 
I acknowledge the following for their contribution to this research: Malcolm Macleod 
and Emily Sena for help in the design of this study, Madeleine Hammar for second 
screening the original dataset, and Siddharthan Chandran, Anna Williams and Charles 
ffrench-Constant for their helpful comments on the research design and interpretation 
of the results. 
 
3.1. Background 
Only a few interventions tested in EAE have translated into the clinic and moreover, 
none have shown reliable long term efficacy. Issues relating to the internal and external 
validity of a preclinical study may compromise its predictive value in translational 
research. For example, in the preclinical stroke literature, studies of low quality, and in 
particular where measures to avoid bias are not reported, estimates of efficacy are 
substantially overinflated (Sena et al., 2007a). In addition, publication bias is prevalent; 
collectively across systematic reviews of 16 interventions the overall effect size reduces 
from 31.3% improvement in infarct volume for 1359 experiments to 23.8% with the 
inclusion of 214 predicted missing studies (Sena et al., 2010). For the same dataset of 
preclinical stroke studies, issues relating to the external validity were identified 
including the use of young animals, those without hypertension or those without 
comorbidities to model a disease which predominately affects an aged, hypertensive 
population which often have comorbidities (van der Worp et al., 2010a). 
 
3.2. Aims and objectives 
Previously systematic review and meta-analysis have provided empirical evidence for 
issues relating to the internal and external validity of a study.  Our aim was therefore to 
determine whether these were also relevant to the preclinical literature on drugs 
tested in EAE. Furthermore, issues relating to external validity are considered likely to 
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be disease specific, and so we set out to determine which, if any, were relevant to the 
EAE literature. Specifically our objectives were to: (1) systematically describe all 
available data for any intervention tested in EAE where improvement was measured 
against change in neurobehavioural outcome, or reduction in inflammation, 
demyelination or axon loss; (2) describe the prevalence of the reporting and impact of 
factors relating to internal validity, including random allocation to group and blinded 
assessment of outcome; (3) assess the external validity of the literature including the 




3.3.1. Electronic search 
We searched Pubmed, ISI Web of Knowledge, and Ovid Embase using the terms 
([multiple sclerosis] OR [EAE] OR [experimental autoimmune encephalomyelitis] OR 
[experimental allergic encephalomyelitis]) AND ([*myelin*] OR [wallerian 
degeneration] OR [inflammation] OR ([axon*] OR [nerve] AND ([degeneration] OR 
[loss] OR [regeneration] OR [survival] OR [damage])). We limited the search to animal 
studies and we imposed no language restrictions.  
 
3.3.2. Inclusion and exclusion criteria 
iii. Systematic Review 
Publications were included if they reported testing an intervention (including all 
pharmacologic agents, dietary modifications, stem-cells, irradiation and treatments 
given in combination) in any in vivo animal model of EAE, delivered via any route 
(including indirectly such as via drinking water) at any stage of the lesion and where 
outcome was reported as a change in neurobehavioural score, axonal loss, 
demyelination or inflammation. Publications were excluded if they assessed the effects 
of environmental enrichment, exercise, stress (including a reduced weaning period) or 
if they used an animal model of MS other than EAE. Publications which reported the 
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ability of an intervention administered during pregnancy to the dam on the pups ability 
to withstand later EAE induction were excluded.  
 
iv. Meta-analysis 
 We included data from publications where they included the number of animals, the 
mean score and a measure of variance (standard error (SEM) or standard deviation 
(SD)) for both an experimental group and control group. Any neurobehavioural 
outcome reported as mean severity scores, mean clinical score and mean cumulative 
clinical scores was valid for inclusion. Where data were presented graphically the 
clinical score on the last day of the treatment was also extracted.  
 
For publications reporting histological data, we included any outcome measured as 
change in axon loss, demyelination or inflammation where these were measured 
directly (e.g. macrophage counting, MRI lesion volume); data were excluded where they 
described indirect measures such as a change in expression of inflammatory markers 
or findings from FACS or ELISA analysis. 
 
3.3.3. Methodological quality 
We assessed the quality of included studies against our six point checklist as described 
in Chapter 2 (section 2.1.3).  
 
3.3.4. Data analysis 
We calculated NMD effect sizes (Section 2.2.2) and pooled these using the random 
effects model. For neurobehavioural outcomes we combined these into three groups: 
(1) mean clinical score and mean cumulative score; (2) mean severity scores (mean 
severity score, the product of mean severity and duration, the product of mean severity 
plus number of exacerbations; and (3) the clinical score on the last day of assessment. 
For these three neurobehavioural scores and three histological outcomes we tested any 
impact of: (i) random allocation to group; (ii) blinded assessment of outcome; (iii) 
overall quality score; (iv) the number of animals used for that comparison; (v) the time 
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of administration; (vi) the time of outcome assessment; (vii) the route of delivery; (viii) 
the animal species; and (x) the sex of the animal. Additionally for histological outcome 
measures we assessed any impact of the CNS section analysed.  
 
To assess for publication bias we used funnel plotting, Egger regression and trim and 
fill on pre-nested data. We adjusted our significance level to p<0.005 for 9 comparisons 
on neurobehavioural scores and p<0.005 for 10 comparisons on each histological 
outcome. We used the Mann Whitney U test to compare quality scores across different 




3.4.1. Search results 
We identified 1382 full publications and 82 conference abstracts (1464 in total) 
published between 1961 and 2009 describing interventions tested in EAE (Figure 3.1). 
Overall, this review includes data in the meta-analysis from 834 publications testing 














3.4.2. Outcome Measures 
Of 1646 publications in the systematic review, 1446 reported neurobehavioural 
outcomes and 1044 reported histological outcomes. Of  these 1044 publications, 1004 





Figure 3.3. A Venn diagram of the reporting of different outcome measures in each of 1464 
publications. (A) shows the publications which reported neurobehavioural scores (Neuro; red) 
and/or demyelination (Demy; green) and/or axon loss (ALoss; blue) and/or inflammation 
(Inflm; grey). In (B) only the relationships between reporting of demyelination (green), axon 
loss (blue) and inflammation (grey) are shown.  
 
3.4.3. Exclusions 
A large proportion of publications were excluded from the meta-analysis, usually due to 
insufficient reporting. Across all of the outcome measures, we were unable to include 
any data from 631 publications (43%). The number of exclusions and the reasons are 
outlined below. 
 
v. Neurobehavioural outcomes 
1446 publications reported neurobehavioural outcomes and we were able to include 
data from 779 publications in the meta-analysis. For 504 of these we were able to 
include all data, but for the remainder (275 publications) we could only include some 
outcomes. We were not able to include any data from the remaining 667 publications. 
Common reasons for exclusion included the absence of data for the variance, the 
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number of animals, or for a control group; the reporting of only dichotomous outcomes 
unsuitable for meta-analysis; and the reporting in abstracts of limited data insufficient 
for inclusion (See Table 1).  
 All Data 
Excluded 
Some Data 
Excluded Missing variance 293 186 
Dichotomous data only 150 n/a 
Abstract without sufficient information 73 n/a 
Calculation error 35 39 
Qualitative data only 25 n/a 
Missing no. of animals 20 24 
Missing no. of animals; missing variance 20 8 
Unsuitable/no control 19 8 
Uninterpretable data 17 n/a 
Neurobehavioural & histological scores combined 4 n/a 
Median/range data only 3 3 
Missing variance; median/range data only 3 1 
Missing variance; unsuitable/no control 2 5 
Duplicated data from another publication 1 n/a 
Missing variance; uninterpretable data 1 n/a 
Missing no. of animals; unsuitable/no control 1 n/a 
Missing no. of animals; uninterpretable data n/a 1 
TOTAL 667 275 
Table 3.1. Reasons for exclusion of publications with neurobehavioural outcomes from the 
meta-analysis.  
 
vi. Histological outcomes 
We identified 1044 publications reporting histological outcomes as changes in axon 
loss, demyelination or inflammation. Of these, we were able to include all relevant data 
from 257 publications, some relevant data from 13 publications and no data from 774 
publications. Reasons for exclusion were similar to those described for 
neurobehavioural outcomes above, and in addition we were unable to extract data from 
216 publications which presented only histological images.  
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 All Data 
Excluded 
Some Data 
Excluded Histological images only 216 n/a 
Missing variance 114 n/a 
No data for sham group 99 1 
Qualitative 72 n/a 
Abstract without sufficient information 60 n/a 
Dichotomous data only 43 n/a 
Missing no. of animals 38 n/a 
Other measurement type 24 n/a 
Not CNS 23 n/a 
Data not shown 20 n/a 
Combined histological score 17 n/a 
Uninterpretable 12 n/a 
Unsuitable/no control 9 n/a 
Neurobehavioural & histological scores combined 5 n/a 
Images only; other measurement type 5 n/a 
No data for sham; missing variance 5 6 
Missing no. of animals; missing variance 4 n/a 
Median/range data only 3 n/a 
Images only; not CNS 2 n/a 
No data for sham; missing no. of animals 1 3 
No data for sham; unsuitable/no control 1 1 
Not CNS; other measurement type 1 n/a 
No data for sham; missing variance; missing no. of animals n/a 1 
No data for sham; unsuitable/no control; calculation error n/a 1 
TOTAL 774 13 
Table 3.2. Reasons for exclusion of publications with histological outcomes from the meta-
analysis.  
 
3.4.4. Estimates of effect size 
The number of publications, the global estimate of efficacy and the estimates of 
between study heterogeneity are summarised in Table 3.3. Overall, the magnitude of 
efficacy was greatest for axon loss (51.8% reduction (95% CI 44.9-58.8)) and least for 
the improvement in mean severity scores. Across all six outcome measures there was 
substantial between study heterogeneity, reflecting anticipated differences between 









Global Estimate of 





















MSS 454 (1892) 33.1% (31.2-35.0) 28,909 92.3% 1153 
MCCS 251 (1075) 39.1% (36.6-41.6) 15,318 93.1% 1068 

















Inflm. 191 (510) 39.9 (36.1-43.6) 5641 95.9% 1251 
Demy. 117 (246) 43.9% (38.2-49.7) 2618 95.9% 1378 
ALoss 58 (113) 51.8% (44.9-58.7) 1196 92.0% 861 
Table 3.3. Summaries of the improvement in six measures of drug efficacy in studies on EAE. 
Animals may have been used to measure efficacy for more than one outcome measure reported 
here. MSS, mean severity score; MCCS, mean clinical and cumulative score; CSLD, clinical score 
on the last day of assessment; Inflm, inflammation; Demy, demyelination; ALoss, axon loss.  
 
3.4.5. Interventions 
We identified 1560 interventions tested in EAE. For the majority (90%) of these they 
were reported in just one or two publications. Here we have reported summary 
estimates of effect size for interventions which were reported in five or more 
publications. These included 26 interventions with efficacy measured as improvement 
in neurobehavioural score, 20 for reduction in inflammation, 10 for reduction in axon 
loss and 18 for reduction in demyelination. Efficacy was highest for FTY720 
(fingolimod) when outcome was measured as an improvement in neurobehavioural 
score or a reduction in inflammation. In total, all but three interventions (12%) had a 
significant improvement in neurobehavioural scores, 9 interventions (45%) 
significantly reduced inflammation, 6 (60%) significantly reduced axon loss and 10 
(56%) significantly reduced demyelination. Only lovastatin had significant efficacy 
across all four outcome measures, followed by FTY720 which had efficacy in 3 of 3 




Figure 3.4. Point estimates of efficacy for the 37 most commonly tested interventions. 
Percentage improvement in neurobehavioural scores (A), and reduction in: inflammation (B), 
demyelination (C) and axon loss (D). Horizontal error bars represent 95% CI, vertical grey bar 
represents the global estimate and 95% CI. Symbol size represents the log of the number of 





Neurobehavioural Scores Axon Loss Demyelination Inflammation 
 
Global (95% CI) 
No. Exps 
(animals) 
Global (95% CI) 
No. Exps 
(animals) 







Aminoguanidine 4.9 (-9 to 18.8) 17 (290) 
96.6 (18.4 to 
174.8) 
1 (13) 
74 (14.9 to 
133.1) 
1 (13) 
-6.2 (-49.4 to 
37) 
7 (55) 
Anti-CD4 52.2 (33.5 to 71) 36 (464) 
4.2 (-25.3 to 
33.6) 
1 (15) 
25 (-10.3 to 
60.3) 
1 (15) 
23.3 (-4.4 to 
51.1) 
1 (15) 
Anti Tumor Necrosis 
Factor 
41 (19.2 to 62.8) 21 (360) - - - - 
-0.1 (-46.6 to 
46.4) 
5 (76) 
Bone Marrow 25.2 (17.4 to 33) 19 (456) 
15.6 (-50.9 to 
82.2) 
2 (16) 
52.2 (35.7 to 
68.7) 
3 (39) 
53.8 (-126.2 to 
233.8) 
1 (6) 
Cyclophosphamide 26.7 (2.7 to 50.6) 24 (695) - - 52.5 (-50 to 155) 1 (13) 46.6 (35 to 58.2) 21 (291) 
Cyclosporin A 22.6 (3.2 to 41.9) 34 (494) - - - - 
46.2 (11.8 to 
80.5) 
1 (16) 
Dexamethasone 26.8 (-5.3 to 58.9) 12 (193) 
37.1 (-10.1 to 
84.4) 
1 (6) 
69.2 (39.1 to 
99.2) 
1 (6) 
62.8 (17.5 to 
108.1) 
3 (31) 
Erythropoietin 37.5 (24.8 to 50.3) 22 (230) - - 
80 (19.6 to 
140.4) 
1 (14) - - 
Oestrogen Hormone 66.6 (57.3 to 75.9) 47 (688) - - 
95.1 (76.7 to 
113.5) 
6 (19) - - 
FTY720 72.7 (60.1 to 85.3) 43 (590) - - 
78.1 (53.2 to 
103) 
2 (21) 
83.3 (63.2 to 
103.3) 
6 (64) 
Glatiramer Acetate 45.7 (33.5 to 58) 26 (470) 
64.6 (30.3 to 
98.8) 
2 (24) 
14.4 (-50.1 to 
79) 
1 (12) 
19.9 (-22.3 to 
62.1) 
2 (37) 
Immunoglobulin 30.7 (19.2 to 42.2) 16 (379) - - 
-2.4 (-14.4 to 
9.5) 
1 (10) 16.5 (-9 to 42) 4 (82) 
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Interferon Beta 36.9 (17.8 to 55.9) 27 (442) 
4.1 (-37.4 to 
45.7) 
1 (11) 
17.6 (-8.6 to 
43.7) 
3 (39) 35.2 (-4 to 74.4) 4 (67) 
Interleukin 10 14.7 (3.2 to 26.2) 36 (478) - - 
-21 (-58.9 to 
16.8) 
9 (27) 8.6 (-8.8 to 26.1) 9 (43) 
Lovastatin 57.5 (33.3 to 81.6) 15 (249) 
42.6 (21.8 to 
63.4) 
2 (32) 
32.5 (22.5 to 
42.5) 
1 (18) 
75.6 (47.3 to 
103.9) 
2 (42) 
MBP 46.3 (38.3 to 54.4) 
162 
(2248) 
- - - - 
53.5 (40.2 to 
66.9) 
25 (324) 
Methylprednisolone 16.1 (-1.9 to 34.2) 21 (378) - - 
21.9 (-85.3 to 
129) 
1 (7) - - 
Minocycline 50.3 (32.5 to 68) 17 (217) 33.3 (7.7 to 58.9) 3 (38) 31.6 (5 to 58.2) 6 (72) 10.3 (-7.5 to 28) 4 (45) 
MOG 71.6 (56.6 to 86.5) 11 (157) - - 
87.3 (80.4 to 
94.2) 
1 (10) 
5.7 (-163.4 to 
174.7) 
2 (28) 
PLP 27.8 (10.3 to 45.3) 14 (174) - - - - - - 
Prednisolone 40.7 (3.5 to 78) 10 (129) 56.4 (16 to 96.8) 3 (18) 
44.6 (6.4 to 
82.8) 
5 (36) 
39.1 (-13.4 to 
91.6) 
2 (15) 
Rolipram 48.3 (23.8 to 72.8) 18 (399) 20.2 (5.6 to 34.8) 1 (14) - - 
45.9 (9.9 to 
81.9) 
7 (63) 
Spinal Cord Protein 59.9 (29.1 to 90.6) 14 (170) - - 
88 (60.6 to 
115.4) 
1 (24) 48.4 (30 to 66.8) 1 (24) 
T Cells 32.2 (16.5 to 47.8) 38 (447) - - - 
 
- - 
T Cell Receptor 39.5 (22.3 to 56.7) 22 (194) - - - 
 
- - 
Vitamin D 38.8 (27.6 to 49.9) 22 (598) - - - 
 
42.1 (33 to 51.2) 3 (56) 
Table 3.4. Global estimates of efficacy for the 37 most commonly tested interventions measured as change in neurobehavioural scores, axon loss, 
demyelination and inflammation.  
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3.4.6. Study quality 
The number of full publications (peer reviewed) and the reporting of study quality 
items are summarised in Table 3.5. Across all publications, the median quality score 
was 2 (interquartile range (IQR) 1-2). Linear regression suggested that there was a 
modest increase in study quality over time (one point increment increase in quality 
every 26 years, R2=16%; p<0.001). 
 
Study Quality Checklist Item Number of Publications (%) 
Peer reviewed publication 1382 (94%) 
Random allocation to group 157 (11%) 
Blinded assessment of outcome* Neurobehavioural outcomes: 242/1446 (17%) 
Histological Outcomes 297/1044 (28%) 
Sample size calculation 4 (<1%) 
Compliance with animal welfare regulations 500 (34%) 
Statement of a potential conflict of interest 106 (7%) 
Table 3.5. The number of publications meeting items on our study quality checklist. *1446 
publications reported neurobehavioural outcome measures and 1044 reported histological 
outcome measures. Of 1026 publications reporting both of these outcome measures, 287 (29%) 
reported blinding only one of these.  
 
We found a significantly larger estimate of efficacy for the reduction in inflammation in 
unblinded studies (47.1% (95% CI 41.8-52.4) for 254 comparisons versus 33.1% (25.8-
40.4) for 256 blinded comparisons; R2=4.01%, P<0.005, Figure 3). No other quality 
items appeared to have a significant impact on other outcome measures. 
 
We were interested to explore differences between those publications reporting their 
data in sufficient detail to allow inclusion and those which did not report such detail. 
For neurobehavioural score, the median number of quality checklist items scored was 
higher for included studies (2; IQR 1-3; n=502 versus 1, IQR 1-2; n=566; Z=-9.9, 
p<0.0001). The median year of publication for the included studies was 11 years later 
(2002, IQR 1995-2006 versus 1991, IQR 1987-1999, Z=-14.0, p<0.0001). Similarly, for 
histological outcomes median quality score was significantly higher in included 
65 
 
publications (2; IQR 2-3; n=257 v 1, IQR 1-2; n=706; Z=-5.7, p<0.001) and median year 






Figure 3.5. Impact of: blinded assessment of outcome on the percentage reduction in 
inflammation (A), the sex of the animal on the percentage improvement in mean severity scores 
(B) and the histological section assessed on the percentage reduction in demyelination (C). 
Vertical error bars represent 95% CI, the vertical grey bar represents the global estimate of 
efficacy for that outcome measure and its 95% CI and the bar width represents the log of the 
number of animals for that comparison.  
 
3.4.7. Publication Bias 
We found evidence for publication bias for all outcome measures using visual 
inspection of funnel plots, Egger regression and “trim and fill” (Table 3.2 and Figure 
3.6). Observed outcomes on the change in mean severity scores were overstated by a 
relative difference of 120.7% compared to the global effect size imputed from trim and 
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fill. This was substantially higher than the other two neurobehavioural outcomes which 
had relative overstatements of efficacy of 4% for the mean clinical and cumulative 
scores, and 0.4% for the clinical score on the last day of observation. Outcomes 
measured as the reduction in demyelination or axon loss both had substantial relative 
overstatements of efficacy (47.9% and 31.4% respectively) whereas there was 
relatively little difference between the effect size for the reduction in inflammation 
before and after trim and fill (1.9%).  
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Bias Confirmed with 
Egger regression 
+ + + + + + 
Bias confirmed with 
METATRIM 
+ + + + + + 
Additional studies 
considered “missing” 
505 40 27 14 74 46 
METATRIM adjusted 






















effect size (%) 
18.1 1.5 0.2 0.7 14.6 13.1 
Relative 
overstatement of 
effect size (%) 
120.7 4.0 0.4 1.9 47.9 31.4 
Table 3.6. The prevalence and impact of publication bias in the EAE literature as assessed by 
funnel plotting, Egger regression and trim and fill.  Column headers: MSS, mean severity score; 
MCSS, mean clinical & cumulative score; CSLD, clinical score on the last day of observation; 




Figure 3.6. Assessing the prevalence and impact of publication bias in the EAE literature using funnel plots with observed estimates of effect size (black 




3.4.8. Sample Size 
Our meta-analysis included data from 47944 animals testing neurobehavioural 
outcomes, 5641 animals testing the change in inflammation, 2618 testing the change in 
demyelination and 1196 animals on the change in axon loss. It is likely that some of the 
animals used for neurobehavioural outcomes might have gone on to contribute to 
histological outcomes, but this was not always the case and it was not always possible 
to determine which cohorts of animals contributed to which outcomes. However, the 
total number of animals contributing data to this analysis lies between 47,944 and 
57,326.  
 
The median number of animals per experimental group for neurobehavioural outcomes 
was 12 (IQR 9-17, 3221 experiments); for axon loss 10 (8-12, 113 experiments), for 
inflammation 9 (6-13, 510 experiments) and for demyelination 9 (6-14, 246 
experiments). The number of animals in an experiment did not account for any of the 
observed heterogeneity for any outcome measure.  
 
Post hoc power calculations have limited validity, but assuming an improvement in 
mean maximal severity of 33% (from our global efficacy analysis), a median standard 
error of 21% and a median of four animals in the control group and eight animals in the 
treatment group, the typical EAE study included here is powered at 64%. Based on 
these data we have provided estimates for the number of animals required to achieve 
different levels of power, the power of a study for different observed effect sizes and 





Figure 3.7. Indicative power calculations. Models of the power of a study using n number of 
animals per group when looking for an effect size of 15%, 25%, 35% or 45% (solid blue, green, 
red and grey lines, respectively, A), the power of a study when observing a specific effect size, 
using 5, 10, 15 or 20 animals per group (long dashed blue, green, red and grey lines, respectively, 
B) and the number of animals required to observe a specific effect size powered at 70%, 80% 
and 90% (short dashed blue, green and red lines respectively, C). 
 
3.4.9. Time to Treatment 
Taking all neurobehavioural scores together, for 3006 comparisons which reported the 
time quantitatively, the median time to treatment was the day of EAE induction (day 0; 
IQR -2 to 8). For 460 inflammation outcomes the median time to treatment was also 
day 0 (IQR 0 to 7), but for demyelination it was day 5 (IQR 0 to 12, 229 outcomes); and 
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for axon loss it was day 7 (IQR 0-10, 106 outcomes; Table 3.7). The remaining 
outcomes were not included in the assessment of the median time to treatment because 
they either did not report this information or it was administered relative to another 
time point such as the day of disease onset, or the time of first relapse, without further 
information to determine this time point.  
 
For the mean severity scores the time to treatment accounted for a significant 
proportion of heterogeneity between observed effect sizes (absolute reduction in effect 





Inflammation Demyelination Axon Loss 
 
N % N % N % N % 
Before Day 0 904 28 105 21 27 11 11 10 
Day 0 706 22 135 26 54 22 18 16 
Day 1-7 571 18 115 23 60 24 26 23 
Day 8-14 614 19 73 14 51 21 36 32 
Day 15+ 211 7 32 6 37 15 15 13 
Other 50 2 19 4 6 2 2 2 
Unknown 165 5 31 6 11 4 5 4 
Total Outcomes 3221 (3006) 510 (460) 246 (229) 113 (106) 
Table 3.7. The different times of administration across outcome measures which had results 
included in the meta-analysis. The number of outcomes which contributed to the meta-analysis 
for time of administration is shown in parentheses (i.e. the times of administration which were 
neither “other” or unknown). “Other” refers to the day of onset of the first neurological deficits 
or another related time period such as the day of the first relapse. 
 
3.4.10. Time of Assessment 
The time of assessment did not have any significant impact on the heterogeneity 
between effect sizes for any outcome measure. The median time of assessment did 
however vary across different outcomes, being day 28 (IQR 20-40) for the 3221 
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neurobehavioural outcomes with a reported a time of assessment, day 21 (IQR 15-32) 
for 510 outcomes on inflammation, day 32 (IQR 20-52) for 246 outcomes on 
demyelination and day 34 (IQR 21-50) for 113 outcomes on axon loss.  
 
3.4.11. Species 
Experiments were carried out in mice (713 publications), rats (583), guinea pigs (145), 
monkeys (17), rabbits (15), marmosets (8), cats (5), chickens (1) and ewes (1); a 
further 18 publications did not report the species used. We did not identify any 
experiments using chickens or ewes which had results suitable for meta-analysis. Meta-
regression did not identify a significant impact of the species on the heterogeneity in 
effect sizes for any of the neurobehavioural or histological outcome measures.  
 
3.4.12. Sex 
Experiments were most commonly carried out using female animals (793 publications) 
with 230 publications reporting using males, 99 using both males and females with a 
further 379 not reporting the sex of the animals used. The sex of the animals accounted 
for a significant proportion of heterogeneity amongst effect sizes where this was 
measured as mean severity scores. The highest effect sizes were seen when 
interventions were tested in both males and females (51.9% (95% CI 43.5-60.2; 109 
comparisons, p<0.005). Effect sizes were similar where experiments were carried out 
in males and females separately or where the sex was not reported (Figure 3.5).   
 
3.4.13. Route of Delivery 
Across all publications which had a result included in the meta-analysis we identified 
40 different routes of delivery used. The most commonly used routes of administration 
were: intraperitoneal (353 publications), oral (140), intravenous (138), subcutaneous 
(121), subcutaneous mini-pump (25), intramuscular (24), intranasal (18), 




The route of delivery accounted for a significant proportion of heterogeneity amongst 
effect sizes for the mean clinical & cumulative scores and the mean severity scores. 
Looking only at the routes of delivery which were used in 5 or more comparisons, for 
the mean cumulative and clinical scores, effect sizes were greatest when administered 
both orally and intraperitoneally (83.2% (95% CI 54.8-111.6); 8 comparisons), 
followed by using a subcutaneous mini-pump (61.2% (49.6-72.8); 50 comparisons) and 
intracerebroventricularly (57.9 (28.9-86.9); 9 comparisons). For the most common 
route of delivery, intraperitoneally, the effect size was relatively low compared to 
others (32.3 (28.3-36.3); 403 comparisons). For the mean severity scores, effect sizes 
were greatest when interventions were administered intradermally (58.6% (32.1-
85.1); 9 comparisons), followed by intrathymic (56.3 (29.2-83.4); 9 comparisons), and 
the subcutaneous mini-pump (53.2 (42.0-64.3); 50 comparisons). Similar to the 
cumulative and clinical scores, the use of intraperitoneal injection was associated with 
a relatively low pooled effect size relative to others (28.5% (25.5-31.6); 659 




Figure 3.8. Estimates of efficacy measured as (A) improvement in mean clinical & mean 
cumulative scores, and (B) mean severity scores for different routes of administration. The 
vertical grey bar represents the global estimate of efficacy and its 95% CI. Symbol size 
represents the log of the number of animals for that comparison. 
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3.4.14. CNS Section Analysed 
The majority of histological outcomes were assessed in the spinal cord (282 of 586 
comparisons on inflammation; 142 of 262 outcomes on demyelination and 67 of 116 
outcomes on axon loss) followed by the combination of the spinal cord and brain (163 
outcomes on inflammation, 87 on demyelination and 43 on axon loss). We found a 
significant impact of the CNS section analysed on the heterogeneity between effect sizes 
for demyelination (Figure 3.5C; p<0.005). Specifically, effect sizes were greatest when 
outcome was assessed in the spinal cord (53.4% (IQR 46.0-60.7) compared to the brain 
(46.4% (28.2-54.7)) and both the brain and spinal cord together (26.6% (14.5-38.7)).  
 
3.4.15. Neurobehavioural scoring method 
We used publications from the year 2000 onwards to summarise the clinical scores 
used to measure EAE. In total this comprised 676 publications. 584 described the 
clinical status of the animal on an ascending scale, typically from grade 0 to 5 where 0 
referred to a normal animal in all but one publication (where it represented a limp tail) 
and 5 typically referred to either tetraplegia, hindlimb paralysis with forelimb 
weakness and/or moribund or death.  Ascending paralysis was typically scored (with 
greater or less detail) as: fully limp tail/tail paralysis (1 point), increasing hindlimb 
weakness and/or forelimb weakness (2), forelimb weakness (3) tetraplegia (4) and 
moribund or death (5 or 6 points). 30 publications described using half points for 
intermediate clinical findings without further description and a further 119 described 
details for half points; however 41 of these reported a half point as the first clinical 
grade (usually referring to partially or fully limp tail) without any further intermediate 
increments. Additionally 3 publications reported 0.25 as the first clinical score 
(referring to distal tail limpness). A further 18 publications didn’t give sufficient 
information to describe the clinical scale, and 48 publications were abstracts with no 
details of the scale used. The maximum scale described in full went up to 11, with 4 
publications reporting a ten point scale. The least descriptive scores were on a 2 (one 





Here we have described a broad systematic review and meta-analysis of all the studies 
testing interventions in EAE, which to our knowledge is the largest in any field of 
animal research. Despite the broad nature of this review whereby we have grouped 
different EAE models and interventions tested, we have generated a number of 
potentially interesting hypotheses relating to study design, as well as a number of 
serious shortfalls in the reporting in this literature.  
 
3.5.1. Reporting in the EAE literature 
The reporting of information is essential to allow the reader to reach an informed view 
of the importance and validity of the reported findings; and indeed to allow inclusion in 
a meta-analysis, was very low. This information includes fundamental data such as the 
number of animals, the mean and a measure of variance for both a treatment and 
control group. Almost half of all peer reviewed publications did not report at least one 
of these. This problem is certainly not unique to the EAE literature however as 
reporting has been found to be poor across the preclinical literature in the life sciences 
(du Sert, 2011; see also Chapter 5). Promisingly though, more and more journals are 
adopting reporting guidelines (Kilkenny et al., 2010) and there is now a modified 
version of the ARRIVE guidelines which are considered most important to the EAE 
literature (Baker and Amor, 2012). We also draw some reassurance from the 
observation that in more recent years the proportion of studies excluded for these 
reasons appears to be falling. 
 
3.5.2. Study Quality and Publication Bias 
In addition to our concerns about reporting, we noted that few publications reported 
measures to reduce bias (random allocation to group and blinded assessment of 
outcome). Our analysis only identified that blinding was significant for inflammation 
outcomes, with higher estimates of efficacy seen in publications which did not report 
blinding. However, we have consistently shown across a number of domains that these 
measures to reduce bias are of importance and moreover, that the prevalence of these 




Only four publications reported a sample size calculation, which may reflect the 
difficulty of performing a meaningful power calculation without a prior meta-analysis 
such as we have performed here. We have therefore used these data to produce some 
guidance as to sample sizes required to give various levels of power. Our post hoc 
power calculation suggests that half the experiments included in this analysis are 
powered at less than 64%. 
 
3.5.3. Time to Treatment 
For the best possible chance of successful translation of efficacy from bench to bedside, 
the design of clinical trials should reflect the conditions in which efficacy has been 
observed in animals. However, in turn these animal experiments should reflect 
plausible study design characteristics of human clinical trials. For both 
neurobehavioural scores and inflammation outcomes, treatments were most commonly 
administered on the day of EAE induction, an observation also made of the SOD1 mouse 
model of motor neuron disease (Benatar, 2007). Furthermore, for mean severity scores 
the effect size dropped with increasing time to treatment. However, interestingly the 
time to treatment was found to be later in experiments reporting demyelination and 
axon loss outcomes. 
 
In EAE, interventions may be efficacious by blocking the induction of disease (where 
mechanisms such as sequestering immunogen or inhibiting the initial immune 
response may be most relevant) rather than through an effect on the primary 
pathophysiology of neuronal and glial injury or the evolution of neurological 
impairment over time. The relevance of such studies to the development of 
interventions for established relapsing–remitting disease, primary and secondary 
progressive disease is not clear. It could be argued that efficacy in EAE studies might 
only be predictive of efficacy in clinical trial if treatment were started after the onset of 
symptoms (some days after induction), as we presently have no way of identifying 




Finally, disease burden in MS reflects a complex interplay between inflammation, 
demyelination, remyelination and neurodegeneration with a temporal shift in 
pathological emphasis from inflammation to neurodegeneration; further work is 
required to describe the characteristics of different EAE models in these different 
domains. Thus, it may be that some of the difficulties in translating efficacy from 
animals to man arises because data from appropriately designed studies modelling MS 
pathophysiology do not provide sufficient insights to likely efficacy in human disease, 
where different endpoints might be considered key, and longer delays to the initiation 
of treatment are unavoidable. 
 
3.5.4. Study Design 
We found that the route of delivery had a significant impact on the effect size for both 
mean severity scores, and mean clinical and cumulative scores with subcutaneous 
pump showing a consistently high effect size across both outcomes and intraperitoneal 
injection showing a relatively low effect size for both. Additionally we found that effect 
sizes were greater for demyelination when the outcome was measured in the spinal 
cord.  
 
The most common outcome measure reported across all publications included in the 
systematic review was neurobehavioural scores of which the mean severity score was 
most often reported. Of the histological outcome measures inflammation was most 
commonly reported followed by demyelination and axon loss. However it was 
interesting to note that demyelination was often reported without any mention of 
axons (251 publications). As suggested previously (Baker et al., 2011), this is not 
necessarily indicative of primary demyelination because axon loss may have occurred, 
or inflammatory infiltrates may have displaced the axons (and thus in both cases there 
is no myelin to lose). It is therefore possible that where we have reported 
demyelination as our outcome measure, this may actually be more indicative of a 
change in inflammation.  
 
Across publications we found very little consistency in the grading system for 
neurobehavioural outcome. Different species have different clinical courses and so 
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whilst it is conceivable for scoring systems to reflect this, there was substantial 
heterogeneity in scoring even within one species. For human clinical trials the 
expanded disability status score (EDSS) is commonly used (Kurtzke, 1983). Like the 
majority of scoring systems for EAE experiments, this is a physician assessed and 
measures increasing disability on an ordinal scale from 0 to 9.5. Endpoints in clinical 
trials are discussed and reported on in some detail to ensure that they are able to 
capture the finer details between patient cohorts. However there appears to be very 
little discussion of the outcome measures used to assess disease in preclinical research.  
 
Using behavioural scales to score EAE is subjective and may vary substantially across 
observers. A wide range of objective neurobehavioural outcome measures exist in, for 
example, the preclinical PD literature (Chapter 4), and yet very few publications report 
objective measures in the EAE literature. Clearly the two (broad) disease models are 
very different in their clinical presentation – in EAE, the rotarod for example might not 
be able to differentiate between mild hindlimb weakness with mild forelimb weakness, 
and severe hindlimb weakness with severe forelimb weakness. Perhaps more 
importantly however is whether the current scoring convention is able to robustly 
measure something that is clinically relevant. Axon loss is considered to be the main 
cause of permanent disability in humans, and so the question is whether 
neurobehavioural scores accurately reflect this pathological change.    
 
3.5.5. Efficacy of Interventions 
The value of a global estimate of efficacy for individual interventions tested in a 
number of unique study design paradigms without an assessment of heterogeneity is of 
limited value. However, we have presented data for the most commonly tested 
interventions in a transparent manner which allows the reader to make inferences 
about the robustness of the experimental data. We have shown here that for a number 
of these interventions there is clear heterogeneity and it demonstrates the need to 
carefully examine the data when there is the potential to use it to inform further clinical 
trials or animal experiments. In our dataset, aminoguanidine was ranked 26th (worst) 
out of 26 interventions for improvement in neurobehavioural scores and 18th out of 18 
interventions for reduction in demyelination; conversely it was ranked 1st (best) out of 
10 interventions for reduction in axon loss and 6th out of 18 interventions for reduction 
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in inflammation. Careful (post-hoc) inspection of the data reveals that there was 
substantial variability in the design of experiments testing aminoguanidine: four routes 
of delivery were used, five different times of administration, of which all but four 
experiments administered the intervention on day 2 or before, two different 
immunogens were used to induce disease, and mean sample sizes across the treatment 
and control groups ranged from 3 to 25 animals. These data should therefore just be 
used as a tool to recognise where further research or careful inspection of data should 
be undertaken.  
 
Interestingly, our broad meta-analysis identified FTY720 as a strong candidate 
intervention. FTY720 was licensed for clinical use in 2010 (under the name of Gilenya) 
as the only current oral intervention for MS and has been shown to have substantial 
efficacy in reducing annualised relapse rate in RRMS patients. With time it will become 
clear whether FTY720 has any effect in the halting neurodegeneration in progressive 
MS. Lovastatin also came out favourably and was the only intervention to have 
significant efficacy across all four outcome measures. However there is limited 
evidence on lovastatin clinically, and to our knowledge no randomised control trials 
have been conducted. An up to date systematic review and meta-analysis of lovastatin 
in animal models of MS would therefore be useful to assess whether robust evidence 
exists to warrant a clinical trial.    
 
3.5.6. Study Limitations 
Meta-analyses can only include data from literature which have adequately reported 
data; as such this review includes a limited number of the total relevant publications. 
We have no doubt that this selection bias will have an impact on the results reported 
for measures of effect size; however, we were still able to include data from over 800 
publications. It is difficult to judge whether the publications which were not included in 
the meta-analysis would be inherently different to those which were included; however 
we have no reason to believe that they would be any more likely to reflect more 




Another source of selection bias in a meta-analysis is publication bias which we have 
found to be prevalent across all of the outcome measures in this review. With such a 
large number of publications being excluded due to poor reporting, it may be that the 
“missing” studies identified in our analysis of publication bias were within those 
identified but excluded. Again though we have no reason to believe that the excluded 
studies are any more likely to report negative results than those which had data 
included. In fact, had we been able to include these studies we may have identified an 
even stronger publication bias.  
 
On this dataset our pre-specified approach for analysis was to use meta-regression as 
opposed to stratified meta-analysis. Meta-regression is a conservative approach, and in 
our experience (see Chapter 7), stratified meta-analysis on such a large dataset tends to 
identify such a large proportion of significant differences that it is difficult to judge 
whether this these differences reflect true underlying differences in the dataset (which 
may well be true), or whether it is a statistical artefact. Extensive modelling of these 
statistical tests on this dataset will shed light on the differences between these 
statistical tests but we believe it was nonetheless important to use the approach we 
know to be more conservative for this analysis. 
 
Another criticism of our approach is the grouping together of EAE studies. There are a 
number of EAE models which follow different disease courses and show different 
underlying pathologies depending on a number of factors including animal species, 
strain, sex and the immunogens used to induce disease. In this review our focus was on 
the reporting in the EAE literature and to identify if there is any homogeneity within 
such an inherently heterogenous disease model. Additionally our approach provides an 
overview which will allow for more detailed reviews to be carried out on any particular 
drug of interest to the research community and enables comparisons to the results 
described here. The entire dataset on which this analysis is based is available at 
www.camarades.info. 
 
Further limitations to this study and systematic review & meta-analysis in general are 





EAE has proven immensely valuable in modelling inflammatory aspects of MS and has 
led to many insights into disease mechanism as well as several licensed treatments for 
early disease courses. However, there remains a great need to identify the next 
generation of therapeutics that will particularly target the unmet need of treatment for 
the progressive phase of disease. However, in this, the largest systematic review of 
animal studies to date, we have shown that the testing in animals of candidate 
interventions for MS has potentially been confounded by limited internal validity (with 
little reported use of randomization, blinding and power calculations), limited external 
validity (with few treatments given at clinically appropriate time points), and 
inadequate reporting. Numerous efforts are now in place to address these issues, 
including the ARRIVE guidelines. This dataset provides evidence that these guidelines 








4. A systematic review and meta-analysis of dopamine 
agonists tested in preclinical models of Parkinson’s disease 
 
I acknowledge the following for their contribution to this research: Evelien Rooke (ER; 
conducted the initial electronic search and data extraction in 2007); Emily Sena (ES), 
Kieren Egan (KE) and Macleod Macleod (MM; all were involved in various aspects of 
the study design process, reference screening, data checking and manuscript editing). 
My contribution includes updating the literature search and data extraction. I 
conducted both the original and updated analysis of the data.  
 
4.1. Background 
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
behind Alzheimer’s Disease (de Lau and Breteler, 2006b). There is a sharp increase in 
the prevalence of PD over the age of 60, with estimates suggesting that as much as 1% 
of this population may be affected (de Lau and Breteler, 2006a), with a lifetime risk of 
1.5% (Lees et al., 2009). The pathological hallmark is the loss of dopamine (DA) 
containing neurons in the substantia nigra pars compacta (SNc), and formation of lewy 
bodies in the surviving cells (Schapira and Jenner, 2011). In turn, this leads to the 
clinical presentation of resting tremor, rigidity, postural instability and bradykinesia 
(Jankovic, 2008). However, these symptoms typically appear when neuronal death has 
exceeded a threshold, somewhere in the region of 70-80% in the SNc (Golde, 2009). As 
with MS, our understanding of the aetiology of PD is unclear, but similarly considered 
to be due to the interplay between genetic susceptibility and an environmental trigger 
(Schapira and Jenner, 2011, Lees et al., 2009), and these two factors define the two 
most common types of animal model for PD (Jackson-Lewis et al., 2012, Duty and 
Jenner, 2011, Bezard and Przedborski, 2011).  
 
There are a number of symptomatic treatment options for PD and these have continued 
to increase with the development of new classes of drugs and new formulations of 
existing drugs. However there remains a need to identify interventions which reliably 
achieve substantial efficacy with minimal adverse effects. Although dopamine agonists 
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should seemingly offer the most pragmatic approach to a disease defined by a 
reduction in dopamine, clinical evidence has not always been convincing (Antonini et 
al., 2009, Stowe et al., 2008, Clarke and Guttman, 2002).  Dopamine itself is unable to 
cross the blood brain barrier and so instead, its precursor, L-DOPA was, and still is a 
popular first-line agent (Rascol et al., 2011). However, L-DOPA is associated with 
motor-complications with longer term use (Thanvi and Lo, 2004) and may even 
accelerate neuronal death (Fahn et al., 2004). A number of dopamine agonists have 
since progressed to clinical use for the symptomatic mono-therapeutic treatment of all 
stages of the disease; or alternatively they are used as an adjunct to reduce L-DOPA 
related motor adverse effects (Antonini et al., 2009). Although they are generally 
considered less efficacious than L-DOPA in relieving motor symptoms, they are 
typically used to reduce L-DOPA associated motor complications. (Bonuccelli et al., 
2009). In addition dopamine agonists are more limited by their numerous adverse 
effects, sometimes so severe that the only viable option is treatment cessation (Lees et 
al., 2009). Despite these setbacks, the clinical efficacy of dopamine agonists has kept 
them in the running as a potential therapeutic option.   
 
4.2. Aims and Objectives 
Our primary aim was to assess the impact of study quality and study design 
characteristics on efficacy reported in the literature on dopamine agonists tested in 
animal models of PD. Specifically our objectives were to: (1) identify publications 
reporting the use of a dopamine agonist in an animal model of PD; (2) report summary 
estimates of efficacy; (3) identify the impact of study design and study quality on the 
reported efficacy; (4) assess for the presence and impact of any publication bias; (5) 
describe the limits and potentials for clinical success; and (6) compare and contrast 





4.3.1. Electronic search 
We identified studies reporting the use of a dopamine agonist in an animal model of PD 
by electronic searching of Pubmed, ISI Web of Science and Embase in September 2009.  
Our search terms were: [Parkinson’s disease] AND ([1-methyl 4-phenyl 1,2,3,6-
tetrahydropyridine OR MPTP OR 1-methyl 4-phenyl pyridinium OR MPP+ OR 6-
hydroxydopamine OR 6-OHDA OR Paraquat OR Maneb OR Rotenone OR 3-nitrotyrosine 
OR Alpha-synuclein OR Reserpine OR Methamphetamine]). Two investigators (ER & 
HV) independently screened all references, with differences clarified by discussion with 
a third investigator (ES). 
 
4.3.2. Inclusion and exclusion criteria 
We included publications in the systematic review if they described the use of a 
dopamine agonist in an animal model of PD where efficacy was measured against a 
neurobehavioural outcome. Outcomes were included in the meta-analysis if the 
number of animals per group, mean outcome and its variance (SEM or SD) were 
reported. We defined a dopamine agonist as a drug with reported agonism at at least 
one class of dopamine receptor irrespective of actions at other dopamine or other 
receptor classes. We therefore made no judgement as to whether dopamine agonism 
was the principal mechanism of action. Indirect dopamine agonists (e.g. the dopamine 
precursor L-DOPA) were specifically excluded. We also excluded studies where 
apomorphine was used exclusively to confirm successful lesioning as part of an 
experimental protocol not testing the efficacy of dopamine agonists.  
 
4.3.3. Data Extraction 
Neurobehavioural outcome measures used were categorised into one of seven 
groupings for further analyses (Table 4.1). Where outcomes were measured repeatedly 
we chose the time at which efficacy was greatest. Information was extracted for aspects 
of quality (see section 4.3.4) and experimental design (animal species and strain, sex, 
intervention tested, anaesthetic used during disease induction). For neurobehavioural 
outcomes the number of animals, mean and variance (standard error of the mean or 
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standard deviation) for the treatment and control group were extracted as well as the 
dose, route of administration and time of administration and assessment. The time of 
lesioning was set to zero and the time of drug administration expressed relative to this.  
 
Neurobehavioural Outcome Description 
Motor activity requiring 
sensory input (MASI) 
Number of mistakes or “no response” errors; pellets 
eaten; steps reached; reaction time (correct 
responses); startle response. 
Spontaneous activity Locomotor/spontaneous activity (measured as beam 
crossings); time spent in: body displacement, 
shuffling, head movement, locomotor activity, 
grooming, jumping, rearing. 
Skilled motor activity Catalepsy; errors per step, number of steps or time to 
traverse on a beam; retention time on rotarod; 
initiation time for stepping; grasping time or hanging 
time. 
Rotational Behaviour Number of spontaneous or drug induced rotations. 
Limb asymmetry Right biased swing; goal directed limb movements; 
contralateral turns or pivots; adjusting steps in 
backhand or forehand direction; turns to the right in 
a maze; ipsilateral rotations; right hand use. 
Parkinson’s disability rating Akinesia score; Parkinson’s rating score (usually out 
of 5); disability score; bradykinesia score. 
Balance and gait Stepping length or width (gait); ankle extension or 
flexion; posture; balance; rigidity. 
Table 4.1. Grouping of the different outcome measures to one of six categories for analysis. 
 
4.3.4. Methodological quality 
We assessed the quality of included studies against our six point checklist as described 
in Chapter 2 (section 2.1.3).  
 
4.3.5. Data analysis 
We calculated SMD effect sizes (section 2.2.2) and pooled these using the random 
effects model (section 2.2.4). To assess the impact of study quality and design 
characteristics we took all neurobehavioural outcomes together and used stratified 
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meta-analysis (Section 2.3.2). Our pre-specified analysis included testing the impact of: 
species, sex, route of administration, time of administration, anaesthetic used during 
lesioning, sample size, aggregate quality score, random allocation to group, blinded 
assessment of outcome, method of lesioning, the intervention tested and the 
neurobehavioural score used.  For either random allocation to group or blinded 
assessment of outcome we pre-specified that if either had a significant impact on 
efficacy in the stratified meta-analysis we would use meta-regression to explore 
whether these had a particular influence on specific outcome measures.  
 
To assess for publication bias we used funnel plotting, Egger regression and trim and 




4.4.1. Search results 
We identified 252 published articles (215 full publications and 37 abstracts) from the 
electronic search, and hand searching identified one unpublished thesis (Appendix 3). 
This review includes data from articles published between 1975 and September 2009, 
with the greatest number published in 2008 (Figure 4.1). Together these reported the 
use of 74 unique dopamine agonists in animal models of PD (Figure 4.2). We were 
unable to include data from 132 publications in the meta-analysis because: (1) they did 
not report critical information such as results from a control group (82 publications); 
data were insufficient or had subsequently been published in greater detail (37 
publications, mostly abstracts), or they used apomorphine as a screening tool to assess 
the level of dopamine depletion (13 publications). The remaining 121 publications (116 
full publications and 5 abstracts) using 47 dopamine agonists reported at least one 
neurobehavioural outcome in sufficient detail to allow meta-analysis. 46 of 121 
publications described crossover studies, where each animal served as its own control, 
with performance under control conditions generally assessed before the treatment 
phase. This review is therefore based on data from 253 sources, and we have been able 
to perform meta-analysis on a subset of 121 publications which included data from 601 
experiments involving 4181 animals. 
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Ten interventions with at least some dopaminergic activity have been, or are in current 
clinical use for PD. Interestingly, for all but pramipexole, data on its use in human 
clinical trials of PD were published before data from animal models of PD (Table 4.2).  
 
 
Figure 4.1. Time course of publications. A histogram showing the number of included articles 










4.4.2. Efficacy of dopamine agonists 
Overall, neurobehavioural outcome was improved by 1.10 SD (95% CI 0.99 to 1.22; 
n=601 comparisons). The efficacy of 47 individual interventions ranged from an 
improvement of 6.57 SDs (0.75 to 12.4) for BAM-1110 to a significant worsening of           
-1.35 (-2.49 to -0.21) for Amantadine (Figure 4.3 and Appendix 5). Overall 29 
interventions significantly improved outcome, only 1 made it significantly worse, and 
17 drugs had no significant effect on outcome. We grouped the outcome measures used 
into seven broad categories (Table 4.1), and these accounted for a significant 
proportion of the between study heterogeneity, with largest effects seen when outcome 
was measured on various Parkinsonism disability rating scales (χ²= 136.6, df=6, 
p<0.004, Figure 4.4A). 
 
For the majority of the ten interventions which are in clinical use, we were able to 
identify a relatively large dataset on their use (Table 4.2). However, we were only able 
to identify one source on amantadine. Data from this publication was suitable for meta-
analysis, although the overall effect size was negative (-1.35 SD (95% CI -2.49 to -0.12)). 
Cabergoline was also found to show no overall improvement. The other 8 interventions 





No. Of Publications1 
(Experiments) 
Average Quality 
Score (out of 6) 
Estimate of Efficacy 
(95% CI) 
First Published     
Animal PD Study 
First Published Human 
PD Trial2 
Amantadine 1 (4) 1 -1.35 (-2.49 to -0.21) 2008 1969 (Schwab et al.) 
Apomorphine 123 (89) 0.6 1.54 (1.19 to 1.9) 1975 1951 (Schwab et al.) 
Bromocriptine 32 (58) 0.4 0.96 (0.73 to 1.19) 1982 1976 (Lieberman et al.) 
Cabergoline 11 (13) 0.6 0.73 (-0.24 to 1.7) 1994 1990 (Jori et al.) 
Lisuride 8 (10) 0.1 1.5 (0.98 to 2.03) 1984 1979 (Lieberman et al.) 
Pergolide 13 (14) 0.5 1.01 (0.26 to 1.76) 1980 1979 (Lieberman et al.) 
Piribedil 8 (26) 0.8 1.07 (0.48 to 1.66) 1992 1974 (Sweet et al.) 
Pramipexole 7 (14) 0.6 1.31 (0.67 to 1.96) 1992 1995 (Hubble et al.) 
Ropinirole 16 (23) 0.7 1.85 (1.39 to 2.32) 1991 1989 (Kapoor et al.) 
Rotigotine 4 (10) 1.5 1.8 (1.1 to 2.51) 2007 2003 (Blindauer et al.) 
Table 4.2. A summary of the evidence from animal studies on interventions with some dopaminergic activity which are in clinical use. 1For references see 




Figure 4.3. Estimates of efficacy of 47 dopamine agonists. The vertical grey bar represents the 
global estimate of effect size and its 95% CI. Horizontal error bars represent 95% CI and symbol 
sizes represent the log of the number of animals for that intervention. Interventions shown in 




4.4.3. Methodological quality 
Few studies reported measures to avoid bias (Table 4.3); the median number of quality 
items scored was 2 out of a possible 6 (interquartile range 1-2) (Appendix 4). Of 253 
publications included in our systematic review, 207 publications (81%) were published 
in a peer reviewed journal, random allocation to group was reported by 40 publications 
(16%), blinded assessment of outcome by 38 publications (15%), and a sample size 
calculation by only 1 publication (<1%). Compliance with animal welfare regulations 
was reported by 100 publications (40%) and a potential conflict of interest by 6 











Random allocation to group 16% 11% 36% 16% 
Blinded assessment of outcome 15% 30%* 29% 22% 
Compliance with animal welfare regulations 40% 34% 57% 56% 
Sample size calculation <1% <1% 3% 0% 
Conflict of interest statement 2% 7% 23% 13% 
Table 4.3. Study quality assessment. The  percentage of publications reporting to meet each 
quality item in the preclinical literature on four neurological diseases, including PD, EAE, focal 
cerebral ischaemia (FCI; (Sena et al., 2007a))  and Alzheimer’s disease (AD; Egan et al, 
manuscript in preparation). The number of publications included in the systematic review for 
each disease is shown in parentheses at the top of each column. *17% of 1446 publications 
reporting neurobehavioural outcomes and 17% of 1044 reporting histological outcomes. 
 
Collectively for all neurobehavioural outcomes there was an inverse relationship 
between study quality and effect size (Figure 4.4B) (χ²=102.3, df=4, p<0.004). 
Reporting of blinded assessment of outcome was associated with significantly smaller 
effect sizes (0.85 SD, 95% CI 0.64 to 1.07, 144 comparisons) than those that did not 
(1.18 SD, 95% CI 1.05 to 1.31, 457 comparisons; χ²=64.4, df=1, p<0.004). Using meta-
regression we found that blinding had a different impact on each outcomes measure 
with the biggest differences seen between skilled motor activity and spontaneous 





Figure 4.4. The improvement in different neurobehavioural outcomes (A), and the effect of 
aggregate quality score (B) blinded assessment of outcome (C) and mean sample size (D) on the 
estimates of effect size, and a funnel plot (E) to test for the presence of publication bias. In A-D 
horizontal error bars represents the 95% CI of overall efficacy; bar width reflects the number of 
animals used. In E the vertical grey bar represents the global estimate of efficacy. 
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4.4.4. Sample size 
The median number of animals was 5 in the treatment group (IQR 4 to 8) and 2 in the 
control group (IQR 1 to 4) giving a median total number of animals per group as 8 (IQR 
5 to 12). The number of animals per group accounted for a significant proportion of 
between group heterogeneity (χ²=57.4, df=4, p<0.004); however there was no clear 
trend between the sample size and reported effect size (Figure 4.4D). 
 
4.4.5. Publication bias 
Our analysis on publication bias was conducted on effect sizes calculated from 876 pre-
nested experiments. Funnel plot inspection and Egger regression suggested a 
preponderance of imprecise studies overstating efficacy which is consistent with 
publication bias (Figure 4.4E), but this was not confirmed by the “trim and fill” iterative 
approach. 
 
4.4.6. Study design characteristics 
vii. Parkinson’s disease model 
Of the 253 publications identified in the systematic review, ten different methods of 
inducing experimental PD were reported. The most common were: 6-
hydroxydopamine striatal lesioning was reported in 136 publications, followed by 
MPTP (105) and reserpine (22). Seven lesioning methods were used in the 121 studies 
included in the meta-analysis, and the method of lesioning accounted for a significant 
proportion of the between study heterogeneity (χ²=197.7, df=6, p<0.004); 
interventions were most effective when disease was modelled by rotenone lesioning, 
whereas dopamine agonists did not improve outcome when the lesion was induced in a 
transgenic mouse model by over-expression of mutated alpha synuclein (Figure 4.5).  
 
viii. Species 
Dopamine agonists were tested in rats (141 publications), non-human primates (101), 
mice (21) and guinea pigs (1) and in one publication the species used was not reported. 
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The animal species accounted for a significant proportion of between study 
heterogeneity (χ²=44.1, df=3, Figure 4.5B); however effect sizes were comparable 
across all species apart from experiments using guinea pigs which was likely due to the 
small sample size.   
 
ix. Sex 
Experiments were most commonly conducted using male animals (130 publications), 
followed by both males and females (31 publications) and females alone (30 
publications). A further 69 publications did not report the sex used. Overall the sex of 
the animals accounted for a significant proportion of between study heterogeneity 
(χ²=58.7, df=3, Figure 4.5C); effect sizes were largest when males were used or when 
the sex was not reported. However the latter may be more of a reflection of study 
quality.   
 
x. Anaesthetic 
Eleven anaesthetics (or combinations) were used during the induction of lesioning for 
experiments with data included in the meta-analysis and these accounted for a 
significant proportion of between study heterogeneity (χ²=52.1, df=10, Figure 4.5D); 
isoflurane was associated with the largest effect sizes, and diazapem & ketamine when 
used in combination were associated with an overall worsening in outcome. Across all 
of the publications in the systematic review, the majority of experiments were 
conducted without using an anaesthetic (71 publications). For 67 publications the 
lesioning method used would suggest that an anaesthetic would have been 
administered, but for these publications it was not reported. The next most common 
anaesthetics included pentobarbital (40 publications), chloral hydrate (22) and 
ketamine (21). 
 
Time of administration 
The median interval between lesioning and administration of treatment was 28 days 
(IQR 13 to 70) and this accounted for a significant proportion of between study 
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heterogeneity (χ²=35.4, df=6, Figure 4.5E). However there was no clear trend between 
the age of the lesion and efficacy.  
 
xi. Route of administration 
For 121 publications with data suitable for meta-analysis, the subcutaneous route of 
delivery was most commonly used (63 publications), followed by intraperitoneal (38), 
oral (19), intramuscular (10), dermal (5), striatal (2) and intracerebroventricularly (1) 
and 3 publications did not report the route of delivery.  Route of delivery accounted for 
a significant proportion of between study heterogeneity (χ²=25.7, df=7, p<0.004, Figure 
4.5F). Of the four most commonly used routes of delivery, subcutaneous injection was 




Figure 4.5. The impact of the method of induction of injury (A), animal species (B), sex (C), 
anaesthetic used during lesioning (D), time to treatment following lesioning (E) and route of 
intervention administration (F) on the estimates of efficacy. Horizontal error bars represents 
the 95% CI; vertical grey bar represents the global estimate of efficacy and its 95% CI; symbol 




4.5.1. Efficacy of dopamine agonists 
Dopamine agonists are routinely used in the management of PD, and we have shown 
here that several have substantial reported efficacy in relevant animal models. Of the 
ten interventions with at least some dopamine agonist activity used clinically 
(amantadine, apomorphine, bromocriptine, cabergoline, lisuride, pergolide, peribidel, 
pramipexole, ropinirole and rotigotine), eight had significant efficacy; cabergoline was 
without effect and amantadine resulted in a significant worsening in outcome. 
Interventions with the highest (BAM-110) and lowest (amantadine) efficacy each were 
reported in only one publication, and because of this and the absence of head-to-head 
comparisons no reliable conclusions about the rank order of potency can be drawn.  
 
It is possible that since this analysis was conducted, further research on amantadine in 
animal models has been conducted. Moreover, our search strategy was broad but not 
deep which may have missed relevant publications from our final list, including those 
on amantadine. Interestingly however, a systematic review of amantadine in clinical 
trials found no reliable effect (Crosby et al., 2003). Conversely, rotigotine had higher 
efficacy and relatively high study quality in the animal models, and moreover, 
rotigotine appears to be a good exemplar of animal data supporting a successful clinical 
treatment as it has shown to be effective in humans (Blindauer et al., 2003).  
 
4.5.2. Study Characteristics 
Our results suggest that dopamine agonists were most potent when tested in male 
animals (discussed in section 4.5.6), in guinea pigs, using the subcutaneous route of 
delivery and when rotenone was used as the experimental model and when isoflurane, 
chloral hydrate or pentobarbital anaesthesia was used. No improvement was seen in 
the alpha-synuclein transgenic model; however it is unclear whether this is a biological 
phenomenon, or these associations are confounded by the quality of the literature. 
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4.5.3. Study Quality 
Measures to avoid bias were infrequently reported. While it is possible that some 
authors might have taken such measures but not reported them, in the experimental 
stroke literature there were no significant differences between actual and reported 
study quality (Samaranayake, 2006), and the same may hold here. This is important 
because we have shown that across a range of animal experiments modelling stroke 
and multiple sclerosis, publications which do not report such measures substantially 
overstate efficacy (Macleod et al., 2008, Macleod et al., 2005c, Sena et al., 2007b, 
Vesterinen et al., 2010). Here we have shown that the same holds for animal 
experiments modelling PD. Because of this our findings for efficacy should be 
interpreted with some caution, and a more detailed review would be required fully to 
assess the impact of these factors. 
 
In addition to these concerns about the quality of studies included in the review a 
further 83 publications could not be included because they had no control group, they 
reported data without reporting its variance, it was not possible to interpret the data as 
presented or too few animals were used per group for an effect size to be calculated.  
 
We hypothesised that study quality would be increasing over time and conducted a 
post-hoc regression analysis to test this (in Sigmaplot Version 11). Encouragingly we 
identified that there was a significant trend with a point increase in quality every 18 
years.  
 
4.5.4. Sample Size 
Animal experiments should be designed to be large enough to have a reasonable 
prospect of detecting a biologically significant difference yet small enough to minimise 
unnecessary use of animals. The required size can be estimated using a sample size or 
“power” calculation, but only one publication reported a sample size calculation. 
Overall the median number of animals per group was five for the treatment groups 
(IQR 4-8) and 2 for the control groups (IQR 1-4). As mentioned in Chapter 3, post-hoc 
power calculations have limited validity, but with a median effect size of 1.12 SD and a 
pooled variance of 0.648, 50% of experiments included in this analysis were powered 
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at 40% or less, that is to say they only had a two in five chance of detecting the 
outcomes reported.  
 
Taken together, these findings provide further support for the development of 
guidelines regarding the conduct (van der Worp et al., 2010a) and reporting (Kilkenny 
et al., 2010) of animal studies. 
 
4.5.5. Publication Bias 
Both funnel plotting and Egger regression suggested publication bias, but this was not 
confirmed by “trim and fill” analysis, in contrast to the experimental stroke literature 
(Sena et al., 2010). This analysis is based on the subset of 121 studies included in the 
meta-analysis, and it may be that were it possible to include the other studies then 
publication bias might indeed have been found. Furthermore, it has been suggested 
that trim and fill is an overly conservative statistical approach to the detection of 
publication bias (Schwarzer et al., 2010), and it may be that with other techniques such 
as the Copas selection model, or a larger dataset, publication bias would be seen. 
Research summaries and considerations about taking novel treatments to clinical trial 
can only assess available data, and given the suggestion that publication bias may exist 
in this literature we advocate the development of research registries similar to those 
adopted in clinical research, that such unpublished sources of data might be identified 
in the development of research summaries.  
 
4.5.6. Comparison with pre-clinical EAE literature 
There were some similarities and differences across the experimental PD and EAE 
literature (Table 4.4). The median quality score were the same and the sample size 
comparable - albeit slightly smaller in pre-clinical PD experiments. However this may 
be explained by the substantially larger proportion of non-human primates used in the 
PD literature (38%) compared to EAE literature (2%). Notable differences included the 
sex ratios and the median time to treatment. The use of females was over four times 
more prevalent in the preclinical EAE literature compared to males which reflects the 
differences in the human condition. Although the evidence has not always been 
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consistent, particularly in predicting the sex ratio, there is substantial evidence from 
epidemiological studies that MS is more prevalent in females and PD is generally 
considered more prevalent in males (Burn, 2007).  
 
Whereas the time to treatment in the EAE literature was commonly on or before the 
time of EAE induction, it was commonly given a month after lesioning in the preclinical 
PD literature. Interventions in MS are aimed at halting progression (disease modifying 
drugs) in a disease marked by neurodegeneration, and outcome is therefore typically 
measured over a long period of time in clinical trials. Conversely in clinical trials of PD, 
interventions are typically aimed at short-term relief from motor symptoms. Thus in 
the EAE literature, the time of assessment relative to intervention administration 
should be, and is, far longer than in experiment PD models, where the assessment can 
be made within minutes of drug administration and measured over the course of 
minutes of hours. However, even relatively short times of assessment relative to drug 
administration adequately reflect a key area of PD research - targeting immediate relief 
from the motor symptoms – as long as the time of administration relative to lesioning is 
long enough to reflect the neurodegeneration in humans. Conversely, the shorter times 
of administration relative to EAE induction are arguably of limited clinical value when 
the key area for research nowadays is neuroprotection.  
 
4.5.7. Limitations 
As mentioned in Chapter 3, there are a number of limitations to our approach. Firstly, 
as described above, our analysis can only include published data, and since positive 
studies are more likely to be published, it is conceivable that our estimates of effect size 
reported here are overstated. In addition, although we have accounted for multiple 








 EAE PD 
Number of publications 
in the systematic 
review (SR) and meta-
analysis (MA) 
SR (1646); MA (834) SR (243); MA (121) 
Median study quality 
(IRQ)* 
2 (1-2) 2 (1-2) 
Time to treatment 
(median day)** 
Neurobehavioural scores & 
inflammation (0) 
Demyelination (5) 
Axon loss (7) 
28 
Median sample size 
across both groups** 
Neurobehavioural scores (12) 
Inflammation (9) 
Demyelination (10) 
Axon loss (9) 
8 
Sex** 
Female (793; 53%) 
Male (230; 15%) 
Both (99; 7%) 
Not stated (379; 25%) 
Female (30; 12%) 
Male (130; 50%) 
Both (31; 12%) 
Not stated (69; 27%) 
Publication bias?** 
Funnel plot, Egger regression and 
trim and fill for three 
neurobehavioural and three 
histological outcomes 
Funnel plot and Egger 
regression. Not 
confirmed with trim 
and fill. 
Table 4.4. A comparison between the preclinical literature on drugs tested in EAE and 




Here we have shown that several dopamine agonists have efficacy in animal models of 
PD including a number which are not currently in clinical use. However, we found 
reported study quality to be limited, and that reported efficacy fell as reported study 
quality increased. We have also found evidence suggesting the presence of publication 
bias, although we have not been able to quantify its impact. The use of systematic 
review and meta-analysis and the data presented here provide a framework for an 
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evidence based approach to the development of new treatments for PD and for the 
design of future animal and clinical studies. In addition we have shown that the 
limitations to clinical efficacy in the EAE literature are prevalent here. However, further 
work is required to fully to elucidate the impact of study quality and design factors on 




5. Assessment of study quality, statistical analysis, and 
reporting of studies across a field of research: a systematic 
survey of the 2008 volume of the Journal of Cerebral Blood 
Flow and Metabolism 
 
I acknowledge the following for their contributions to this research: Kieren Egan (KE) 
for second screening the publications against the checklist; Peter Schlattmann (PS) for 
assessing the statistical design reported in each publication; Ulrich Dirnagl (UD) and 
Malcolm Macleod (MM) for overseeing the study design; and Amelie Deister (AD) for 
obtaining the PDFs. 
 
5.1. Background 
As described in the Chapter 1, drug efficacy identified in animal studies of MS has not 
always translated into clinically effective treatments (Chapter 3, Vesterinen et al., 
2010). This “translational roadblock” is also particularly evident in the cerebrovascular 
research field, where despite numerous promising preclinical trials, only a few 
treatments of proven efficacy are available (Dirnagl, 2006, Macleod et al., 2009a, 
O'Collins et al., 2006). Moreover, a number of systematic reviews and meta-analyses on 
the preclinical research in this field have demonstrated that low study quality at 
various stages in the research process might have reduced their internal validity, 
leading to falsely positive findings (Macleod et al., 2004, Macleod et al., 2005b, Macleod 
et al., 2005c, Macleod et al., 2005a, Sena and Macleod, 2007, Sena et al., 2007b, Wheble 
et al., 2008, Macleod et al., 2008, van der Worp et al., 2010a, Dirnagl, 2006, Banwell et 
al., 2009, Frantzias et al., 2011).  
 
An extensive literature has accumulated with a primary focus of quality assessment of 
clinical trials, specifically assessing study design, statistical analysis, and trial reporting 
(Altman, 1998, Sarter and Fritschy, 2008, Glantz, 1980). This paved the way for 
establishment of standards for conducting and reporting clinical trials—namely the 
initialisation and implementation of practices such as Cochrane 
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(http://www.cochrane.org), CONsolidated Standards of Reporting Trials (CONSORT) 
(http://www.consort-statement.org), web-based trial databases (e.g., 
http://www.clinicaltrials.gov, http://www.controlled-trials.com), and STrengthening 
the Reporting of OBservational studies in Epidemiology (STROBE) 
(http://www.strobe-statement.org) (Moher et al., 2001b, Moher et al., 2001a, Bellolio 
et al., 2008). These measures have vastly improved the validity of clinical trials and 
ultimately their impact on patients (Moher et al., 2001a). However, in the translational 
preclinical realm, and particularly in translational cerebrovascular medicine, such 
approaches have been advocated more recently, e.g., Stroke Academia Industry 
Roundtable (STAIR) (http://www.thestair.org) and Collaborative Approach to Meta-
Analysis and Review of Animal Data from Experimental Studies (CAMARADES, 
http://www.camarades.info) (Macleod et al., 2009b, Dirnagl, 2006). Despite the lessons 
learned through clinical trial quality assessment, few studies have formally investigated 
such factors in the basic science and translational preclinical trial realms (Dirnagl, 
2006). Those that have, included publications from more than one scientific journal and 
assessed publications across various research fields (Kilkenny et al., 2009, Ioannidis, 
2005, Nieminen et al., 2006, Schroter et al., 2008). To our knowledge, no systematic 
investigation focusing on study design, statistical analysis, and reporting in the field of 
translational cerebrovascular research has been carried out. 
 
5.2. Aims 
The aim of this study was to establish a baseline for the changes which might occur as a 
result of the adoption of reporting guidelines. To achieve this we chose to assess 
articles in the Journal of Cerebral Blood Flow and Metabolism (JCBFM) which is a 
leading journal of the International Society for Cerebral Blood Flow and Metabolism, as 
it stands at the interface between basic and clinical neurovascular research. Specifically 
our objectives were to compile a comprehensive checklist and apply this to assess the 
scientific reporting, experimental design and statistical analysis of all original articles 
published in the 2008 volume of the JCBFM.  
 
The JCBFM is a relatively high impact journal (5.008), and is ranked 20th of 121 journals 
in endocrinology and metabolism, and 11th out of 68 in hematology and 14th out of 243 
107 
 
in neuroscience (Thomson Reuters, 2011). Therefore we hypothesised that the overall 
quality of the studies would be high, reflecting the journals’ position in this field.   
 
5.3. Methods 
5.3.1. Search strategy 
We downloaded electronic copies of all full publications in volume 28 of JCBFM (issue 1, 
January 2008 to issue 12, December 2008 inclusive). We screened each publication and 
categorised them according to study type: animal (including rodents, primates, canines, 
and birds), in vitro, or human studies, review articles, commentaries, communications, 
errata, and corrigenda. 
 
5.3.2. Inclusion and exclusion criteria 
Review articles (8 publications), commentaries or communications (21), or errata and 
corrigenda (8) were excluded from further analysis. 
 
5.3.3. Study questionnaire 
We developed a comprehensive study quality checklist to capture the key aspects of the 
reporting of (1) experimental design, (2) experimental analysis and statistics, and (3) 
the overall quality of reporting. Such checklists for reporting standards are commonly 
used in other research domains (particularly in clinical trials), and we began by 
creating a catalogue of possible checklist items from publications in these other 
domains. Some items thus identified were clearly not relevant to original articles in 
JCBFM, and after exclusion of these, we selected 15 main items and 9 supplementary 
items which, in our view, captured most of the important aspects of study reporting, 




5.3.4. Assessment process  
For all items apart from the reporting of specific test statistics (question 8) and the 
appropriateness of the statistical tests used (question 8a; see next section), two 
nonblinded reviewers (H.V. and K.E.) independently assessed each publication against 
the questionnaire. For each question it was reported whether the publication met the 
criteria (yes), did not meet the criteria (no), the criteria was not applicable to that 
publication (n/a), or insufficient information was given to assess the criteria 
(unknown).  
 
5.3.5. Assessing test statistics 
An independent, expert reviewer (P.S.), blinded to the authors and their institutes, 
assessed for the presence of specific test statistics (question 8) and whether the 
analytical test statistics were appropriate for the underlying experimental design 
(question 8a). In a statistical analysis, the method of choice depends on the type of data, 
e.g., numerical or categorical, as well as on the structure and distribution of data. Thus, 
it was investigated whether the chosen analysis was suitable for data presented. For 
example, for a comparison of three groups with repeated continuous measurements, it 
was checked whether an appropriate method, such as an analysis of variance with 
repeated measures was chosen. To do so, statistical details reported in the selected 
publications were extracted and given to the reviewer alongside the publications. 
Moreover, the order in which publications were presented was randomised and the 
reviewer was blinded to authors, institution, journal, volume number, and digital object 
identifier number of the publications. Inter-observer agreement κ-Statistics, 
representing the extent of agreement between the two scorers (H.V. and K.E.), were 
calculated for each item, except for 8a. As κ is highly affected by the prevalence of t-
positive scores, we also calculated separate indices of the proportionate agreement in 
the observers’ positive (“yes”) and negative (“no”) decisions (Feinstein and Cicchetti, 














1 Was a primary/research hypothesis stated? 
1a Was an aim/purpose of study stated? 
2 Was the design randomised? (Dirnagl, 2006) 
3 Was allocation concealed? 
4 Was outcome assessment blinded? 
5 
Was a statement about sample size given? (e.g., a priori power analysis) (Altman, 
2002) 
6 
Was study design stated? (Andersen, 1990). Assessed from the abstract e.g. 
randomised controlled trial; crossover trial.  
















8 Were specific test statistics reported? (Altman, 2002) 
8a Were statistical tests appropriate for study design? 
9 Was a measure of variance reported? (Andersen, 1990) 
9a Were S.D. reported? 
9b Were S.E.M. reported? 
9c Were confidence intervals reported? 
10 
Were the units of analysis specified? (Andersen, 1990; Altman, 2002). I.e. can we tell 
which animals contributed to each endpoint? 
10a Were individual data points reported (e.g., in a plot)? 










Were numerical values only given in graphs? (regarding primary hypothesis/main 
experiment) (Altman, 1998) 
12 Was mortality/number of dead quantified and stated? (Andersen, 1990) 
13 Was the source of experimental organism/cells given? (species, strain, etc.) 
13a 
Was the laboratory/company stated where experimental organism was acquired 
from? 
13b Was the age of the experimental organism given? 
13c Was the weight of the experimental organism stated? 
14 Was a control group reported? (Andersen, 1990) 
15 Was a conflict of interest statement given? 
Table 5.1. The study questionnaire used to assess the design, analysis and statistics, and 







A total of 193 original scientific publications were published in JCBFM in the year 2008. 
Of these, 95 (49%) described animal studies, 49 (25%) described in vitro experiments, 
34 (18%) included human participants, 8 (4%) were review articles, and 29 (15%) 
were of other types. Of the 193 total publications, 156 were original studies. Quality 
assessment of these studies was performed using the checklist presented in Table 5.1. 
The proportion of animal, cell culture, and human studies meeting each of the checklist 
items is given in Table 5.2, and is summarised in Figure 5.1. Further summary statistics 





Animal (n=190) In Vitro (n=98) Human (n=68) Overall (n=312) 







1 Primary/Research Hypothesis stated? 51 (27) - - 32 (33) - - 24 (35) - - 93 (30) - - 
1a Aim/Purpose of study stated? 181 (95) - - 90 (92) - - 67 (99) - - 300 (96) - - 
2 Randomisation? 39 (22) 13 (7) - 14 (15) 3 (3) - 5 (8) 6 (9) - 46 (15) 13 (4) 7 (2) 
3 Allocation concealment? 14 (8) 6 (3) - 2 (2) 3 (3) - 3 (5) 3 (4) - 17 (6) 10 (3) - 
4 Blinded assessment of outcome? 28 (15) - - 13 (13) - - 17 (25) - - 46 (15) - - 
5 Statement about sample size given 2 (1) 1 (1) - 2 (2) 1 (1) - 0 (0) - - 2 (1) 1 (0) - 
6 Is study design stated? 6 (3) - - 2 (2) - - 9 (13) - - 16 (5) - - 














8 Are specific test statistics reported? 84 (88) - - 36 (73) - - 31 (91) - - 132 (85) - - 
8a Are applied statistical tests appropriate for 
study design? 
73 (77) - - 42 (88) 1 (2) - 30 (88) - - 127 (81) - - 
9 Measure of variance reported? 183 (97) 2 (1) - 95 (99) 2 (2) - 66 (99) 1 (1) 3 (4) 302 (97) 2 (1) - 
9a Standard deviation (s.d.) reported? 86 (47) 8 (4) - 36 (38) 2 (2) 14 (15) 44 (66) 1 (1) 3 (4) 150 (50) 9 (3) 25 (8) 
9b Standard error of the mean (s.e.m.) reported? 92 (51) 8 (4) - 47 (49) 2 (2) 14 (15) 24 (36) 1 (1) 3 (4) 140 (46) 9 (3) 25 (8) 
9c Confidence interval (C.I.) reported? 5 (3) 8 (4) - 1 (1) 2 (2) 14 (15) 5 (7) - - 10 (3) 9 (3) 25 (8) 
10 Units of analysis given? 85 (34) 1 (1) - 37 (38) 1 (1) - 40 (62) 3 (4) - 140 (46) 5 (2) - 
10a Are individual data points reported 24 (13) - - 16 (16) - - 22 (32) - - 59 (19) - - 









11 Numerical values only given in graphs? 110 (59) 2 (1) - 50 (52) 2 (2) - 28 (41) - - 163 (53) 2 (1) - 
12 Mortality/Number of dead stated? 16 (9) 19 (10) - 6 (8) 24 (24) - 4 (8) 19 (28) - 22 (8) 53 (17) - 
13 Source of experimental organism/cells 
given? 
158 (92) 19 (10) - 82 (93) 10 (10) - 23 (100) 45 (66) - 224 (93) 71 (23) - 
13a Laboratory/Company stated where 
experimental organism was acquired from? 
91 (53) 19 (10) - 51 (57) 9 (9) - 13 (54) 44 (65) - 133 (55) 68 (22) - 
13b Age of experimental organism given? 75 (42) 11 (6) - 38 (46) 16 (16) - 50 (77) 3 (4) - 145 (50) 23 (7) - 
13c Weight of experimental organism stated? 108 (60) 11 (6) - 38 (46) 16 (16) - 19 (29) 3 (4) - 149 (52) 23 (7) - 
14 Is a control group reported? 162 (86) 1 (1) - 80 (82) 1 (1) - 49 (73) 1 (1) - 254 (82) 3 (1) - 
15 Conflict of interest statement given? 54 (28) - - 23 (23) - - 31 (46) - - 94 (30) - - 
Table 5.2. The total number of animal, in vitro, and human studies meeting each of the checklist items (yes, not applicable (n.a.), and unknown (U)) as 
assessed by both reviewers in relevant publications (those which were not n.a.). Some publications reported more than one type of subject (animal, in vitro, 
and human) and are therefore represented more than once. Values in brackets represent percentages. Only one reviewer assessed questions 8 and 8a, and 




Figure 5.1. Comparison of the results obtained by two reviewers (HV: solid colour; KE: diagonal 
stripes) assessing the publications presenting all included publications (N=156, yellow), animal 
studies (N=95, blue), in vitro studies (N=49, green), and those involving human participation 
(N=34, red). X axis values indicate the corresponding question number as it appeared on the 
questionnaire (see Table 5.1. The study questionnaire used to assess the design, analysis and 
statistics, and reporting of studies in JCBFM), and y axis values represent the number of 




In this systematic survey of 156 original research articles published in JCBFM in 2008 
we identified a number of potential shortcomings in their reporting, study design and 
statistical analyses.  
 
Scientific findings are disseminated to the public domain predominately via publication 
in relevant journals; thus adequate reporting is essential. Articles should be the 
primary source of information necessary to replicate the experiment and/or assess its 
internal and external validity. However, issues relating to poor methodology and 
reporting are prevalent across the field of preclinical cerebrovascular research and 
these are thought to contribute to the translational failures (Dirnagl, 2006, Sena et al., 
2007a, Phillips et al., 2008, Fisher et al., 2009, Crossley et al., 2008, Jerndal et al., 2010, 
Dirnagl and Macleod, 2009). Moreover, these concerns are not unique to this field. As I 
described in Chapter 3, inadequate reporting was extremely prevalent in the preclinical 
EAE literature, and study quality was poor. Moreover, others have found similar results 
when surveying animal experiments in general (Kilkenny et al., 2009), medical 
research in general (Altman, 2002), and statistics in experimental and clinical medical 
papers (Holmes, 2004, Zinsmelster and Connor, 2008, Phillips et al., 2008, Glantz, 1980, 
Hoffmann, 1984, Garcia-Berthou and Alcaraz, 2004)  
 
Ethical considerations regarding the use of animals in research and the well-being of 
patients dictate that experiments be conducted and analysed according to good 
laboratory or clinical practice (GLP, GCP), and that reporting of the results be 
comprehensive, accurate, and transparent. More than a decade ago, following an 
analysis of deficiencies in the quality and reporting of randomised clinical trials, journal 
editors, epidemiologists, and statisticians have published the CONSORT statement and 
the CONSORT checklist of items to include when reporting a randomised trial (Moher et 
al., 2001b). Since then, the quality of reporting and quality in general of randomised 
clinical trials has greatly improved, which has at least in part been attributed to this 
process (Plint et al., 2006, Hopewell et al., 2010). The current study was conducted to 
further raise the awareness of quality issues in neuroscience research, and to further 
the implementation of a CONSORT-like statement in experimental medical research.  
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5.5.1. Specific Checklist Items 
xii. Purpose/aim and hypothesis 
A clear statement on the objective of a study or its main hypothesis being tested is 
critical for the reader to assess the appropriateness of the study design, methods, 
analysis, and implications. We found 30% of publications explicitly stated a primary 
research hypothesis; however, 97% indicated the aim or purpose; 44% indicated both, 
and only 3% gave neither a hypothesis nor an aim (percentages given herein represent 
the mean of both reviewers). Interestingly, the reporting of these was only slightly 
higher in human clinical studies where the regulatory environment is stricter than 
experimental or in vitro studies (see Figure 5.1, Table 5.2). Where a study hypothesis is 
well defined and an analysis protocol agreed in advance of experiments being 
conducted, the risk of chance associations being considered of significance are 
diminished. Moreover, this is the laboratory equivalent of the post-hoc subgroup 
analysis of clinical trial data, which can at best be considered hypothesis generating 
only. Where a clear hypothesis is stated, data presented that are not relevant to this can 
be interpreted appropriately  (Andersen, 1990).  
 
xiii. Randomisation, allocation concealment, blinded assessment 
of outcomes 
The importance of taking adequate measures to reduce bias – and thus to improve the 
internal validity of a study – has been described extensively in the clinical and 
preclinical literature. Where these are not reported, there is consistent evidence to 
suggest that effect sizes are overinflated, and moreover that these contribute to 
translational failures. In the present study, fewer than 20% of publications reported 
three key measures to reduce bias, namely randomisation, allocation concealment and 
blinded assessment of outcome. This is broadly similar preclinical MS and PD literature 
(Chapter 3 and 4 respectively) for which we have data for the prevalence of reporting 
of randomisation and blinded assessment of outcome (for comparison see Table 4.3 in 
Chapter 4). In the few publications in the present study in which randomisation was 
mentioned, it was unclear whether proper procedures were followed. Moreover, in 
some studies, randomisation or blinded assessment may not have been feasible, or 
indicated. However, as reporting of these items is not common, it is often not possible 
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for readers to assess whether such studies are indeed flawed. It should be noted that in 
two recent studies focusing on experimental stroke studies, roughly 50% of the 
included studies reported randomisation (Minnerup et al., 2010, Philip et al., 2009).  
 
xiv. Sample size 
Only 1% of the studies reported either sample size calculations or power analyses, or 
the effect size that could have been detected, given the variance of data and the preset 
levels for α (risk of committing a type I error, or false positive) and β (risk of 
committing a type II error, or false negative) (Sterne et al., 2001, Mulaik, 1997, 
Schlattmann and Dirnagl, 2010b). Again this percentage is broadly similar to that of the 
preclinical MS and PD literature and provides further evidence that sample size 
calculations are rarely conducted across the field of preclinical experiments. The 
statistical power of a study informs us not only about the risk of false negatives but it is 
also directly related to the reproducibility and positive-predictive value of the 
experimental results (Ioannidis, 2005). Again, in some of the studies in this survey, a 
priori sample size calculations would not have made sense. However, for the majority 
of studies, they would have been helpful in designing experiments. Most studies 
included here were in fact grossly underpowered; with sample sizes of 10 per group 
(which is at the high end of sample sizes found), an α-value of 0.05 and a β-value of 0.8, 
effect sizes of 1.33 times the SD can be detected (two-sided, independent samples t-
test). As variance in most of the reported experiments is quite high (e.g., SD 30% of the 
mean), this implies that these studies are only powered reliably to detect a 32% mean 
change in outcomes, such as infarct volume or neurobehavioral score. 
 
xv. Study design 
We established the design of the study if it was reported in the abstract. However, the 
process of categorising and assessing the study design of the included publications was 
not trivial. In fact this was not so much due to problems with individual manuscripts, 
but rather because well-established nomenclature is only available for clinical trials 
(e.g. randomised control trial, cohort study, phase 1 trial, etc…).  The implementation of 
an analogous terminology for the field of experimental research would be of substantial 
aid in understanding the design and implications of a study. Interestingly however, 
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despite a range of analogous terminology available to describe the design of human 
studies, this information was missing almost as often as in the experimental studies.   
 
xvi. Inclusion and exclusion criteria, mortality, control group  
Reporting inclusion and exclusion criteria in the ‘Methods’ section, and exclusions, 
dropouts, or mortality (including the reasons behind it) of the experimental groups in 
the ‘Results’ section is another key element to prevent bias and to improve the internal 
validity of a study. We found that <20% (29/156) of the publications reported inclusion 
and exclusion criteria. Mortality was reported in only 8% (20/129) of studies in which 
it was relevant; a further 27 studies reported for instance imaging findings, human 
participants, or purely in vitro experiments. We propose that it should be made 
mandatory to publish mortality rates in animal experiments, as this would prevent the 
masking of a severe bias which could, e.g., result from excluding severely affected 
animals in only one of the experimental groups. Control groups are crucial measures to 
safeguard that an effect is a true effect of the manipulation or condition under study, 
and to minimise the effect of other, unintended variables on the results. More than 80% 
of the publications reported the use of control groups. Assuming that in a fraction of 
articles, control groups would not have made sense, this figure is comforting as it 
points to a widespread use of this key element of the scientific method.  
 
xvii. Experimental animals and study subjects: 
Adequate reporting of the specific characteristics of a study (including the animal 
species, strain, sex, sub-strain, supplier, genetic background, age, weight, comorbidities 
etc…) is necessary both to be able to replicate the experiment, and to assess the 
implications of the study. In a systematic review and meta-analysis of NXY059 or 
nicotinamide in experimental stroke, performance was significantly higher in animals 
without comorbidities (Macleod et al., 2004, Macleod et al., 2008). These models are of 
limited value for a disease commonly associated with comorbidities such as 





xviii. General reporting of statistical analysis 
Specific test statistics were reported in 85% of the assessed publications. Of those, 
expert statistical assessment revealed that 81% (127/156 relevant publications) of the 
studies used appropriate approaches and test. The remaining articles either used 
inappropriate statistical analyses or did not supply the reader with sufficient 
information to comprehend the reported results. The lack of information made it 
difficult to evaluate the appropriateness of given statistical tests, and moreover, of the 
156 assessed studies, 3 did not provide enough information to judge the 
methodological quality. When performing statistical analysis, the method of choice 
depends on the type of data, e.g., numerical or categorical, as well as on the structure 
and distribution of data. In all studies assessed, the choice of statistical method was 
appropriate for the type of data under study. However, in terms of structure, the results 
were different. Among others factors, the structure of the data is given by the number 
of groups considered, e.g., one, two, or more than two groups. If the number of groups 
is larger than two, applying multiple t-tests without correcting for multiple 
comparisons is not appropriate. This error occurred in 4 of the 156 studies reviewed. 
Often, a more complex design is chosen, e.g., when several measurements per animal or 
subject are taken. In this case, the data points are dependent as we are measuring on 
the same subject. This introduces a correlation between individual measurements. In 
such cases, statistical tests that require independent data, such as the unpaired t-test or 
an analysis of variance, are not appropriate. This error occurred in 22 of the 156 
assessed studies.  
 
xix. Measure of variance  
A high proportion of publications included a measure of variance (151/155; 97%). 
Authors most commonly chose to report SDs (49%), followed by SEM (46%) with far 
fewer choosing confidence intervals (4%).  A further 9% of relevant publications did 
not state the type of variance reported. Although popular because it produces smaller 
whiskers in graphs for descriptive purposes, SEM is not considered an acceptable 
measure. The latter is an estimate for the precision of estimating the mean, not a 




xx. Units of analysis, data points  
Most of the assessed studies represent data numerically, and more or less directly 
indicate the unit of analysis (e.g., an Eppendorf tube, right or left hemisphere, a single 
animal, a group or a cage of animals). Nonetheless, in some cases, the experimental 
unit/unit of analysis could not be identified. Data for individual study objects (instead 
of only presenting group data) were found in 30 publications, and raw data were 
provided in 17 publications. Reporting raw data and individual data points can help the 
reader to assess the quality and dispersion of results. As most studies were reporting 
on rather low numbers of subjects, and because most journals allow almost unlimited 
publication of additional data as Supplementary material on the website of the journal, 
we strongly encourage authors to provide as much detailed information as useful and 
possible. This, in many cases, includes the plotting of individual data points in scatter 
plots and the listing of numerical values in tables (Schlattmann and Dirnagl, 2010a).  
 
5.5.2. Limitations  
Our survey has a number of limitations. None of the dichotomised percentages 
(yes/no) of the items of our questionnaire (Table 5.1) can be interpreted as quality 
statements in themselves. For example, if it is said that 85% of all studies did not use 
allocation concealment, then it must be kept in mind that not all studies may have 
allowed designs in which allocation could be concealed, or allocation concealment may 
have not made sense. We have repeatedly alluded to this constraint in the above 
discussion. In any case, these numbers present a first overview on the reporting and 
statistics practices of the surveyed volume. Our approach was to define criteria and 
then apply them to all publication categories (such as experimental, animal, and 
clinical) rather than to define criteria specific to each. Although there might be 
concerns that not all criteria would be appropriate in each publication category, in fact 
this was not the case; each criterion was scored as being present in at least one 
publication from each category and at worse, one-third of publications in a category 
could be scored (source of experimental organism, human studies). Even with criteria 
specific to each publication category, we would have some in which criteria were not 
appropriate, and we believe that our approach has the benefit of being simple and 
broadly applicable. It might be argued that some of the questions used in this survey 
may not be answered in an unambiguous manner. For example, we might have 
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answered question 1: Primary/ research hypothesis stated? with ‘no’, because the 
hypothesis was not explicitly phrased as such (‘In our study we tested the hypothesis 
that.’), but the author of the study might object because he might insist that the 
hypothesis reveals itself allusively from the text. However, we argue that a suitably 
skilled reader should be clearly presented with all the relevant information of a 
scientific communication, which includes aims, purpose, and hypotheses, to be able to 
understand, analyse, and potentially replicate the findings. To assess potential bias of 
the assessor, we used two assessors, and found a very high degree of inter-rater 
agreement. In all categories, questions were more often answered by the scorers with 
‘no’ than with ‘yes’. For many questions, a score of ‘yes’ was low. This in some instances 
lead to low κ -values despite high agreement between scorers, as κ is not reliable for 
rare observations because it is affected by the prevalence of observations. Restricting 
our analysis to JCBFM may introduce bias, which precludes generalisation of our results 
to studies published in other journals. This is very unlikely, as JCBFM is one of the top-
ranked journals in the field of experimental cerebrovascular and stroke research. 
Standards for publication, authors, reviewers, etc., are similar to other journals in the 
field, such as Stroke. We have opted to restrict our analysis to this journal, as its scope 
was ideally suited to survey experimental studies and clinical proof-of-concept studies. 
We hypothesise that surveying related journals, and even scientific journals in other 
experimental-translational areas in life sciences would yield very similar results.  
 
5.5.3. Conclusions  
In this systematic survey, we found indicators for deficiencies in the design, reporting, 
and statistical analysis of the original articles in a recent volume of JCBFM, one of the 
leading journals in the cerebrovascular field. There is ample indirect and direct 
evidence that this is not a problem unique to this particular journal, or even research 
field. We, along with others (Kilkenny et al., 2009, e.g. Fisher et al., 2009, Macleod et al., 
2009b, Percie du Sert, 2011, du Sert, 2011), believe that quality issues in experimental 
life sciences are an important reason for why we are currently facing roadblocks to 
translation from bench to bedside (and vice versa). Only a joint effort of the scientific 
community (authors, readers, reviewers, editors, professional societies, etc.) can 
improve the current situation. The results of our study, together with a thorough 
analysis of the measures that were successfully taken in clinical medicine to improve 
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study quality, indicate some of the action points. We propose that, in analogy to the 
CONSORT statement, a set of standards for reporting of experimental studies in 
biomedicine is used. Like with CONSORT, journal editors need to adopt these 
standards. Journals need to educate their readers and create awareness in areas, such 
as proper study design and analysis. Indeed, Kilkenny et al (2011) have recently 
proposed such reporting guidelines (Animal Research Reporting In Vivo Experiments, 
ARRIVE; http://www.nc3rs.org/ARRIVE) using the CONSORT statement as a 
foundation. Reviewers need to be more critical regarding missing hypotheses, 
deficiencies of experimental design, insufficient statistical power, or inadequate 





6. The relationship between treatment related effects on 
neurobehavioural and histological outcomes in EAE: a 
systematic approach to regression and path analyses 
 
I acknowledge the contribution of Malcolm Macleod and Emily Sena for help with the 
study design and interpretation of results.  
 
6.1. Introduction 
Inflammation is widely considered to be the driving force behind the classic relapsing-
remitting MS (RRMS) disease course which the majority (70%) of patients follow. 
However, 65% of these patients transition to secondary progressive MS (SPMS) 
(Compston and Coles, 2008), and 10-15% first present with a progressive disease 
course (Miller and Leary, 2007). For both of these the permanent and increasing 
disability is thought to be caused by axon loss (Trapp et al., 1999), which can occur 
independently from inflammation and demyelination (Bruck, 2005). With this in mind, 
it is perhaps not surprising that the clinically available disease modifying interventions, 
all of which are immune-modulatory or immunosuppressive are biased towards the 
treatment of RRMS (Lim and Constantinescu, 2010).  
 
As described in Chapter 3, the vast majority of experiments on EAE measure efficacy as 
a change in neurobehavioural score which is typically measured on a 0 (healthy) to 5 
(moribund or death) scale. This grades the characteristic ascending paralysis seen in 
most varieties of EAE. Previously we have used systematic review and meta-analysis to 
summarise the efficacy of interventions when they have been measured against 
neurobehavioural (Vesterinen et al., 2010) and histological outcomes including axon 
loss, demyelination and inflammation (Chapter 3). With axon loss being a target for 
current drug research, we aimed to use this systematic approach to assess the extent to 
which axon loss is being measured in publications, and to assess the relationship 




Specifically our objective were to: (1) summarise the outcome measures which are 
reported in the preclinical literature reporting interventions tested in EAE; (2)  pool 
data from experiments where more than one outcome are measured in the same cohort 
of animals; (3) use meta-regression to assess the extent to which treatment related 
effects in one outcome measures are associated with the treatment related effects in 
another; and (3) use meta-pathway-analysis to hypothesise the sequence of treatment 




The present analysis was carried out on a subset of the data previously extracted onto 
the CAMARADES Data-Manager which are described in Chapter 3. Specifically, we 
included in this analysis publications reporting valid (see below), quantitative data for 
two or more outcomes which included axon loss, demyelination, inflammation or 
neurobehavioural scores where these were measured in the same cohort of animals. 
Outcomes were valid if we could extract the number of animals, a mean score and its 
variance (SEM or SD).   
 
Any neurobehavioural outcome measured on a clinical scale was valid for inclusion. In 
initial analyses we grouped these into three categories which were later combined for 
the purposes of assessing the effect of time to treatment: (1) mean severity scores 
(mean severity score, the product of mean severity and duration, the product of mean 
severity plus number of exacerbations); (2) mean clinical scores and mean cumulative 
scores; (3) the clinical score on the day that the histological outcome was quantified. 
For publications reporting quantifiable histological data, we included any outcome 
measured as change in axon loss, demyelination and/or inflammation whereby these 
were measured directly; thus we excluded publications where the researcher 
manipulated the system for measurement using methods other than staining e.g. 
change in DNA expression of inflammatory markers, results from a FACS or ELISA 
analysis. Some publications reported a “histological score” which combined data from 
inflammation and demyelination, and we excluded these from our analyses.  
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6.2.2. Data Analysis 
For individual comparisons we calculated effect sizes as SMDs to account for the lack of 
reported data for sham animals for a large proportion of comparisons (see section 
2.2.2). We used meta-regression to identify the relationship between treatment related 
variations in different outcome measures. We conducted the meta-regression analyses 
in Stata (section 2.3.2) which gave us adjusted R2 values which we have expressed as 
percentages and hereafter refer to as R2. We made the assumption that the changes in 
neurobehavioural scores are a consequence of changes in EAE which might be detected 
in histological outcomes. Therefore we took the effect sizes for neurobehavioural 
scores as the dependent variable. Where the relationship between different histological 
outcome measures was being assessed we took inflammation as the independent 
variable; and where we assessed the relationship between axon loss and demyelination 
we conducted two regression analyses so that both were treated as the dependent and 
independent variables in turn.  
 
We considered values of R2>1% and <9 to be small effects (weak relationships), >9 and 
<25 to be medium sized effects (moderate), and >25 to be large effects (strong). These 
are based on the estimates for the strength of correlation coefficients described by 
Cohen (1988)  which we squared to represent the equivalent values for R2. 
 
6.2.3. Path Analysis 
We used the adjusted R2 values from the results of the meta-regression analysis to 
predict the pathway to improvement in neurobehavioural scores. Our aim was to 
assess the extent to which improvements in neurobehavioural scores, individually or in 
combination, are mediated through any of the three histological outcomes. Attempts to 
assess the impact of interventions on the pathway of improvement by categorising into 
anti-inflammatory and neuroprotective agents was not carried out because it was 
predicted that the vast majority of interventions would be anti-inflammatory; 
furthermore, because there were so many interventions tested the number of 




The strength of the association between treatment related effects for each of two 
outcome measures represents the total effect (XTOTAL) for that pair. That is, XTOTAL is the 
R2 value calculated in section 6.2.2 for that pair of outcome measures. This value 
includes both direct and indirect pathways. For example, the impact of inflammation on 
neurobehavioural scores may be mediated by the direct effects of improvement in 
inflammation, or this process may be mediated by indirect effects through 
demyelination and/or axon loss; or some combination of the above. The meta-pathway 
analysis thus allows us to compute the strength of these direct and indirect 
relationships and use these to build a model of the pathway to improvement in 
neurobehavioural scores.  
 
We first computed the direct effect (XDIRECT) of treatment related improvements in one 
outcome measure to improvements in another outcome measure. Thus for each pair of 
outcome measures, XDIRECT is the residual variance calculated by subtracting the 
strength of the indirect pathway from the known total variance, XTOTAL (Equation 6.1). 
To calculate the strength of the indirect relationships between outcome measures we 
multiplied the R2 values for the steps in the indirect pathway. For example, if the 
relationship between A and B is 0.6, and between B and C is 0.6, the strength of the 
indirect pathway between A and C is 0.36.  
 
Equation 6.1                   (         ) 
And thus,  
                  (         ) 
Where XTOTAL is the R2 value for the strength of the association between that pair of outcome 
measures, and XINDIRECT is calculated as the sum of each individual indirect pathway, shown in 
Figure 6.1. 
 
To build the model of the pathway to improvements in neurobehavioural score we 
made two initial assumptions: firstly, that inflammation is the first step in the model 
and neurobehavioural scores are the last step in the model; and secondly that a 
relationship exists between every pair of outcome measures. We sought to establish 
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whether evidence exists to retain these relationships or to exclude them by calculating 
the direct effects between each pair of outcome measures in the following order: 
1. inflammation and axon loss: this was assumed to be either direct, or mediated 
through improvements in inflammation on demyelination or axon loss (Figure 
6.1B);  
2. inflammation and demyelination: this was assumed to be direct or mediated 
through improvement in axon loss (Figure 6.1C );  
3. inflammation and neurobehavioural scores: this was assumed to be direct or 
mediated through: (i) inflammation on demyelination, and demyelination on 
axon loss); (ii) inflammation on axon loss; (iii) inflammation on demyelination; 
(iv) inflammation on axon loss, and axon loss on demyelination (Figure 6.1D);  
4. demyelination and neurobehavioural scores: this was assumed to be direct or 
mediated through effects of demyelination on axon loss (Figure 6.1E);  
5. axon loss and neurobehavioural scores: this was assumed to be direct or 
mediated through axon loss on demyelination (Figure 6.1F).  
 
After each step we excluded the direct pathway in subsequent steps if the strength of 
the association (XDIRECET) was less than 1%. For example, if XDIRECT between inflammation 
and demyelination is less than 1%, the mediated effects of (I-A-D) would be deleted 
from step 3, such that the direct effect of inflammation on demyelinating is the same as 
the R2 value calculated previously. 
 
We predicted that the strength of the relationship between different outcome measures 
would change depending on the time of drug administration. Therefore we categorised 
the data into four broad times of administration and carried out the path analysis on 
each of the following datasets: (1) grouping all times of administration together; (2) 
prior-treatment: where the drug was administered on or before day 0; (3) early 
treatment: where drugs were administered between day 1 and day 8; late treatment: 
where the drug was administered after day 8. Additionally we took the meta-regression 
estimate for the strength of the relationship between outcomes for rolling six day 
epochs. Six days was the lowest epoch for which data were available to investigate the 
strength of the relationship between the independent and dependent variable. We used 




Figure 6.1. Steps taken in the meta-pathway analysis, shown in order from A to F. We used the 
equations shown to calculate the strength of the direct pathway (XD; green arrows) by 
substituting in R2 values which correspond to the overall strength of the association between 
those two outcome measures (XTOTAL). Where an indirect path (XINDIRECT; red arrows) consisted of 
more than one pair of outcomes, for example, going from inflammation to demyelination to axon 
loss to neurobehavioural scores (denoted here as I*D*A*N), we multiplied the R2 values (which 
in this example would be (X TOTAL(ID) * X TOTAL(DA) * X TOTAL(AN)). The direct effect is the total 
association strength minus the sum of the association strength in each indirect pathway. If 




6.3.1. Extracted Data 
We had previously identified 1464 publications on drugs tested in EAE. Of these, 1036 
publications reporting more than one outcome measure, regardless of the type of data 
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(quantitative or qualitative) or the validity of the outcome (whether required 
information for inclusion in a meta-analysis was reported, i.e. the number of animals, 
mean score and its variance) or whether the outcomes were measured in the same 
cohort of animals (Figure 6.2). 99% of publications reported neurobehavioural 
outcomes (1446/1464), either as the only outcome measure (420/1464) or in 
combination with other endpoints (1026/1464).  
 
Histological endpoints were reported in 1044 publications, of which the majority used 
change in inflammation as their endpoint, either alone (618/1044) or in combination 
with either axon loss and/or demyelination (386/1044). In total, axon loss was 
reported in 117 (of 1464) publications and demyelination by 388 publications. Of the 
1036 publications reporting more than one outcome measure, 291 publications 
reported more than one valid outcome suitable for meta-analysis from the same cohort 
of animals of which there were 620 individual cohorts. The majority of cohorts had two 
outcomes reported (437/620 cohorts; 198/291 publications), followed by three 
outcomes (118/620 cohorts; 63/291 publications) and substantially fewer cohorts had 





Figure 6.2. Quorum chart of the progression from our original literature search for drug studies 
in EAE to the publications used in the analysis presented here. The Venn diagrams represent (A) 
the number of publications reporting any data for any combination of reported outcome 
measures; (B) valid data for two or more outcomes from the same cohort of animals, taking into 
account neurobehavioural scores; or (C) only taking into account reporting of valid data in the 
same cohort where histological outcomes are measured. Neurobehavioural scores (Neuro.) are 
shown in red, demyelination (demy.) in green, axon loss (ALoss) in blue and inflammation 
(Inflm.) in grey. 16 publications reported data for a different combination of outcome measures 
in unique cohorts of animals and are therefore represented more than once in B and C 




6.3.2. Relationship between outcome measures 
xxi. Different neurobehavioural scores; combined treatment times 
(Figure 6.3) 
Our dataset includes 248 nested outcomes for mean severity scores; 173 nested 
outcomes for mean clinical and mean cumulative scores; and 336 outcomes for the 
clinical score on the day of histological assessment. Taking all times of drug 
administration together, histological outcomes appeared to be the most strongly 
associated with the change in mean severity scores, and most weakly associated with 
the change in clinical score on the day that histological changes were quantified (Figure 
6.3). Axon loss was relatively weakly associated with changes in all three 
neurobehavioural scores compared to inflammation; however it was interesting to note 
that of the three histological outcomes it was the outcome most strongly associated 
with the changes in the clinical score on the day that histological outcome was 
quantified. In total 5 of 9 of our analyses were classified as strong (R2>25%: all three 
histological outcome measures versus mean severity scores; and inflammation or 
demyelination versus mean clinical and cumulative scores), and 4 were considered 
moderate in strength (R2>9 and <25%:  axon loss versus mean clinical and cumulative 
scores, and all three histological outcomes versus the clinical score on the day of 





Figure 6.3. The relationship between improvement in (A) axon loss, (B) demyelination or (C) 
inflammation with improvement in: neurobehavioural score on the mean severity score (left 
hand panels); the mean clinical cumulative score (middle panels); and the day that histological 
changes were measured (right hand panel). The relationships were assessed using meta-
regression between each pair of outcomes where they were measured in the same cohort of 
animals. The adjusted R-squared and the number of comparisons are shown on the graphs for 
each pair of outcome measures. Symbol size represents the precision of the dependent variable. 
 
xxii. Combined neurobehavioural scores; combined treatment 
times (Figure 6.4) 
Taking all times of administration together and all neurobehavioural outcomes 
together, the strongest relationship was between the improvement in inflammation 
and demyelination (R2=84.5%; Figure 6.4). In total, 5 of 6 pairs of outcome measures 
were considered to have strong relationships and one was classified as moderate 




Figure 6.4. The relationship between different outcome measures when all different times of 
administration are taken together. See Figure 6.3 for more details. 
 
xxiii. Combined neurobehavioural scores; prior-treatment (Figure 
6.5, top panels) 
We assessed the relationship between outcome measures where the time of 
administration was either before or on the day or EAE induction. The strongest 
relationship was identified between the improvement in inflammation and 
demyelination, and the weakest between axon loss and neurobehavioural scores. In 
total 3 of 6 pairs of outcomes were considered to have strong relationships 
(inflammation versus demyelination; demyelination versus axon loss; inflammation 
versus axon loss) and the remaining three were considered to have moderate 
relationships. Thus histological outcome measures accounted for a greater proportion 
of variation in other histological outcome measures than neurobehavioural scores.  
 
xxiv. Combined neurobehavioural scores; early treatment (Figure 
6.5, middle panels) 
Taking the data from studies where the drugs were administered from day 1 to 8 
inclusive (“early treatment”), we found a stronger relationship between all outcome 
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measures in comparison to the prior treatment. We found that all of the pairs of 
outcomes had strong relationships (R2>25%).  
 
xxv. Combined neurobehavioural scores; late treatment (Figure 6.5, 
lower panels) 
For studies which administered interventions from day 9, we identified a strong 
relationship between all pairs of outcome measures (Table 6.1) with the strongest 
between improvement in inflammation versus demyelination, and inflammation or 
demyelination versus axon loss.  
 







Neurobehavioural Scores    
Axon Loss n/a   





Neurobehavioural Scores    
Axon Loss n/a   






Neurobehavioural Scores    
Axon Loss n/a   





Neurobehavioural Scores    
Axon Loss n/a   
Demyelination n/a n/a  
Table 6.1. A heat map of the strength of relationships between outcome measures when 
improvement was measured in the same cohort of animals. Strong relationships (R2>50%) are 
shown in green, moderate relationships (R2>20% and <50%) are shown in orange and weak 




Figure 6.5. The relationship between different outcome measures when drugs are administered 
prior to EAE induction (upper two pannels), as early treatments after EAE induction (middle 




6.3.3. Pathway to improvement in neurobehavioural scores 
Using meta-pathway analysis we first assessed the pathway to improvement in 
neurobehavioural score when we grouped all times of administration together. As 
shown in Figure 6.6A, all of the effects on neurobehavioural score appear to be 
mediated through effects of inflammation on demyelination, and demyelination on 
axon loss.  
 
We expected that the pathway would be sensitive to the time of drug administration 
and so we next assessed the pathway for drugs administered at prior-treatment times 
(on or before day zero). We identified a weak relationship between inflammation and 
neurobehavioural scores, and axon loss and neurobehavioural scores. The majority of 
the effects on neurobehavioural scores appeared to be mediated via improvements in 
demyelination (Figure 6.6B) which equated to greater than two thirds of the overall 
effects (Table 6.2). For early treatments (between day 1 and 8 inclusive), there was a 
strong relationship between inflammation and demyelination through which a large 
proportion of the effects on neurobehavioural outcome were mediated through the 
effects of inflammation on demyelination (Figure 6.6C). For late treatments 
(administered after day 8), the improvement in neurobehavioural was partly mediated 
through the effect of inflammation on demyelination, and demyelination on axon loss 







Figure 6.6. The proposed pathways to improvement in neurobehavioural scores for all times of 
administration (A), prior treatment or on the day of EAE induction (B), early treatment between 
days 1 and 8 (C) or late treatment from day 9 (D). Percentages represent XDIRECT calculated as 
shown in Figure 6.1 along with the number of comparisons. The width of the arrow is the 
relative strength of the relationship. * and ** represent the strength of the relationship between 
inflammation and neurobehavioural scores, and demyelination and axon loss respectively for 
























Prior <1/3 >2/3 >0 
Early 0 1 0 
Late 0 0 1 
Table 6.2. The proportion of the variation in neurobehavioural scores which can be explained 
by change in inflammation, demyelination or axon loss. All values are rounded to the nearest 
third. For example, from Figure 6.6, a very small proportion of variation in axon loss (direct or 
mediated) can explain variation in neurobehavioural scores; a larger proportion (7% which 
have labelled here as less than a third) is via direct effects, and the remaining variation is 
explained by variation in demyelination, either directly or mediated through variation in 
inflammation.  
 
6.3.4. Time of administration 
By grouping the meta-regression data into 6-day rolling epochs for the time of 
administration, we identified a poor relationship between both the improvement in 
inflammation and neurobehavioural scores (R2=6%) and between demyelination and 
neurobehavioural scores with increasing times of administration (R2=5%). However 
the strength of the relationship between improvement in axon loss and 







Figure 6.7. The strength of the relationship between axon loss and neurobehavioural scores 
over time. Relationship strength was assessed by meta-regression on effect sizes over 6 day 
rolling epochs. The symbol size represents the log of the number of comparisons.  
 
6.4. Discussion 
Here we have described the relationship between treatment related improvements in 
four outcome measures using novel methodology based on a systematic approach. 
Beyond the limitations of this study (described below), this approach was used to 
minimise bias and it provides further insights into the usefulness of a repository of data 
from animal studies. 
 
6.4.1. Outcome measure reporting 
Roughly 70% of publications on drug efficacy in EAE conduct their analysis using more 
than one endpoint (1036/1464 publications). Over 98% include change in 
neurobehavioural scores as one (or all) of their measures of efficacy. Axon loss is the 
least reported measure of efficacy; however this dataset also includes publications 
dating back to the early 1960’s, when there were high expectations for anti-
inflammatory medications – a trend which lasted until the end of the 20th century when 




6.4.2. Relationship between outcome measures: treatment related 
improvements 
The treatment related improvements in the three histological outcomes and 
neurobehavioural scores appears to depend on the method of measuring the 
neurobehavioural score. There was a particularly poor correlation when the outcomes 
were measured on the same day. Moreover, the relationship with change in 
inflammation was especially weak, whereas the strongest relationship was with the 
change in axon loss.  This is perhaps reflected by an early improvement in 
inflammation, which diminishes with time as more consequential pathological changes 
are emerging (i.e. axon loss) and thus when they are both measured at the same (later) 
time point, the improvement in neurobehavioural score is not reflected by the 
treatment effect on inflammation.  Interestingly the relationship with axon loss appears 
to not change substantially between different measures of neurobehavioural score. 
However, from these data the relationship between neurobehavioural scores and axon 
loss or demyelination is not clear. In animal models and humans, demyelination can 
undergo some repair, mediated by oligodendrocytes. Conversely, endogenous repair 
mechanisms do not seem to act on axon loss (Xie and Zheng, 2008). Moreover, a simple 
observation of the magnitude of the axis of the graphs presented in this analysis shows 
that interventions had the least benefit in reducing axon loss compared to other 
outcome measures.  
 
6.4.3. Time to treatment and path analysis 
The categories for time to treatment were chosen based on subjective biological 
plausibility, and to ensure roughly equal group sizes. Our analysis suggests that pre-
treatment of EAE leads to a relatively weaker association between changes in 
histological and neurobehavioural outcome measures, and that they are even relatively 
weak correlates of improvement in each other. The meta-pathway analysis suggests 
that the route to improvement in neurobehavioural scores may be mediated through 
direct effects on inflammation, as well as its mediation through demyelination and that 
improving axon loss plays a minimal role in mediating these effects. We were unable to 
ascertain the strength of the direct effects of change in axon loss on neurobehavioural 
outcomes and therefore it is possible that interventions simply prevent axon loss from 
occuring. The particularly poor relationship between improvement in 
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neurobehavioural scores and axon loss is possibly indicative that this pathological 
change hasn’t occurred before both are assessed. In fact there appears to be no role for 
axon loss when we analysed data from experiments which gave early treatments with 
all the effects coming from improvement in inflammation which is either mediated, or 
through direct improvement in demyelination. Improvement in axon loss appears to be 
more important at later time points in terms of its ability to affect neurobehavioural 
scores; shown also in Figure 6.7. This is perhaps not surprising given that axon loss is 
thought to be the cause of permanent disability; thus at later time points, if axon loss 
has improved it is feasible to expect neurobehavioural scores to also improve. At earlier 
time points it is conceivably far more difficult to disentangle the complex relationship 
between endogenous and exogenous repair mechanisms on inflammation and 
demyelination and the subsequent interaction with neurobehavioural scores. We found 
that the relationship between inflammation or demyelination and neurobehavioural 
scores did not change as the time of administration increased. These data therefore 
support the notion that axon loss should be a key target for drug research.   
 
6.4.4. Limitations 
An important limitation to this study is that aggregating data from such a wide range of 
disease models and study design paradigms can mask important observations which 
are unique to certain experiments. For example we have grouped together different 
EAE models (which may have different clinical and histological responses) and 
different drugs (which may have different drug targets, such as inflammation or 
neurodegeneration). Secondly, meta-analysis relies on adequate reporting of crucial 
information (number of animals, mean and variance per group) and thus we had to 
exclude a large volume of data on this basis. Moreover, this analysis was based on the 
relationship between outcomes where they were reported from the same cohort of 
animals; however, we were at times unable to ascertain whether this was the case. 
Thirdly, our approach is hypothesis generating and based on observation only 
(described in more detail in Chapter 9). Therefore we urge caution when using these 
data to make interpretations about the relationship between outcomes and the 
pathway to improvement in neurobehavioural scores, and highlight that our 




Lastly, we have shown that publication bias is an issue in the preclinical EAE literature 
(see Chapter 3). Consequently our analyses may be subject to two types of positive 
reporting bias: (1) studies which reported negative results across all outcomes may not 
be in the public domain at all; and (2) where interventions had a non-significant impact 
on one outcome measure, and a significant impact on the other, it may be that only 
sufficient data was reported for the significant outcome which would not be eligible for 
inclusion in our study. The latter could result in the relationship strengths being 
overstated. In addition, as I mentioned in the discussion of Chapter3, where 
demyelination is reported without mention of the presence of axons, we cannot 
ascertain whether primary demyelination has occurred, or whether axons have simply 
been displaced by the inflammatory environment. Thus the relationship between 
demyelination and inflammation described in this analysis may be confounded by this. 
 
In addition to these concerns, we made the observation that for some pairs of outcome 
measures, all of the variation in one could be explained by the variation in the other 
(adjusted R2 of 100%). Careful inspection of the data revealed that this was due to there 
being such low heterogeneity in the dependent variable (tau2 was less than 1) and so all 
of it could be explained by variation in the independent variable. These results should 
therefore be interpreted with caution. 
 
6.4.5. Conclusions 
Our novel methodology demonstrates how meta-analysis estimates of efficacy can be 
used to unpick the pathways to improvement in a disease model. The findings that we 
have reported are assumption free, apart from our chosen start point (reduction of 
inflammation) and end point (improvement in neurobehavioural scores). Using these 
methods we observe that variation in the change in neurobehavioural scores can be 
explained in part by variation in axon loss, and moreover, that the strength of the 
relationship increases over time. Our data support the rationale that axon loss is a key 
therapeutic target for the improvement in disability in EAE.  
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7. Assessing methodological differences in meta-analysis of 
data from preclinical trials 
 
7.1. Background 
An effect size is the quantifiable magnitude of the relationship between two groups (e.g. 
a control and treatment group). There are a number of methods available to quantify 
this relationship and extensive literature on their merits and conditions with which 
each is appropriate (for example see: Nakagawa and Cuthill, 2007, Baguley, 2009, 
Durlak, 2009). Typically these methods fall into one of three categories: effect sizes for 
correlations, odds ratios and differences between means (Borenstein, 2009), the latter 
of which has been used in this thesis. Within each of these categories, there are yet 
further methods to choose from. Herein, I will only refer to some of the methods used 
to calculate effect sizes for the difference between means.  
 
Standardised effect sizes are commonly referred to as the d family of calculations. This 
is named after Jacob Cohen, whose effect size calculation, Cohen’s d, or just d for short, 
was the first of any effect size described (Cohen, 1962). In this thesis I have used 
Hedge’s g which is essentially the same as Cohen’s d but takes into account a correction 
factor for small sample sizes, which were found to be common in the dataset I extracted 
(the median sample sizes were less than ten for both the preclinical research on EAE 
and PD). The correction factor lies between >0 and <1, with larger sample sizes tending 
towards 1, which are therefore more closely in line with the value for Cohen’s d 
(Cooper et al., 2009).  
 
The classic alternative to the SMD is the raw difference in means, in which the 
calculation method is, as the name suggests, simply the difference between the mean in 
the control group and the treatment group. With SMDs, problems can arise during the 
process of standardisation, and thus the advantage of raw differences in means is that 
their calculation does not rely on variance. Additionally, the unit of the effect size is in 
the same scale as the original units which are intuitive to interpret. The unit of SMD is 
standard deviations (SDs) which are not as easy to interpret; for example a change of 1 
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SD is not necessarily clear in terms of drug efficacy (Bond, 2003, Baguley, 2004). It has 
also been suggested that the unit of an SMD is less meaningful if the reader does not 
know how they were calculated or what factors influence them (Baguley, 2009). 
However, the clear disadvantage of this approach is that the scale must be identical 
across every outcome measure in the dataset. Thus, despite its merits, it is sometimes 
not appropriate to meta-analyse raw differences in means.  
 
In Chapter 2, I introduced an alternative metric, the normalised mean difference (NMD; 
section 2.2.2i) where the mean outcome in the group with the smallest deviation from 
the mean in the sham group is expressed as a proportion of the mean score which has 
the greatest deviation from the mean in the sham group. Similarly, the standard 
deviation (SD) for each group is recalculated as a proportion of this same mean value. 
This approach has similar benefits to the raw difference in means and has the 
advantage of being more widely applicable. In fact the normalised mean difference can 
be calculated for any data where the mean score for an unlesioned animal is either 
reported or can be inferred, as this calculation relies on converting all values to the 
same scale for which the baseline is required. However, this also provides a 
disadvantage to this approach; in our experience data for the sham group are often not 
reported when it is required (described in further detail in the results section) and 
therefore we cannot always calculate this effect size.  
 
Meta-analysis involves aggregating effect sizes from a number of studies. Where these 
are calculated on data from different study designs and therefore where the underlying 
treatment effect may be different, it is both useful and often strongly advised to conduct 
a formal assessment on the potential sources of heterogeneity (Thompson, 1994, 
Thompson and Sharp, 1999, Higgins and Thompson, 2002). As described in Chapter 2, 
we used two methods to calculate heterogeneity: Cochrans Q and the newer I2 value 
(section 2.3).  Cochrans Q can be used to stratify heterogeneity (herein referred to as 
stratified meta-analysis; section 2.3.2i). On this we can calculate a p value for the 
likelihood that the amount of heterogeneity is due to chance alone; that is, confirming 
the null hypothesis that the samples are from the same population. However, Q is 
documented as being underpowered in the test for heterogeneity where sample sizes 
are small, and over-powered to detect a significant result when there are many studies, 
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a situation which cannot be ruled out in the dataset described in this thesis (Hardy and 
Thompson, 1998).  
 
At different stages in this thesis we have applied two methods to calculate effect sizes: 
NMDs and SMDs. All things being equal, our preference has been to calculate NMDs as 
the effect sizes are more intuitive to interpret. However, under certain circumstances 
we have been unable to calculate NMDs because too few experiments reported data for 
sham or it could not be inferred. Thus for the EAE literature we calculated NMDs as 
data for sham were largely available, and for the preclinical PD literature where these 
data were rarely reported and could not be inferred we calculated SMDs.  
 
We also used two methods to perform assessments on heterogeneity: meta-regression 
and stratified meta-analysis. For the preclinical PD literature we performed stratified 
meta-analysis because this approach reflected the common practice at the time that the 
pre-specified analysis methods were chosen. We performed meta-regression on the 
data from EAE studies because this is a more recent method and we have made the 
observation that it is also more conservative than stratified meta-analysis. However, to 
our knowledge, this assumption (that meta-regression is a more conservative 
approach) has not been formally investigated on a large collection of real data from 
animal studies which are heterogeneous. 
 
7.2. Aims and objective 
In this study I set out to explore and describe the differences between the main 
methodological choices available in the meta-analysis of data from animal studies. 
Specifically my objectives were to use the same dataset to: (1) explore the differences 
between estimates of effect size calculated as NMDs and SMDs; (2) explore the 
differences in performance of meta-regression and stratified meta-analysis in 
estimating differences between strata; and (3) explore the impact that the two effect 





 Summary of use Strengths/Weaknesses 
Standardised 
mean difference 
Place all measures of outcome 
onto a single, standardised 
scale by dividing the 
difference in means by a 
measure of the standard 
deviation in one or both 
groups. 
Applies to a wide range of 
research. Does not require data 
for a sham group. 
Raw difference 
in means 
Simply the difference between 
mean in the control group and 
mean in the treatment group. 
Only applicable if the 
measurement scales are the same. 
However, it is the most intuitive 
measure of effect size if it is able 
to be applied to the data. Does not 
require data for a sham group. 
Normalised 
mean difference 
The effect size is the 
proportion of the mean value 
in one group against the mean 
score in the other group. 
Unit of effect size is intuitive (% 
change). However, value for the 
mean in the sham group must be 
reported or able to be inferred. 




We used all of the available data from all drug studies on EAE published prior to 
October 2009 and calculated both an NMD and a Hedge’s g SMD effect size for each 
comparison. Both of these calculations have unique situations in which the effect size 
cannot be calculated (described in Table 7.1); therefore we only included data where 
both could be successfully computed.  
 
Because our aim was to explore methodological differences only, we randomly 
relabelled the values for each of the groupings in our analysis. That is, for example for 
blinded assessment of outcomes which has two possibilities, “yes” and “no”, we 
randomly relabelled these as “blinded 1” and “blinded 2”. The relabeling was consistent 
across each analysis such that for example “blinded 1” always coded for the same value.  
 
We carried out analyses on three types of neurobehavioural score: (1) mean severity 
scores (mean severity score, the product of mean severity and duration, the product of 
mean severity plus number of exacerbations); (2) mean clinical scores and mean 
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cumulative scores taken together; (3) the clinical score on the last day of observation; 
and three measures of histological outcome: (1) inflammation; (2) demyelination; and 
(3) axon loss.  
 
7.3.1. Comparing effect size calculations and methods of exploring 
heterogeneity 
To explore sources of significant heterogeneity we used the methods described in 
Chapter 2 (section 2.3.2). Specifically we explored the impact of the following variables 
on each outcome measure: (1) route of drug delivery; (2) species; (3) sex; (4) time of 
drug administration; (5) time of outcome assessment; (6) the mean number of animals 
in the nested comparison; (7) quality score based on our 6 point checklist (section 
2.1.3); (8) blinded assessment of outcome; (9) random allocation to group; and (10) for 
three histological outcomes we assessed the impact of the CNS section observed. 
 
In meta-regression, data for continuous variables can be entered directly, and produces 
an equation of the line of best fit. To allow for comparison with stratified meta-analysis 















Study Design Characteristic Raw Data Type Categories 
Blinded assessment of 
outcome 
Dichotomous 2 (yes; no) 
Random allocation to group Dichotomous 2 (yes; no) 
Overall quality score Ordinal 6 (maximum checklist items) 
Route of drug delivery Categorical 40 identified 
Animal species Categorical 8 identified 
Animal sex Categorical 4 (male; female; both; unknown) 
Time of administration (days) Continuous scale 7 (day <0; 0; 1-7; 8-14; >15; day of 
onset or other; unknown) 
Number of animals per Group Continuous scale 4 (1-4; 5 or 6; 7-9; 10+) 
Time of assessment (days) Continuous scale 5 (<16 days; 16 to 30; 31 to 45; 
>45; unknown) 
Histological section analysed Categorical 4 (spinal cord; brain; brain & spinal 
cord; unknown) 
Table 7.2. The categories that each study design characteristic were split into for the analysis 
on sources of heterogeneity.  
 
7.3.2. Publication bias 
We assessed for publication bias using effect sizes calculated as both NMDs. We used 
funnel plotting, Egger regression and trim and fill (section 2.5).   
 
7.3.3. Statistics 
Our analyses were purely observational and therefore we only report descriptive 
statistics and three levels of significance for our assessment of heterogeneity using 
meta-regression and stratified meta-analysis (p<0.005 shown in green; p<0.01 shown 
in orange; p<0.05 shown in red). We performed no formal comparison of the number of 




7.4.1. Included and excluded data 
Our initial dataset included 1464 publications from which we were able to extract 6709 
individual comparisons on 6 outcome measures from 881 publications. For this 
analysis we excluded 773 outcomes from 189 publications because they did not 
describe data for a sham group and they could not be inferred. However, of these 773 
publications 172 still had at least one outcome suitable for meta-analysis, and hence 
5935 outcomes from 864 publications were carried forward. Of these, we excluded a 
further 449 comparisons from 167 publications which could have neither an SMD or 
NMD calculated. These were excluded when the measure of variance in both the control 
and treatment group was zero and thus the calculations for effect size and standard 
error of the comparison therefore include a division by zero. We excluded a further 89 
comparisons from 20 publications because an SMD could not be calculated. Of the 187 
publications with data excluded at this stage, 155 still had at least one outcome suitable 
for meta-analysis. Thus our final analysis included 5395 un-nested outcomes from 832 
publications on which we could calculate both an SMD and NMD effect size (Figure 7.1).  
 
We performed random effects meta-analysis and analyses on heterogeneity on nested 
data comprising:  1866 comparisons on mean severities, 1064 on mean clinical & mean 
cumulative score, 1198 on the clinical score on the last day of observation, 495 on 
inflammation, 239 on demyelination, and 113 on axon loss. On these we performed a 
total of 698 random effects meta-analyses (349 each for NMDs and SMDs, shown in 





Figure 7.1. Quorum chart of the progression from the literature search and inclusion in the 
systematic review (described in more detail in Chapter 3) to the analysis on methodological 
differences. *The Venn diagram shows the number of publications excluded from the meta-
analysis for either not being able to have an NMD calculated (red circle), not being able to have 
an SMD calculated (green circle; 89 comparisons) or neither calculated (overlap between 
circles; 452 comparisons).  Further exclusions of data are described in Chapter 3. The number of 
comparisons refers to un-nested data. Some publications still had at least one outcome suitable 






 MSS MCSS CSLD Inflm Demy ALoss 
Blinded assessment of outcome 2 2 2 2 2 2 
Random allocation to group 2 2 2 2 2 2 
Overall quality score 5 6 5 4 4 4 
Route of drug delivery 31 23 32 20 15 11 
Animal species 8 5 6 6 5 4 
Animal sex 4 4 4 4 4 4 
Time of administration (days) 7 7 7 7 7 7 
Number of animals per Group 4 4 4 4 4 4 
Time of assessment (days) 5 5 5 5 5 5 
Histological section analysed n/a n/a n/a 4 4 3 
Total number of Analyses 68 58 67 58 52 46 
Table 7.3.  The number of strata within each category shown in Table 7.2 for which we 
calculated a random effects meta-analysis effect size using both NMDs and SMDs. The total 
number of calculations equals 349. Abbreviations: MSS, mean severity scores; MCS, mean 
clinical and cumulative scores; CSLD, clinical score on the last day of observation; Inflm, 
inflammation; Demy, demyelination; and ALoss, axon loss.  
 
7.4.2. Global effect size calculations 
Global estimates of efficacy are shown with their 95% confidence intervals in Table 7.4. 
For each outcome measure the direction of effect was positive. For both methods of 
effect size calculation, axon loss had the highest magnitude of efficacy, followed by 
demyelination, the clinical score on the last day of observation, inflammation, mean 
clinical & cumulative scores, and mean severity scores. We calculated Z scores (effect 
size/standard error) to compare the precision of our estimates and found that global 


















Mean severity score 33.0 31.0-35.0 32.6 0.85 0.79-0.90 29.9 
Mean clinical & 
cumulative score 
38.8 36.0-41.5 27.3 0.99 0.92-1.07 25.1 
Clinical score on last 
day of observation 
41.5 38.6-44.3 28.8 1.05 0.98-1.13 27.1 
Inflammation 39.5 2.20-35.2 18.0 1.03 0.90-1.15 16.3 
Demyelination 43.2 37.6-37.6 15.1 1.13 0.94-1.32 11.6 
Axon loss 51.6 3.72-44.4 13.9 1.48 1.22-1.74 11.1 
Table 7.4. The random effects meta-analysis estimate of global efficacy, 95% CI and Z score for  
effect sizes calculated as NMDs and SMDs.  
 
7.4.3. Effect sizes in strata 
Across the 349 comparisons made between random effects estimates of effect sizes 
calculated for NMDs and SMDs, we observed that the majority (89%) were in 
concordance in terms of their direction of effect size (positive, negative or neutral) as 
shown in Table 7.5. Just 39 comparisons were not in concordance with their direction 
of effect.  
 
  SMD 





Positive 240 36 0 
Neutral 3 69 0 
Negative 0 0 1 
Table 7.5. The number of matching positive, negative and neutral random-effects effect sizes 
calculated as NMDs and SMDs. The shaded grey boxes are those which are concordant between 







7.4.4. Exploring sources of heterogeneity 
Across all six outcome measures a total of 55 out of a possible 57 analyses were 
significant when effect sizes were calculated as NMDs and heterogeneity was assessed 
by one or other method (Table 6, 7 and 8). All 55 of these were identified as significant 
using stratified meta-analysis and 15 of these were significant using either method. All 
analyses which were significant using meta-regression were also identified as 
significant using stratified meta-analysis. 
 
When effect sizes were calculated as SMDs, 38 of 57 analyses were significant where 
heterogeneity was assessed using one or other method. Just two analyses were 
significant using meta-regression where they were not significant using stratified meta-
analysis: blinded assessment of outcome for inflammation and the histological section 
analysed for demyelination were significant using meta-regression only.  
 
A total of 15 analyses were significant where we used meta-regression with effect sizes 
calculated using one or other method. All 15 were significant where effect sizes were 
calculated as NMDs, and 4 of these were also significant for SMD effect sizes. All of the 
significant analyses on SMD effect sizes were also significant on NMD effect sizes. 56 of 
the possible 57 analyses were significant when we used stratified meta-analysis on 
effect sizes calculated by one or other method. 55 of these were significant for NMD 
effect sizes, and 38 were significant for SMD effect sizes. Only one of the 36 analyses 
















Meta-Regression 15 (26%) 4 (7%) 15/57 
Stratified Meta-
Analysis 
55 (95%) 36 (63%) 56/57 
TOTAL* 55/57 38/57 56/57 
Table 7.6. Summary statistics for the number of study design characteristics which were 
statistically significant when effect sizes were measured as NMDs or SMDs and heterogeneity 
assessed using meta-regression or stratified meta-analysis. Percentages of the total number of 
analyses are shown in parentheses. *The total number of unique study design characteristics 
which were significant across one or other method. 
 
 
Figure 7.2. Venn diagrams of the number of significant findings identified using (A) meta-
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 Blinded Assessment of Outcome       
Random Allocation to Group       
Overall Quality Score       
Route of Drug Delivery       
Animal Species       
Animal Sex       
Time of Administration (Days)       
Number of Animals per Group       
Time of Assessment (Days)       

















 Blinded Assessment of Outcome       
Random Allocation to Group       
Overall Quality Score       
Route of Drug Delivery       
Animal Species       
Animal Sex       
Time of Administration (Days)       
Number of Animals per Group       
Time of Assessment (Days)       
Histological Section Analysed N/A N/A N/A    
Table 7.7. A heat map of the number of study design characteristics which accounted for a significant proportion of between study heterogeneity across six 
outcomes using meta-regression on normalised mean differences and standardised mean differences. Colour coded p valued: green p<0.005, orange p<0.01 
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Blinded Assessment of Outcome       
Random Allocation to Group       
Overall Quality Score       
Route of Drug Delivery       
Animal Species       
Animal Sex       
Time of Administration (Days)       
Number of Animals per Group       
Time of Assessment (Days)       



















Blinded Assessment of Outcome       
Random Allocation to Group       
Overall Quality Score       
Route of Drug Delivery       
Animal Species       
Animal Sex       
Time of Administration (Days)       
Number of Animals per Group       
Time of Assessment (Days)       
Histological Section Analysed N/A N/A N/A    
Table 7.8. A heat map of the number of study design characteristics which accounted for a significant proportion of between study heterogeneity across six 
outcomes using stratified meta-analysis on normalised mean differences and standardised mean differences. Colour coded p valued: green p<0.005, orange 
p<0.01 and red p<0.05. 
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7.4.5. Impact of group sample size 
We used hypothetical data to demonstrate the impact of the sample size on effect sizes 
when calculated as SMDs. As shown in Figure 7.3, for different raw data the computed 
effect size is only stable when there are roughly ten or more animals per group. 
Additionally the data range which effect sizes are constrained to depends on the values 
for the mean scores and variance. The greater the difference between the mean scores, 
and the smaller the variance, the broader the range of effect sizes that they are 
constrained to. 
 
Figure 7.3. The effect size for Hedges G is dependent on the number of animals when the mean 










7.4.6. Impact on publication bias 
For the purposes of this exploratory analysis we grouped neurobehavioural outcomes 
together. 
 
xxvi. Funnel plotting 
We identified a clear publication bias using funnel plotting for all four outcome 
measures where effect sizes were calculated as SMDs (Figure 7.4). Funnel plotting on 
NMD effect sizes produced less clearly defined funnel shapes, whether taking into 
account potential skew which would occur with publication bias or not. Where a scale 
is used to grade animals, with zero representing the value for sham, there is a 
reasonable likelihood that some interventions or experimental designs will result in an 
effect size of 100% when calculated as an NMD; that is, the treatment animal is scored 
as zero, and the control animal is scored as anything greater than zero. Contrastingly, 
there is no upper or lower limit for SMDs, and two sets of animals with the same scores 
can have different effect sizes as it depends on more than just the mean scores in either 
group. Thus, the funnel plots for NMD effect sizes show a clear ceiling and floor effect, 
whereby a reasonably large proportion of studies reach 100% improvement which 
skews the funnel shape.  
 
It can be seen in Figure 7.4D (NMD effect sizes, left hand panel) that the percentage 
improvement was greater than 100% for some comparisons. Lesioned animals can 
conceivably perform better than unlesioned, sham animals. For example, if the outcome 
measure is “number of axons”, there is no upper limit for this outcome measure and so 




Figure 7.4. Funnel plots of normalised mean differences (left hand panels) and standardised 
mean differences (right hand panels) plotted against precision for (A) neurobehavioural scores, 
(B) inflammation, (C) demyelination and (D) axon loss. Extracted data are shown as black 
symbols and missing studies identified with a trim and fill analysis are shown in red.  
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xxvii. Egger regression 
For both NMD and SMD effect sizes the intercept of the regression line with the origin 
was positive, indicative of a preponderance of small, positive studies (Figure 7.5).  
 
We assessed the goodness of fit of the regression line by comparing R2 values. For each 
outcome measure the R2 value was smaller for SMD data (shown in Figure 7.5), 
suggesting that the regression model was less robust on these data. In addition to this, 
when we conducted Egger regression on SMD data, we observed distinctive arcs in the 
graph. The number of animals per group has a bearing on the estimate for standard 
error of the comparison for both NMD and SMD effect sizes. However, it also has a 
bearing on the estimate of effect size for SMD, constraining it to certain values, seen as 
these distinctive arcs (see section 7.4.5). This is more easily demonstrated using a large 
dataset and thus we have plotted examples of this using real data (Figure 7.6).  
 
For these reasons we would typically use the formula shown in the methods chapter as 
our estimate of the precision (see section 2.5.2). This generates a pooled standard 






Figure 7.5. Assessment of publication bias using Egger regression of normalised mean 
differences (left hand panels) and standardised mean differences effect sizes (right hand panels) 
calculated on (A) neurobehavioural outcomes, (B) inflammation, (C) demyelination and (D) 




Figure 7.6. Data used for Egger regression when the pooled standard error is used. The data 
form arcs which depend on the number of animals per group. Symbols in red represent negative 





xxviii. Trim and fill  
For neurobehavioural and inflammation outcomes, trim and fill identified a 
substantially higher number of missing studies for SMD effect sizes (893 versus 199 
respectively for neurobehavioural scores and 149 versus 3 for inflammation). 
Contrastingly, for demyelination and axon loss, the results were comparable across 
both NMD and SMD effect sizes; and both showed the same relatively large decrease in 









































Missing studies 199 3 57 45 










Absolute difference in 
effect size (%) 
1.8 0.3 14 13.9 
Relative difference in 
effect size (%) 
5 0.80 37.4 29.4 
Relative difference in 
number of studies (%) 































Missing studies 893 149 42 52 










Absolute difference in 
effect size (SD) 
0.44 0.38 0.26 0.73 
Relative difference in 
effect size (%) 
61.1 48.1 25.1 55.5 
Relative difference in 
number of studies (%) 
19.4 17.3 13.8 27.2 
Table 7.9. Assessment of publication bias using effect sizes calculated as NMDs and SMDs 
across four outcome measures. The number of publications contributing to each analysis is 
given in the column headers. Abbreviations: N, neurobehavioural scores; I, inflammation; D, 




In this assessment of methodological differences in meta-analysis, we have used the 
dataset from the largest meta-analysis of preclinical studies. With a number of methods 
available to choose from, it is not always clear in which circumstances each should be 
used. We have attempted to model the differences between the two most common 
methods of calculating effect sizes and assessing sources of heterogeneity in the data 
from animal studies, namely SMD and NMD, and meta-regression and stratified meta-
analysis respectively.  
 
7.5.1. Effect size calculations 
We observed that there was a discrepancy between data that could have an SMD and 
NMD effect size calculated. Our pre-specified protocol was to use data which could have 
both effect sizes calculated; thus we had to exclude a substantial proportion of 
experiments because they did not report sham data or it could not be inferred. This 
provides evidence for a situation in which using SMDs is preferable – that is, upon 
inspection of the extracted data, prior to running any assessments of heterogeneity, if 
there are a number of comparisons for which sham data is required but not available, 
calculating SMDs may be a preferred option. However, it should be noted that a larger 
number of comparisons could not have SMDs calculated due to calculation errors (such 
as there being too few animals per group, or components of the equation cancelling 
each other out to result in a value of zero as a numerator). Therefore if all else is equal, 
the choice between the two effect sizes could be justified based on the proportion of 
comparisons which can be included in either analysis.  
 
7.5.2. Publication Bias 
We identified publication bias on both SMD and NMD effect sizes using all three 
methods. Trim and fill identified a greater proportion of missing studies on SMD effect 
sizes. It could therefore be considered more conservative to assess publication bias on 
NMD effect sizes as fewer missing studies are identified. However, it could equally be 
considered more conservative to use SMD effect sizes as they would generate a more 
conservative estimate of the overall global estimate of efficacy when the hypothesised 
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missing studies are taken into account. In addition it is likely that NMD effect sizes 
might be less likely to identify publication bias because the effect sizes are constrained 
by a ceiling and floor effect (typically -100% to +100%). 
 
In addition, we found that Egger regression was not as robust using SMD effect sizes. 
Furthermore, we found that if we use the standard error in our measure of precision, 
we observed clear arcs in the data which may limit the validity of this test.  
 
7.5.3. Assessing sources of heterogeneity 
Our analysis suggests that meta-regression is more conservative as we found that 
substantially more study design characteristics accounted for a significant proportion 
of heterogeneity when assessed using stratified meta-analysis. However, our approach 
was not able to determine whether stratified meta-analysis is in fact accurate, and 
whether meta-regression is overly conservative.  
 
7.5.4. Limitations and Future directions  
Our analysis has provided empirical evidence for some of the key differences between 
two common methods of calculating effect sizes and assessing sources of heterogeneity. 
However, the main limitation to our approach is that we have been unable to provide 
empirical evidence for the circumstances in which one method may be superior to 
another. To explore this in more detail we propose to conduct a bootstrapping analysis. 
Since we know the distribution of data for a particular test (e.g. blinded assessment of 
outcome where the distribution is roughly 20% yes to 80% no), we can generate 
random samples from our dataset which follow this distribution. Thus if we run 
stratified meta-analysis and meta-regression on e.g. 1000 samples of 10% of the total 
dataset we can establish whether the analyses report significant differences at the 5% 
level for these randomly constructed contrasts, or whether they are more conservative 
than this. 
 
A second limitation to our analysis is the likelihood of spurious findings. We calculated 
a total of 114 tests on heterogeneity (9 variables for all six outcome measures and an 
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additional variable, the histological section analysed, on three histological outcomes, 
calculated on both SMD and NMD effect sizes). Taking a cut-off p value of 0.05, we 
would expect to have found roughly 6 spurious results. However, the number of 
significant findings for these approaches was so large that we do not think that this is 
an important weakness.  
 
7.5.5. Conclusions 
Our analysis has demonstrated the fundamental differences which are observed when 
different methods are used to calculate an effect size for a meta-analysis and when we 
assess sources of heterogeneity on data from animal studies. We have not provided 
details on which method a researcher should use, but rather provide a transparent and 
objective comparison. Based on these observations, we have found that NMDs appear 
to give more precise estimates of global effect size. In addition we found that meta-
regression was more conservative than stratified meta-analysis, although again we 
have not assessed the sensitivity and specificity of these tests. Despite this limitation, 
researchers should bear in mind these differences when conducting meta-analyses on 




8. A systematic approach to identify putative drugs for a 
clinical trial of secondary progressive multiple sclerosis 
 
This study was conducted in collaboration with the following: Siddharthan Chandran 
(SC) Emily Sena (ES), Malcolm Macleod (MM), Kieren Egan (KE), Cadi Irvine (CI), Afiyah 
Tariq (AT), Gary Carmichael (GC) and Jeremy Chataway (JC).  
 
The drug selection committee meeting included the following: David Baker (DBa), Gina 
Cranswick (GC), Doug Brown (DBr), Graziella Filippini (GF), Gavin Giovannoni (GG), 
Andy Haines (AH), Lorraine Smith (LS), Sue Pavitt (SP), Ursula Utz (UU), Christopher 
Weir (CW).  
 
My contributions include involvement in the study design & data extraction, all of the 




Secondary progressive multiple sclerosis (SPMS) represents an unmet target of drug 
research, with no proven disease modifying treatments available (Humphries, 2012). 
Efforts to slow progression over the last 20 years have been resoundingly negative with 
immunosuppressive (eg cyclophosphamide, cyclosporine), immunomodulatory (eg 
beta-interferon) and immunotolerance (eg myelin basic protein) (Ulzheimer et al., 
2010). More effective trial designs have been developed incorporating multi-arm, 
multistage and adaptive approaches, but clearly are of no value without potentially 
effective drugs being tested. Moreover, a better understanding of the pathophysiology 
underpinning the transition from RRMS to SPMS highlights the need to identify 
potential neuroprotective agents, rather than immunomodulatory agents which are 





Recently there has been increased interest in providing safe and efficacious therapies 
which can be administered orally. Prior to the clinical approval of fingolimod (FTY720), 
all disease modifying treatments (DMTs) were administered by injection, which over a 
long period of time can lead to poor compliance (Cox and Stone, 2006, Treadaway et al., 
2009). Investigations of other potential orally active agents are underway (e.g. 
cladribine, laquinimod and teriflunomide) (Rammohan and Shoemaker, 2010, Gold, 
2011); however it remains important to continue trying to identify oral interventions 
which will halt, or at the very least slow down, the neurodegeneration in SPMS.  
 
Clinical trial design should either be based on sufficient evidence from animal studies, 
or there should be sufficient evidence of safety and predicted efficacy from other 
clinical trials. Systematic review and meta-analysis are useful for providing a 
comprehensive overview of a field of research. They have been extensively applied to 
clinical research (most notably by the Cochrane collaboration) to provide an objective 
overview of the evidence for safety and efficacy of specific interventions for specific 
diseases. They have also been applied to preclinical research (most notably by the 
Camarades collaboration) to identify limits to efficacy and provide evidence for the best 
design of clinical trials.  
 
8.2. Aims 
Our primary aim was to identify putative, orally administered interventions which 
might target SPMS, using systematic review and meta-analysis. We applied these 
techniques to the available evidence from clinical trials on four other 
neurodegenerative diseases: Alzheimers disease (AD), motor neuron disease (MND), 
Parkinson’s disease (PD) and Huntingdon’s disease (HD). We shortlisted interventions 
for further analysis of their safety, efficacy and quality if they had: been tested in one 
MS trial and at least one other disease; at least one MS trial; or not been tested in MS 
but had been tested in at least 3 other diseases. These were also checked for efficacy in 
the most common animal model of multiple sclerosis, experimental autoimmune 
encephalomyelitis (EAE). To our knowledge, this is the first time such an approach has 




8.3.1. Search strategy 
To identify all of the clinical trials in HD, PD, AD, MND and MS, we searched three online 
databases (PubMed, ISI Web of Knowledge and Embase) as well as the UK clinical trials 
database (www.clinicaltrials.gov, accessed August 2011); additionally we screened the 
MS database held by the Cochrane group to identify any further clinical trials on MS. We 
used the following search terms with results not limited by language or date: [multiple 
sclerosis OR Alzheimer’s disease OR motor neuron disease OR Parkinson’s OR 
Huntington]. We included case reports, uncontrolled case series, non-randomised 
parallel group studies, crossover studies and randomised controlled trials which 
reported efficacy or safety. References were exported to Reference Manager and three 
reviewers (CI, AT & GC) independently excluded duplicates and screened titles and 
abstracts for relevance against our pre-defined inclusion and exclusion criteria (Table 
8.1), with differences resolved by discussion with a fourth reviewer (HV).  
 
8.3.2. Hierarchy to short list interventions 
At each stage of the short listing process, data were extracted and analysed using a 
Microsoft Access Database held by CAMARADES6. Six steps, outlined below, were taken 
to identify the final short-list of candidate interventions for SPMS. 
 
i. Summary of interventions tested in clinical trials  
To summarise the number of interventions tested orally in any of the five diseases, we 
extracted basic information from each publication including: publication ID, author 










Inclusion Criteria Exclusion Criteria 
 Reporting primary data. 
 Reports of qualitative or 
quantitative data on either 
safety or efficacy for an 
intervention, treatment or 
pharmacological agent 
delivered orally in all types of 
human clinical trial design.  
 Studies reporting any change in 
clinical status (relapse 
frequency, disability 
progression, behavioural 
symptoms) or changes in 
biomarkers of clinical status 
(magnetic resonance imaging 
(MRI), blood, cerebral spinal 
fluid (CSF))  
 Publications reporting on oral 
interventions in combination 
with other oral agents   
 Reports on MS must describe 
patients with any form of 
progressive disease. 
 Publications reporting secondary 
analysis of previously published 
clinical trial data. 
 Non pharmacologic agents such as 
acupuncture, aromatherapy, 
physiotherapy, or exercise. 
 Reports on interventions already in 
clinical use for MS which are 
administered by any route including 
orally (i.e. methylprednisolone; 
interferon beta-1a; interferon beta-
1b; mitoxantrone; natalizumab; 
glatiramer acetate).  
 Reports on Fingolimod as it has 
recently been approved for oral 
administration in humans.  
 Reports on levodopa treatment for 
Parkinson’s disease. 
 Protocols for potential clinical trials.  
 Articles on relapsing-remitting MS. 
 Combination treatments where an 
oral and a non-oral intervention are 
administered. 
Table 8.1. Inclusion and exclusion criteria used to assess the relevance of each report. 
 
ii. Selection of interventions for further investigation 
We carried forward interventions for further investigation if they had either been 
tested in MS at least once, or had been tested in at least 3 of 4 other diseases. Two 
clinicians independently (SS and JC) reviewed the long-list of interventions to exclude 









Exclusion Criteria Code for Subsequent Tables 
Lack of evidence of efficacy/biological plausibility A 
Immune-suppressant B 
Steroid C 
Combination drug D 
Symptomatic relief only E 
Ongoing/ recently completed late trial F 
Better same class alternative G 
Adverse side effect profile. H 
Table 8.2. The criteria used to exclude the long list of drugs which met the inclusion criteria 
shown in Table 1 and had either been tested in MS at least once, or had been tested in at least 3 
of 4 other diseases.  
 
iii. Evidence for efficacy, safety and study quality 
One author (MM) assessed all of the reports on the short-listed candidate interventions 
identified in the previous step against pre-defined criteria. Each report was graded on a 
scale of one (worst) to four (best) for their reported evidence on each of: quality (Table 
8.3), efficacy and safety (Table 8.4). The four point scales for safety and efficacy was 
defined using criteria agreed upon by three clinicians (MM, SC and JC). Study quality 
was assessed against a combination of criteria defined by GRADE (Verhagen et al, 
1998), CAMARADES (Macleod et al, 2004) and through a Delphi process (Atkins et al, 
2004), to give a potential maximum score of 21 points from which a final quality score 
of 1 to 4 was allocated based on median and interquartile ranges. We additionally 
categorised the size of each study on a 1-4 scale (Table 8.4), and this was used in the 
calculation for the overall score assigned to each drug. In addition, we extracted the 
following information: clinical trial type (e.g. RCT, un-controlled, cross-over etc), 
clinical trial phase, mean age of the patients, sex of the patients, dose, duration of 






iv. Evidence of efficacy from preclinical studies 
We screened the short-listed interventions against our updated database, funded by the 
MS-Society, containing systematically identified reports of drugs tested in EAE, the 
most common animal model of MS. Where available, we generated summary estimates 
of efficacy for each intervention, measured as a standardised mean difference change in 
neurobehavioural scores, axon loss, demyelination and inflammation which were 
pooled using random effects meta-analysis. Additionally we assessed the publications 
against our 6 point quality checklist (Vesterinen et al., 2010), comprising of: (1) 
publication in a peer reviewed journal; and reporting of: (2) random allocation to 
group; (3) blinded assessment of outcomes; (4) a sample size calculation; (5) 
compliance with animal welfare regulations; and (6) a statement of any potential 
conflicts of interest.  
 
v. Summary estimates  
We generated summaries for each intervention including: clinical trial type, type of 
disease, median efficacy, safety and quality scores, the number of patients, study 
duration, dose, and overall score for the publication. Additionally we tabulated the 
number of publications awarded each of grades 1-4 for efficacy versus safety, efficacy 
versus quality and safety versus quality.  
 
The overall score for each publication was calculated as the product of the scores for 
efficacy, quality, safety and study size and of the log of the number of publications 





Tick boxes: Yes (1 point); No (0 points) 
 Peer Review Publication1  
 Statement of Potential Conflicts of Interest1  
 Sample Size Calculation1 
 Random Allocation to Group1,3 
 Allocation Concealment1,2,3 
 Blinded Assessment on Outcome1,2 
 Outcome Assessor Blinded3 
 Patient Blinded3 
 Care provider Blinded3 
 
Options: Yes (1 point); No (0 points); Not Clear (0.5 points)   
 Were the groups similar at baseline regarding the most important prognostic 
indicators?3 
 Were the eligibility criteria specified?3 
 Were point estimates and measures of variability presented for the primary outcome 
measures?3   
 Was there an intention to treat analysis?3 
 Complete accounting of patient and outcome events?2 
 Non-selective Outcome Reporting3 
 No other limitations3 
 
Options: N/A; Definitely Yes (Low risk of bias; 1 point); Probably Yes (0.75 points); Probably 
No (0.25 points); Definitely No (High Risk of Bias; 0 points) 
 Was selection of treatment and control groups drawn from the same population?2 
 Can we be confident that patients received the allocation treatment?2 
 Can we be confident that the outcome of interest was not present at start of the study?2 
 Did the study stratify on variables associated with the outcome of interest or did the 
analysis take this into account?2 
 Can we be confident in the assessment of the presence or absence of prognostic factors?2 
 Can we be confident in the assessment of outcome?2  
 Was the follow up of cohorts adequate?2  
 Were co-interventions similar between groups?2 
Table 8.3. The criteria adapted from the CAMARADES quality checklist1, GRADE2 and Delphi3 to 






Not Described (1 point) 
SUSARs (suspected unexpected serious adverse reaction) or mortality (1 point) 
SAE’s (Severe adverse events) only(2 points) 
AE’s only (3 points) 
No adverse effects reported (4 points) 
EFFICACY 
Not presented (1 point) 
Definite worsening (1 point) 
Neutral (2 points) 
Non-significant improvement (3 points) 
Significant improvement (4 points) 
PATIENT SAMPLE SIZE 
1-10 patients (1 point) 
11-100 patients (2 points) 
101-1000 patients (3 points) 
1001+ patients (4 points) 
Table 8.4. The criteria used to assess safety, efficacy and patient sample size.  
 
vi. Candidate drug selection committee  
The final short-list of candidate oral interventions was discussed in a face-to-face 
meeting with a panel of experts including: 5 neurologists, 1 MS patient representative, 1 
member of the MS-Society research committee, 1 expert on the animal models of MS and 
3 scientists that conducted part of the research and analysis. Interventions were 
scrutinised in detail with an emphasis on safety, efficacy, biological plausibility, 
pharmacological criteria such as CNS penetration as well as mechanistic class of action. 
Animal data were also considered where the clinical data were supportive. 
 
After each of three rounds of reviewing, a number of candidate interventions were 
excluded from further consideration based on a lack of evidence for any of safety, 




8.4.1. Search Results 
Our initial electronic search of Pubmed identified 10,969 publications of which 956 met 
out inclusion criteria (Figure 8.1). Subsequent searches of other online databases and 
the Cochrane database of clinical trials of MS identified a further 419 publications 
meeting our inclusion criteria. In total this analysis is based on 1375 publications which 
reported an orally administered drug in a clinical trial of MS, AD, PD, HD or MND.  
 
Of these 1375 publications, 13 interventions from 93 publications were tested in one MS 
clinical trial and at least one other disease; 21 interventions from 336 publications were 
tested in two or more MS clinical trials; 76 interventions from 144 publications were 
tested in one MS clinical trial; and 10 interventions from 102 publications were not 
tested in any MS clinical trials but were tested in at least three other diseases. The 
remaining 700 publications were not carried forward for further analysis.  
 
8.4.2. Selection of interventions for further analysis  
Our criteria above gave a long-list of 120 candidate interventions from 675 publications. 
All 120 interventions were screened against the exclusion criteria in Table 8.2. 68 
interventions from 247 publications fell into one or more of the exclusion categories 
(Table 8.5), leaving 52 interventions from 428 publications in the short-list which we 










Figure 8.1. A quorum chart of the progression from the literature search to the final selection of seven candidate interventions. Round 1 and 2 refer to the 
two discussion sessions held with a panel of experts. 
175 
 
Drug Exclusion Criteria Code 
MK-677 A 
15+- Dexoxyspergualin B 
4 Ammonium Phosphate A 
Adrenocorticotropic Hormone C 
Adrenocorticotropic Hormone 1-17 C 
Amantidine/Isoprinosine D 
Anastal No meaningful data 
Antithymocyte Globulin B 
Arachidonic Acid A 
Azathioprine B 





Cannabis extract F 




Cranberry Juice A 
Cyclophosphamide B 
Cyclophosphamide/predisone B 
Cyclosporin A B 
D1 A 
Dantrolene Sodium E 
Delta-9-tetrahydrocannabinol F 
Desmopressin A 
Di Huang Cong Ji A 
Donepezil H 




Fatty Acids G 
Fumarate (BG00012) F 
































Tripterygium Wilpordii A 
Vigabatrin H 
Vitamin D/Calcium/Magnesium D 
Table 8.5. The category each intervention fell into for exclusion. See Table 8.2 for codes.  
 
8.4.3. Summarising the evidence 
Across the 52 candidate interventions, the median overall drug score was 13.6 
(interquartile range (IQR) 8.9-27.3). Dextromethorphan/quinidine had the highest 
overall score with 56.2, followed by amantadine (55.2) and memantine (51.6). 
Conversely, the lowest scoring drugs were cyproheptadine (0.9), diazepam (1.8) and 
atromid (2.4; Table 8.6).   
 
vii. Quality 
The median quality score was 2.3 (IQR 2 to 3). Three interventions were given the 
highest score (4) for quality: ibudilast, dextromethorphan/ quinidine and L-
amphetamine sulphate. All three received relatively high overall drug scores: 
dextromethorphan received the highest score of all 52 interventions, ibudilast and L-
amphetamine sulfate were both reported in one publication each but had an overall 
score of 25.3 and 32.5 respectively, reflecting relatively high grades across each 





The median efficacy score was 2.6 (IQR 2.1-3). Three interventions received the highest 
efficacy grade (4): misoprostal, oxcarbazepine and moclobemide. However these all 
received overall drug scores in the lowest quartile because they were reported in just 
one publication each. The drugs assigned the lowest scores for efficacy were rolipram 
(1.5), omega 3 fatty acid (1.8) and pentoxifylline (1.8).    
 
ix. Safety 
The median safety grade was 2.3 (IQR 2-3). Vitamin D/calcium, carbamazepine and 
myelin were the only interventions to receive grades of 4. Each drug was reported in 
one publication but vitamin D/calcium had a relatively high overall score reflecting high 
scores across each assessment criteria (3 for efficacy, 4 for quality and 2 for the patient 
sample size). Carbamazepine and myelin scored 3.6 and 12 overall.  
 
x. Patient Sample Size 
The median grade for the patient sample size was 2 (IQR 1.9-2.3). No clinical trial 
included in our analysis used more than 1000 patients and so the highest grade 
achieved by any intervention was 3 which was assigned to L-amphetamine sulphate, 
dextromethorphan/quinidine, ibudiblast and MaxEPA oil. Interventions tested in the 
smallest clinical trials in terms of patient sample sizes included cyprheptadine, isoniazid 
and rolipram, moclobemide and carbamazepine which all used between one and ten 
patients, thus scoring 1 point each. 
 
8.4.4. Evidence from EAE studies 
We identified pre-clinical literature on 34 of the 52 candidate interventions tested in 
EAE. The majority of the literature was on myelin basic protein (126 publications), 
followed by vitamin D (17), minocycline (12) and rolipram (10). The median quality 
score, measured against our 6 point quality checklist was 1 (IQR 1 to 2). Reporting of 
random allocation to group and blinded assessment of outcome was generally low but 
for many interventions it was difficult to make inferences on study quality as they were 


















3,4-Diaminopyridine 3 2.3 2.3 2.7 1.3 11.4 
4-Aminopyridine 10 2.7 2.5 3.0 2.1 44.4 
Amantadine 57 3.1 2.4 2.2 1.9 55.2 
Aspirin 2 2.0 1.5 3.0 2.5 10.7 
Atomoxetine 3 2.7 3.3 3.0 1.7 26.8 
Atromid 1 2.0 1.0 2.0 2.0 2.4 
Bromocriptine 4 1.9 2.5 1.8 1.5 8.6 
Carbamazepine 1 3.0 4.0 1.0 1.0 3.6 
Coenzyme Q10 9 2.2 1.9 3.2 2.3 30.6 
Creatine 12 2.1 2.3 2.7 2.4 35.9 
Cyproheptadine 1 3.0 1.0 1.0 1.0 0.9 
dextromethorphan 7 2.5 2.7 2.3 1.9 26.2 
Dextromethorphan/ 
Quinidine 
3 3.3 2.3 4.0 3.0 56.2 
Diazepam 1 3.0 1.0 1.0 2.0 1.8 
Fluoxetine 5 2.4 2.2 2.6 1.6 17.1 
Gabapentin 8 2.7 2.5 2.9 2.5 46.7 
Ginseng 1 3.3 3.0 2.0 2.0 12.0 
Glucosamine Sulfate 1 2.5 3.0 4.0 2.0 18.1 
Hydroxyzine/Caffeine 1 3.0 3.0 1.0 2.0 5.4 
Ibudilast 1 3.5 2.0 4.0 3.0 25.3 
Imipramine 2 2.0 2.0 3.0 2.0 11.5 
Isoniazid 4 2.8 2.5 2.3 1.0 10.8 
L-amphetamine sulfate 1 3.0 3.0 4.0 3.0 32.5 
Levamisole 2 3.2 2.0 3.0 2.0 18.1 
Levetiracetam 3 3.7 2.0 1.7 2.0 14.7 
Linoleic Acid 4 2.5 1.0 2.3 2.5 9.8 
Linomide 3 3.0 1.3 2.7 2.3 15.0 
lipoic acid 2 2.0 2.0 2.0 2.0 7.6 
Lithium 11 2.0 1.4 2.4 1.5 10.2 
MaxEPA Oil 1 3.0 1.0 3.0 3.0 8.1 
Melatonin 7 2.1 2.6 2.1 2.0 21.2 
Memantine 34 2.7 2.0 2.6 2.4 51.6 
Milacemide 4 2.0 2.3 2.5 2.0 15.7 
Minocycline 11 2.3 2.6 2.3 2.2 31.9 
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Misoprostol 1 4.0 3.0 1.0 2.0 7.2 
Moclobemide 1 4.0 3.0 1.0 1.0 3.6 
Modafinil 8 2.9 2.4 3.1 2.1 44.4 
Myelin 1 2.5 4.0 2.0 2.0 12.0 
Naltrexone 8 2.2 2.6 2.1 1.8 20.6 
Omega 3 Fatty Acid 2 1.8 3.0 2.0 2.0 10.0 
Oxcarbazepine 1 4.0 2.0 1.0 2.0 4.8 
Pemoline 2 2.0 2.0 2.5 2.0 9.5 
Pentoxifylline 2 1.8 1.0 2.5 2.5 5.5 
Pirfenidone 3 3.1 3.0 2.3 2.0 25.8 
Riluzole 16 2.4 1.8 2.4 2.0 24.6 
Rolipram 2 1.5 3.0 1.5 1.0 3.2 
Selegiline 11 2.7 1.9 2.7 2.3 34.2 
Tolbutamide 1 3.0 3.0 2.0 2.0 10.8 




1 2.5 3.0 2.0 2.0 9.0 
Vitamin D/Calcium 1 3.0 4.0 4.0 2.0 28.9 
Vitamin E 9 2.1 2.0 3.0 2.4 31.1 
Median (IQR) 3 (1-7) 3 (2-3) 2 (2-3) 2 (2-3) 2 (2-2) 14 (9-27) 
Table 8.6. The summary statistics on safety, efficacy and quality for 52 candidate interventions. 
















Axon Loss Demyelination Inflammation 
4-Aminopyridine 1 1.0 0 0 n/a n/a n/a n/a 
Amiloride 2 1.5 0 1 
1.3 (0.9 to 1.7; n=4; 
123 animals) 
0.2 (-4.5 to 4.8; n=2; 
22 animals) 
-1.4 (-2.7 to -0.1; 
n=1;12 animals) 
n/a 
Amphetamine 1 1.0 0 1 
-0.6 (-1.5 to 0.3; 
n=2;30 animals) 
n/a n/a 
13.5 (-6 to32.9; 
n=4; 30 animals) 
Aspirin 3 1.7 2 0 n/a n/a n/a n/a 
Atomoxetine 1 1.0 0 1 
0.8 (-0.4 to 2.0; 
n=1; 12 animals) 
n/a n/a n/a 
Bromocriptine 2 1.0 0 1 
0.9 (0.4 to 1.4; n=3; 
70 animals) 
n/a n/a n/a 
Caffeic Acid 
Phenethyl Ester 
1 2.0 0 0 
-1.5 (-2.4 to -0.5; 
n=1; 24 animals) 
n/a n/a n/a 
Calcium 2 1.5 0 0 n/a n/a n/a n/a 
Calcium + Vitamin 
D 
1 1.0 0 0 n/a n/a n/a n/a 
Carbamazepine 1 2.0 0 0 
1.2 (-1.7 to 4.1; 
n=2; 24 animals) 
n/a n/a n/a 
Cyproheptadine 3 1.3 1 1 
6.5 (1.7 to 11.4; 
n=4; 32 animals) 
n/a n/a n/a 
Dextromethorphan 1 1.0 0 1 
0.1 (-0.2 to 0.5; 
n=4; 133 animals) 
n/a n/a n/a 




Ginseng 1 2.0 0 0 
4.7 (3.1 to 6.2; n=1; 
28 animals) 
n/a n/a n/a 
Glucosamine 1 2.0 0 1 n/a n/a 
0.7 (-0.3 to 1.8; 
n=3; 20 animals) 
0.6 (-0.4 to 1.7; 
n=3; 20 animals) 
Imipramine 
Hydrochloride 
2 1.0 0 0 n/a n/a n/a n/a 
Levamisole 3 1.3 2 1 





Linoleic Acid 4 0.0 0 2 
0.1 (-0.4 to 0.7; 
n=10; 88 animals) 
n/a n/a n/a 






Linomide 5 0.8 0 2 
1.5 (-0.3 to 3.2; 
n=8; 192 animals) 
n/a n/a 
1.8 (1-2.5; n=4;51 
animals) 
Lipoic Acid 6 1.7 2 2 





1 (-0.7-2.6; n=3;53 
animals) 
Lithium 3 1.7 0 0 
1.7 (0.5 to 2.9; n=4; 
80 animals) 
n/a n/a n/a 
MBP 126 1.1 8 38 







Melatonin 1 1.0 0 0 
1.1 (0.1 to 2.2; n=1; 
17 animals) 
n/a n/a n/a 
Memantine 2 2.0 0 1 
2.7 (1.6 to 3.7; 






Minocycline 12 1.6 3 6 
0.9 (0.6 to 1.3; 
n=23; 311 animals) 






Myelin 9 1.4 2 1 
0.7 (-0.5 to 1.9; 




1 (0.4-1.5; n=6;68 
animals) 
Pentoxifylline 6 1.3 2 1 
0.2 (-0.3 to 0.7; 
n=13; 170 animals) 
n/a n/a 
4 (2-6.1; n=1;14 
animals) 
Propentofylline 1 1.0 0 1 n/a n/a n/a n/a 
Riluzole 2 1.0 0 1 
3.5 (2.3 to 4.8; n=7; 
119 animals) 





Rivastigmine 1 2.0 0 0 
1.4 (0.8 to 2.1; n=2; 
56 animals) 






Rolipram 10 1.2 1 5 
0.8 (0.3 to 1.4; 
n=22; 528 animals) 





Vitamin D 17 1.6 5 4 
0.9 (0.5 to 1.4; 




Vitamin E 1 1.0 0 0 n/a n/a n/a n/a 
Table 8.7. Summary data for 34 of the 52 candidate interventions which had been tested in EAE including: the number of publications which randomly 
allocated to group and/or blinded their assessment of outcome; and summary estimates for effect size, presented as: (random effects estimate of efficacy 




8.4.5. Drug Selection Meeting 
Detailed discussions of each of the 52 drugs were first undertaken based on individual 
drug summaries using the core selection / exclusion criteria (Table 8.2) with particular 
emphasis on safety and efficacy. This led to 20 drugs being excluded (Table 8.8). The 
remaining drugs then underwent further scrutiny including examination of source 
publications by the whole group as well as NIH clinical trials site and animal data 
where relevant. Again using the core criteria 25 further drugs were excluded (Table 
8.8).  
 
After the two rounds of discussion the candidate interventions for a clinical trial were 
narrowed down to a final list of seven (Table 8.9) which had been selected based on 
sufficient evidence of efficacy, safety and quality and an appraisal of the preclinical 
data. The final list included: oxycarbamazepine, amiloride, fluoxetine, pirfenidone, 
PUFA class (poly unsaturated fatty acids which include linoleic Acid, lipoic acid; 
















































Clofibrate (trade name Atromid) H 














Tolbutamide A and H 




























Carbamazepine G and H 
Coenzyme Q10 A 
Creatine E and H 
Cyproheptamine A and E 
Dextromethorphan/ quinidine E 
Gabapentin G 
Glucosamine sulfate A 
Hydroxyzine/caffeine A 
L-amphetamine sulfate H 
Levetiracetam A 







Tranycypromine A and H 
Vinpocetin/Propentofylline/ Theofylline G 
Vitamin D/ Calcium A 
Table 8.8. Interventions excluded after round 1 and 2 of discussion with a panel of experts. For 




Intervention Class of action 
Amiloride Acid sensing ion channel 1 blocker, potassium 
sparing diuretic 
Fluoxetine SSRI, antidepressant 
Ibudilast PDE(4)I 
Oxycarbamazepine Voltage sensitive sodium channel blocker, 
anticonvulsant 
Pirfenidone Antagonises synthesis of TGF-beta & TNF-alpha; 
antifibrotic/anti-inflammatory 
PUFA class (Linoleic Acid, Lipoic 
acid; MaxEPA, Omega3) 
Complex group of dietary supplement 
Riluzole Glutamate release inhibitor/inactivation of voltage-
dependent sodium channels 




In this chapter I have described the process of using systematic review and meta-
analysis to select and critically appraise publications on clinical trials, leading to a final 
shortlist of seven candidate interventions which may be suitable for a clinical trial of 
SPMS.  
 
8.5.1. Systematic approach to drug selection for clinical trials 
Systematic review and meta-analysis have been used extensively in the life sciences 
and beyond. They have established themselves as important tools for assessing the 
efficacy of interventions in preclinical and clinical trials, as well as predicting limits to 
efficacy such as the influence of study design characteristics and the internal & external 
validity of included studies. Moreover, in Chapter 6 I described a novel use of these 
tools in establishing the relationships between outcome measures, and the pathway to 
improvement in one outcome via mediation of other disease mechanisms. In this study 





The necessary applications to proceed to clinical trial are traditionally put forward by 
research groups or pharmaceutical companies who have evidence of efficacy from 
animal studies on the drug of interest. Furthermore, the choice of drug selection in 
preclinical trials is based simply on the research directions of that group, or via large 
scale pharmacologic screening based on, for example, knowledge of specific receptors 
or targets of interest for a particular disease. Our approach is both unique for two 
reasons. Firstly, our approach includes potential useful clinical trials which may have 
been lost in the midst of, for example, inadequate funding to continue research. 
Secondly, using data from clinical trials which have already taken place, and by having 
adequate evidence of safety as one our criteria for inclusion in the final shortlist, we are 
potentially able to bypass much, or all of the preclinical testing phases. Typically it 
takes more than five years to reach FDA approval from animal testing and so our 
approach is useful to be able to reduce this time gap.   
 
8.5.2. Short-listed interventions 
From our initial literature search of over 15,000 publications, our selection process 
narrowed down 1375 potentially relevant publications to seven interventions which 
met all of the critical criteria. Initially we generated a long-list of interventions; these 
were drugs which had been tested either in MS at least once, or in two or more other 
diseases. Because our aim was to identify a drug which could be taken forward to a 
large scale clinical trial, we only carried forward interventions which had at least been 
tested in MS as these are more likely to meet the necessarily approval from regulatory 
boards, and thus potentially minimise the time to clinical approval. However, the drugs 
which did not meet these selection criteria are listed as they present a useful range of 
interventions which may warrant further investigation, either in adequately designed 
preclinical trials, or smaller phase one clinical trials.  
 
8.5.3. Limitations 
As described in previous chapters, there are a number of limitations of systematic 
review and meta-analysis in general. Importantly, these are methods hypothesis 
generating only and are not deemed as a substitute for a high quality, adequately 




approach is potentially useful for designing such a trial. Secondly, to our knowledge we 
included all the available evidence, and moreover we tried to increase the sensitivity 
and specificity of our search strategy by including broad search terms and by multiple 
researchers going through the same reference lists. However, as publication bias is 
prevalent in clinical research (Dwan et al., 2008, Hopewell et al., 2009), it is possible 
that our analysis did not include all of the negative or non-significant studies. We 
attempted to minimise this bias in two ways. Firstly, we included the reference library 
from the Cochrane collaboration which has all of the clinical trials they have identified, 
including hand searched research which is not in the public domain. Secondly, our 
discussions with the panel of experts included knowledge of any potentially missing 
studies, or of any research groups which may have conducted research on the short-
listed interventions.   
 
8.5.4. Conclusions 
We have identified and described a novel method to identify putative drugs for clinical 
trial which may be useful for the development of further clinical trials. Furthermore, 
our approach narrowed down the focus of investigation to seven drugs with adequate 
evidence of safety and efficacy from high quality clinical trials which may be useful for a 











At the start of this thesis I summarised some of the issues surrounding translational 
failures in the life sciences. My focus was on MS for which there are major treatment 
gaps. The primary objective of this thesis was to describe the application of systematic 
review and meta-analysis to the preclinical literature on EAE to summarise the scope of 
the literature and to try and identify potential reasons for the failure to translate 
reliably the efficacy from bench to beside.  Other objectives were: to compare the 
findings in the EAE literature to the literature on another neurological disease with 
limited translational success (PD); explore the relationship between different measures 
of drug efficacy in EAE; to explore the differences between the methods I used; and to 
describe my experience of using systematic review and meta-analysis to identify 
putative interventions for SPMS. The following sections summarise the main questions 
I have tried to address, the conclusions I have drawn, the limitations to my approach, 
and some potential avenues for future research.   
 
9.1. Why have interventions for MS failed to translate from  EAE to 
the clinic? 
9.1.1. What was known prior to this research? 
 
“An animal model is defined as an animal that has a disease or 
injury similar to the human condition. Ideally, it should have a 
similar aetiology and function to the human equivalent, and it is 
necessary that as many aspects of the disease are replicated as 
possible to avoid confounding and misleading results, which in turn 
may hinder the development of new therapeutic approaches” (Lane 
and Dunnett, 2008) 
 
MS is a complex and heterogeneous disease. More than a century after its formal 
recognition by Charcot, there are still a number of fundamental unknowns; for example 
we do not know with any certainty what causes MS and how the pathophysiological 
processes interact to cause neurological impairment. Owing to this it has been argued 




autoimmunity, it does not adequately recapitulate the complexities and true nature of 
MS. Therefore it could be argued that EAE may be violating the conditions described by 
Lane and Dunnett in the above quote. In fact there is large community that believe that 
MS is not an autoimmune disease at all, and that inflammatory processes are secondary 
to neurodegeneration (Stys et al., 2012). The biological underpinnings of MS and EAE, 
and their differences, are beyond the scope of this thesis; however, while the findings I 
summarise below make little inferences to the role that biological factors play, it is 
important to keep in mind that these are clearly important. 
 
9.1.2. The importance of adequate study quality 
There has been extensive literature published on the inadequacies of clinical trials, 
from their methodological design and implementation to their reporting (described in 
Chapter 5). In more recent years there has been increased momentum in exploring 
whether these inadequacies exist in the preclinical literature as it is clear that animal 
studies may bear some of the clues to translational failures. Systematic review and 
meta-analysis of preclinical studies of stroke, glioma, Alzheimer’s disease, intracerebral 
haemorrhage (ICH) (Frantzias et al., 2011, Sena et al., 2007a, Egan et al. under review, 
Hirst et al. under review) and more broadly (Kilkenny et al., 2009) have generally 
found study quality to be poor. Importantly, I have found the same trend across 1464 
publications on EAE, 253 publications on experimental PD studies, and 95 publications 
on animal experiments in the 2008 volume of JCBFM. 
 
Two aspects of study quality were of particular concern. Firstly, measures to reduce 
bias were rarely reported in the preclinical literature on EAE, PD and in the 2008 
volume of the JCBFM. For the preclinical EAE studies, where outcome was measured as 
the reduction in inflammation, I found that efficacy was substantially overstated in 
studies which did not report blinding their assessment of outcome. This finding was 
also found in the preclinical PD studies where improvement was measured as change in 
neurobehavioural outcomes. We have also previously shown that for the publications 
which report the most commonly tested interventions in EAE, lack of reporting of both 
randomisation and blinded assessment of outcome led to substantial overstatements of 
efficacy measured as improvement in neurobehavioural outcomes (Vesterinen et al., 





The importance of randomisation of animals prior to experimentation is perhaps not as 
obvious as the importance of blinding the assessment of outcome, particularly when 
the animals are genetically inbred, commercially sourced, and group-allocation is done 
prior to disease induction. However, because animals respond differently to their 
environment it may be more difficult to “catch” a more active animal in a cage – 
perhaps an indication of the animal’s health and stress levels at the start of the trial. 
Thus active and docile animals may end up being treated in a manner that is not 
entirely random. 
 
Secondly, across all of the publications reviewed in this thesis (1464 on EAE, 253 on 
PD, and 312 from the JCBFM) just 7 reported a sample size calculation. Although it 
provides little comfort, this trend is the same across the preclinical literature as a 
whole (Kilkenny et al, 2009, Baginskaite unpublished findings). It is not clear why so 
few publications report sample size calculations, however it is clear that there are a 
number of incentives to keep the numbers low: ethics, cost and time.  
 
Calculating the required sample size is not a trivial matter, and this may go some way to 
explain why they are so rarely conducted. A sample size calculation is conducted to 
estimate the probability that if there is a true treatment effect of a given size, the 
statistical test will detect it. Calculating the minimum required sample size involves 
careful consideration of a number of factors, as well as their predicted values. These 
include: the type 1 error (alpha; the predicted rate of picking up a false-positive effect 
which is usually pre-set at 0.05), the power (1-beta; the predicted rate of avoiding 
picking up a false-negative effect, which is often set at 80%), the smallest effect of 
interest (the minimum difference between the treatment and control group which 
would be of biological/clinical relevance), and the variability (usually expressed as the 
standard deviation of the treatment effect) (for more details see: Noordzij et al., 2010). 
Nowadays several tools are available to aid in these calculations including online 
resources (Lenth, 2007, Lenth, 2006-9) and publications describing calculation 
methods and the practical issues that may arise (for example see: Chapman and Seidel, 





We have used post-hoc power calculations to give a rough estimate of the power to 
detect differences between the treatment and control group for the preclinical EAE and 
PD literature. Although post-hoc power calculations comes with their limitations 
(Hoenig and Heisey, 2001), our estimates suggest that the median study is powered at 
64% for EAE studies and 40% for PD studies. However if we also take into account the 
probability that a substantial proportion of experiments on which we based these 
calculations reported inflated estimates of efficacy (because they did not randomise or 
blind their assessment of outcome), then it is likely that for high quality studies which 
have taken these measures, our power calculations underestimate the number of 
animals required.  
 
9.1.3.  The importance of adequate reporting 
Experiments should be replicable and robustly designed to minimise the risk of false 
findings which may be exceptionally common (Ioannidis, 2005). Being able to replicate 
and assess the robustness of an experiment relies on adequate reporting. We identified 
a number of areas for concern. In particular in the EAE literature a large proportion of 
studies across the dataset did not report the number of animals, the variance, or the 
type of variance reported. These are all crucial for assessing the robustness of a study, 
and we urge caution in interpreting data from studies which do not report these. 
Kilkenny et al, (2009) have found a similar trend across a range of preclinical literature, 
with 4% of 271 publications not reporting the number of animals in either the methods 
or the results section.  
 
The ARRIVE guidelines (Kilkenny et al., 2010) aim to pave the way for improvements in 
the conduct and reporting of preclinical experiments in the same way that the 
CONSORT statement has improved these in clinical trials (Plint et al., 2006). This thesis 
has provided a foundation for such guidelines to exist in the field of preclinical research 
as I have provided empirical evidence from the largest systematic review of preclinical 
experiments to show that the issues addressed in these guidelines are likely to be 





To further reduce the impact of bias, it has been proposed that multi-centre animal 
studies be set up (Bath et al., 2009). There are a number of advantages to this approach. 
First and foremost, scientific research should be collaborative as this sparks new ideas 
and may improve study design. Lastly, adequate sample sizes may be difficult to 
achieve due to limited resources. In our group, we found that we would need over 300 
animals per group (using a sample size calculation) to conduct a specific preclinical 
stroke experiment. With limited resources and funding the project progressed no 
further. However, taking a multi-centred approach, the number of animals required 
could be shared between centres, reducing the resources required by each research 
group. 
 
9.1.4. The impact of publication bias 
We identified a substantial publication bias in the EAE literature using three 
approaches including a quantitative analysis to predict the number of missing studies 
and their impact on the global estimate of efficacy.  In addition, two out of the three 
approaches identified publication bias in the preclinical PD literature.  
 
Where studies are small and give imprecise estimates of treatment effects, some will 
overstate efficacy and some will understate efficacy. This provides the background for 
publication bias, such that there is a bias towards publication of the small, imprecise, 
positive studies rather than the small, imprecise, neutral studies. Two important 
considerations are raised from these observations. Firstly, it is ethically questionable to 
use animals for research which will never reach the public domain. Even if these 
studies are underpowered, it does not mean that they are not valuable to others 
conducting a trial on the same intervention. For example, case studies and pilot studies 
are both important contributors. It is important however that such a limitation is 
mentioned in a publication so results can be interpreted in this context. Secondly, 
publication bias can lead to the overstatement of efficacy in meta-analyses. An 
advantage of meta-analysis is that they include all available evidence and where the 
sample size is small, less weight will be given in the overall estimate of efficacy. 
Crucially, even larger negative studies are less likely to be published, and so a drug may 




Publication bias was described by Rosenthal in 1979, and has since been formally 
identified in both clinical (Easterbrook et al., 1991, Hopewell et al., 2009, Dwan et al., 
2008) and animal experiments (Sena et al., 2010). The identification of this in clinical 
research came first, and has since led to registries of clinical trials. These registries 
allow investigators to know whether a drug has been tested and where the study has 
been conducted. However, there is no such registry of animal experiments, and 
therefore personal communication and/or publication are the only methods of finding 
out whether a study has been conducted. The solution to this problem is not 
immediately apparent. Ideally, all animal experiments would be pre-registered on a 
central database; however this raises the issue of intellectual property. A solution to 
this problem may be to register core information such as the class of drug under 
investigation. 
 
With no immediate solution to hand, our approach is to continue to raise awareness of 
the issue of publication bias by providing empirical evidence for its existence and 
impact. Our hope is that this will encourage more researchers to be transparent in their 
approach, and for prestigious journals to encourage preregistration of animal studies in 
the same way that this has occurred in clinical research.   
 
9.2. How else can systematic review and meta-analysis be used to 
improve translational efficacy? 
In this thesis I have described two novel uses of systematic review and meta-analysis. 
In Chapter 6 I described how they can be used to assess the relationship between 
different outcome measures in the preclinical literature; and in Chapter 8 I described 
how these were used to identify putative candidate drugs for a clinical trial of SPMS.  
Conclusions from these are described in turn below. 
 
9.2.1. Identifying drug targets 
We found that the majority of publications on EAE report neurobehavioural outcomes, 
most commonly as a mean severity score, a mean clinical score, a mean cumulative 




histological outcomes which are considered to be key drug targets, namely 
demyelination and/or axon loss. We found that neurobehavioural scores were not 
always strong correlates of changes in histological outcomes, and moreover that 
histological outcomes were not always strong correlates of each other. This implies that 
these may represent different underlying pathological processes. Interestingly 
however, we also found that the relationship between the improvement in axon loss 
and neurobehavioural scores increased with later times of administration. This 
provides empirical evidence to support the idea that axon loss is a key drug target to 
successfully alter disability when more clinically relevant times of administration are 
used. We conclude that drugs targeting axon loss when administered at a clinically 
relevant time point may offer substantial hope for successful translation to the clinic.  
 
9.2.2. Evidence based clinical trial design 
In our interest to explore further the potential uses of systematic review and meta-
analysis we applied these to clinical literature to identify putative interventions for a 
clinical trial of SPMS. The methods were designed using all of our experience in 
conducting systematic reviews of animal studies and the key aspect to this was the 
collaborative approach. Whilst all of the data extraction and analyses were conducted 
in Edinburgh, the feedback on the protocol and the final drug selection committee was 
multi-national. This included a member of the MS Cochrane group which provided 
useful feedback from the perspective of an expert in the field of systematic review and 
meta-analysis of clinical research. By identifying all of the relevant clinical trials on a 
number of other neurodegenerative diseases as well as MS, and assessing their 
evidence for safety, efficacy and quality, we have been able to identify seven 
interventions which have sufficient high-quality evidence to warrant further 
investigation and potentially be taken forward to a clinical trial.  
 
9.3. Which are the most suitable methods for the systematic review 
and meta-analysis of preclinical studies? 
To provide a more solid foundation to the choices of methods used in this research, we 
explored the differences between NMD and SMD effect sizes, and stratified meta-




have preferentially chosen NMDs over SMDs as the unit of NMDs are intuitive 
(percentage change). In addition, when meta-regression became more accessible to use 
in statistical software and it was shown to be robust, this was our preferred choice as it 
is a more conservative approach than stratified meta-analysis. Our exploratory 
analyses on these methods demonstrated the similarities and differences using real 
data. The advantage of this is that hypothetical data do not necessarily take into 
account the impact of outliers and unusual situations, for example when a control 
group performs better than a sham group. We found that in general NMD effect sizes 
were more precise, and Egger regression was more robust on these effect sizes. We also 
found that meta-regression was substantially more conservative, and particularly on 
SMD effect sizes.  
 
A limitation to this analysis is that it was descriptive and therefore no firm conclusions 
could be drawn. However in Chapter 7 I proposed a series of steps which could be 
taken to formally and empirically assess our hypotheses.  
 
9.4. Limitations 
There are a number of limitations to our approach which are described below.  
 
9.4.1. Systematic review 
As mentioned in Chapter 1, systematic reviews should be transparent, replicable and 
efforts should be taken to avoid bias. Transparency refers to reporting of clear 
methodology and this has been made more straightforward in recent years by the 
publication of the PRISMA checklist and flow-chart (Moher et al., 2009). These 
publications came out after the initiation of the research in this thesis, and thus the 
flow diagram is not easily applied to the systematic reviews of EAE studies in this thesis 
as it is based on multiple searches. Owing to the large number of hits in the literature 
search it was also not possible to give a reason for exclusion of articles which is a 
PRISMA-checklist item. Indeed, while we have made efforts to ensure the reporting of 
our methodology was clear, the replicability may be affected by not reporting clear 





We attempted to minimise selection bias by using multiple electronic databases for our 
initial literature search which was screened by at least two independent reviewers for 
all but the updated literature search on EAE studies. However, although our initial 
search strategy for EAE studies (on Pubmed in 2007) was broad, it was not deep and 
thus we may have initially missed relevant publications. Our updated literature search 
was broader, but while we made every attempt to identify all relevant studies it is 
nonetheless possible that relevant studies were not identified. However, while there 
may be some missing studies, these are likely to affect only our estimates of efficacy 
where we have reported these for individual drugs. However, where a systematic 
review and meta-analysis of an individual drug or drug group is conducted, the 
literature search should be more focused and include an attempt to identify 
unpublished research.  
 
9.4.2. Meta-analysis 
Meta-analyses are post-hoc, observational studies and therefore only hypothesis 
generating. While we have made a number of interesting observations relating to the 
EAE and PD literature, such as the differences between routes of delivery, they should 
be used merely to inform the design of future studies. Furthermore, discussion about 
study quality and its potential impact on reporting effect sizes is only intended to be 
thought provoking, and to raise further awareness that these issues are relevant to 
animal studies.   
 
Our estimates of efficacy, both globally and for individual strata should be interpreted 
with caution for several reasons. Firstly, it is possible that our observations that 
efficacy is higher under certain study design conditions may in fact be statistical 
artefact or due to collinearity with other study design variables, or both. Secondly a 
meta-analysis can involve conducting large numbers of exploratory analyses of 
heterogeneity. In this thesis we avoided large numbers of analyses as it raises the 
likelihood of a type 1 error. We pre-specified our analyses based on biological 
relevance and scientific interest. In addition we used Bonferroni correction to adjust 




from our estimates of efficacy for individual interventions relies on the assumption that 
the outcome measure is clinically relevant, or that it is a suitable surrogate marker for a 
relevant outcome. Indeed, it may be that neurobehavioural outcomes are not relevant 
measures of drug efficacy. Our approach is to be transparent and to simply summarise 
the available data. Thus we have summarised the four outcome measures most 
commonly reported without any prior assumptions about their clinical relevance.  
 
9.4.3. Lumping oranges and giraffes7 
Another criticism of meta-analyses is the lumping together of studies which are 
fundamentally different. Main concerns relate to the grouping of: different models 
which behave differently in terms of clinical and/or pathological manifestations; 
different interventions which may have different physiological targets; and studies with 
different aims, such as those which target the prevention of disease versus those which 
target established disease.  
 
All of the results we have presented from meta-analyses of preclinical studies should be 
interpreted with these concerns in mind. However, in order to group only similar 
studies together, we would need to make prior assumptions. In our experience this is 
too difficult to perform adequately. For example, assigning each individual intervention 
to a drug group would perhaps be useful, but arguably most drugs could fall into more 
than one category, and developing a systematic and robust approach to drug 
classification is difficult. Additionally, whilst we could for example separate individual 
EAE or PD models into the method used to induce them, perhaps along with the specific 
species used, there could essentially be no limit to this disaggregation. It is our belief 
that one advantage of meta-analysis is that these prior assumptions are not made.  
 
Nonetheless, particular animal models or interventions may be targeted towards 
specific aspects of the clinical disease, and grouping these different studies together 
will inevitably mask these crucial nuances. We propose that whilst this is a criticism of 
the current work, it may be useful to conduct systematic reviews and meta-analyses on 
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individual drugs. This would allow for a far more in depth analysis on the effect of these 
study design characteristics. Furthermore, we propose that such analyses would be 
most valuable for interventions which have been or are in clinical use (either licensed 
or in clinical trials) as we can gain insights into which experiments have translated 
most successfully to the clinic.  
 
9.5. Future Directions 
This thesis has provided a firm foundation for assessing the improvements which may 
come about as a result of relevant reporting guidelines. In our experience, some journal 
editors are extremely accommodating and actively encourage the critical appraisal of 
their journals so that they can set foundations for improvement. Indeed the review of 
JCBFM in Chapter 4 was conducted at the request of the editor with the aim of 
repeating this analysis at a later time to establish whether the improvements have 
occurred as a result of publication guidelines adopted by the journal. We propose that 
such an analysis may be a useful contribution to the journals which publish EAE 
studies. An approach to this may be to assess a proportion of the journals which 
publish the greatest volume of EAE literature against the ARRIVE guidelines and the 
more specific guidelines proposed for EAE research (Baker and Amor, 2012). Such an 
analysis would provide a useful baseline for the  changes which might occur and 
further reveal the current state of reporting which may have already improved since 
more journals have adopted the ARRIVE guidelines.  
 
Another potentially interesting avenue for further research is in the revealing 
characteristics about the choice of language in reviews. For example, in discussing how 
EAE has been used for the successful translation of efficacy of natalizumab, it has been 
noted that “it substantially reduced EAE when administered before and even during 
clinical disease” (Wekerle, 2008); and it was “thereby effective in preventing EAE” (Mix 
et al., 2010).  Minor distinctions in the choice of language are either accidental or may 
reflect the opinion of the author. In the case of the first quote above, it is perhaps 
implied that it is unexpected, or perhaps a bonus that the intervention was efficacious  
at a later time of administration. The second quote makes the same point, and in this 
case the author makes no reference to the drugs’ success at a later time of 




the translational success. Thus it may be useful to systematically assess the reviews on, 
for example, a particular drug in a disease model to assess which evidence authors 
provide for the reasons for translational success or failure. The data in this thesis have 
provided a framework for critically analysing original preclinical research; however, 
the research I have proposed would provide another aspect of critically appraising 
review articles with a view to encouraging readers not to take published literature at 
face value. 
 
Our assessment of quality was based on a broad checklist of items which made it 
possible to assess a large number of publications as none of our items were open to 
subjective interpretation (they were either reported or not). Newer reporting 
guidelines (e.g. ARRIVE) advocate the assessment of, for example, the suitability of the 
title or the use of adequate statistics. Since these are now recognised as the gold 
standard quality assessment items it would be beneficial to further assess these against 
the preclinical EAE literature. As a criticism to our approach here, it could be argued 
that it is unreasonable to assess publications from earlier epochs against the guidelines 
of the current scientific era; however, it is interesting to note that randomisation, 
blinding and compliance with animal welfare regulations were each reported in at least 
one of 32 included publications from the 1960’s (the earliest decade of research 
included in our analysis). Not unexpectedly, neither a sample size calculation nor a 
statement of a potential conflict of interest were reported in this decade.  
 
9.6. Recommendations for future EAE studies 
All of the analyses described in the prior chapters have demonstrated the usefulness of 
a large repository of data from animal studies for which this is just one of many in this 
field. Beyond the limitations of the these studies, we believe that there is now sufficient 
evidence, from both here and elsewhere, to recommend that studies testing the efficacy 
of candidate drugs in animal models of MS should take (and report) measures to 
improve their internal validity, such as randomisation and the blinded assessment of 
outcome; that sample size calculations should be performed and reported; and that the 
preclinical testing should focus on testing efficacy under clinically relevant conditions 
including the initiation of treatment at some time after the induction of injury, using 




Although high-quality, pragmatically designed studies do exist, and their researchers 
should be commended as such, evidence from this thesis show that they are too few 
and far between and thus they may be difficult to identify.   
 
9.7. Conclusion 
An on-going debate in MS research is whether EAE is useful for predicting therapeutic 
success in the clinic. The translational success rate has not been promising and this has 
led some to believe that EAE is not relevant at a pathophysiological level. As a 
consequence of the secondary analyses I have conducted and described on data from 
EAE studies, it is my opinion that the translational limitations are at least in part due to 
study design rather than biological underpinnings. EAE is a model of 
neuroinflammation and autoimmunity and it is considered that these two processes 
occur in MS to some extent. For realistic expectations of how interventions will perform 
in humans we would firstly need to try to align the pathophysiological process being 
targeted in EAE with the corresponding pathophysiology of the human disease. 
Secondly interventions should be tested at times which reflect what we achieve in the 
clinic. Thirdly, efforts should be made to use EAE models to their potential by, at the 
very least, taking measures to reduce bias and reporting the experiment with sufficient 
detail to assess their internal and external validity. Finally I would reason that there 
will be far more weight to the debate on EAE’s utility when we have evidence from high 
quality, pragmatically designed experiments using a model of EAE which reflects an 
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Jadavji,N 2009 +    +  2 
Jenkins,O 1985 +      1 
Jenner,P 1986       0 
Jenner,P 1992 +      1 
Jeon,M 2007 +    +  2 
Jiang,H 1993       0 
Jiang,H 1993 +      1 
Jin,F 2008 +    +  2 
Johnson,B 1994       0 
Johnson,B 1995 + +     2 
Johnston,L 2001       0 
Johnston,L 2008 +  +  +  3 
Johnston,M 2001       0 
Johnston,M 2003       0 
Kaariainen,T 2008 +    +  2 
Kalda,A 2009 + +   +  3 
Kashihara,K 1996 + +     2 




Name & Initial 2 Year (1) (2) (3) (4) (5) (6) Quality Score 
Kaur,S 1994 +      1 
Kenny,A 1986 +      1 
Koller,W 1980 +  +    2 
Koller,W 1986 +      1 
Koller,W 1987 +      1 
Kreisler,A 2008      + 1 
Kuno,S 1996       0 
Kuno,S 1997 +      1 
Kuno,S 1998 +      1 
LaHoste,G 1990 +      1 
Laloux,C 2008 +    +  2 
Larramendy,C 2008 + +   +  3 
Lee,J 2001 +      1 
Levesque,D 1999   +    1 
Lindgren,H 2007 +    +  2 
Liu,W 2007 +    +  2 
Lorenc-Koci,E 1999 +    +  2 
Loschmann,P 1992 + +     2 
Loschmann,P 1997 + +     2 
Luan,L 2008 +    +  2 
Luquin,M 1993 +    +  2 
Maneuf,Y 1997       0 
Maneuf,Y 1997 +      1 
Maratos,E 1998 +      1 
Marin,C 2009 +    +  2 
Marin,R 2008 +    +  2 
Maurin,B 2001       0 
May,C 1994 +      1 
McCall,R 2005 +    +  2 
McElroy,J 1995 +      1 
McLaughlin,W 1992       0 
Meloni,E 2000 +      1 
Menon,M 1976 +      1 
Mera,T 2009 +    +  2 
Metz,G 2000       0 
Michaelides,M 1997 +      1 
Mierau,J 1992 +      1 
Mignon,L 2007 +    +  2 
Mihara,K 2008 +  +  +  3 
Milioli,E 2007 +      1 
Millan,M 2004 +  +  +  3 
Ming,M 2009 +     + 2 
Miyagi,M 1996 +      1 
Mohanasundari,M 2006 +    +  2 




Name & Initial 2 Year (1) (2) (3) (4) (5) (6) Quality Score 
Nakagawa,M 2004 +      1 
Neisewander,J 1991 + +     2 
Nomoto,M 1987 +      1 
Nomoto,M 1988 + +     2 
Nomoto,M 1993 +      1 
Nomoto,M 1998 +  +  +  3 
Nomoto,M 1998 +      1 
Norton,D 1992       0 
Nowak,P 2008       0 
Obeso,J 2001       0 
Olsson,M 1995 +      1 
paterna,J 2007 +      1 
Pearce,R 1999 +    +  2 
Piercey,M 1992       0 
Pollack,A 1997 +    +  2 
Pollack,A 2001 +    +  2 
Popoli,P 2000 +  +  +  3 
Prat,G 2000 +    +  2 
Prikhojan,A 2000 +      1 
Ravensoft,P 2001       0 
Reavill,C 2000 +    +  2 
Robertson,H 1992 +      1 
Rose,S 2007 +  +  +  3 
Rouillard,C 1990 +      1 
Rupniak,N 1989 +      1 
Rupniak,N 1990 +      1 
Samadi,P 2008 +    +  2 
Samadi,P 2008 +    +  2 
Scheller,D 2007 + + +  +  4 
Schmidt,W 2008 + +   +  3 
Schneider,A 1994 +      1 
Schneider,J 1994 +      1 
Senthilkumar,K 2007 +    +  2 
Serpa,K 1997       0 
Shiosaki,K 1996 +      1 
Shropshire,A 1995       0 
Silverdale,M 2002   +    1 
Silverdale,M 2003   +  +  2 
Silverdale,M 2004 +  +  +  3 
Silverstrin,R 2009 +    +  2 
Simola,N 2008 +    +  2 
Sit,S 2002 +      1 
Smith,L 1992       0 
Smith,L 1992       0 




Name & Initial 2 Year (1) (2) (3) (4) (5) (6) Quality Score 
Smith,L 2000 +    +  2 
Smith,L 2002 + +   +  3 
Smith,L 2002 +    +  2 
Smith,L 2006 +  +  +  3 
Spooren,W 1999 + +     2 
Starr,M 1994 +      1 
Starr,M 1994 +      1 
Stephenson,D 2005 + + +  +  4 
Stockwell,K 2008 +  +  +  3 
Stockwell,K 2009 +  +  +  3 
Sun,J 2006 +    +  2 
Tanaka,K 2006       0 
Temlett,J 1989 +      1 
Toriumi,H 2009 +    +  2 
Treseder,S 1998  + +    2 
TurleLorenzo,N 2006 +   + +  3 
Van Kampen,J 2006 +    +  2 
Vermeulen,R 1993 + + +    3 
Vermeulen,R 1994 + + +    3 
Vermeulen,R 1994 + + +    3 
Voith,K 1984 +      1 
Wachtel,H 1992 +      1 
Waddington,J 1979 +      1 
Wakamatsu,M 2008 +  +  +  3 
Wang,J 2004 + +     2 
Wang,J 2007 +    +  2 
Warraich,S 2009 + + +  +  4 
Wei,P 2007 +      1 
woiciechowsky,C 1995 +      1 
Wu,T 1997       0 
Xinglian,T 1997 + +     2 
Xu,L 2008 + +   +  3 
Yarkov,A 2003 +    +  2 
Yoon,E 2007 + +   +  3 
Yuan,C 2008 +    +  2 
Yuan,H 2004 +    +  2 
Zhang,H 2007 + +   +  3 
Zhao,X 2009 +     + 2 





Appendix 5. Summary of dopamine agonists tested in animal models of Parkinson’s disease 
Highlighted interventions are those in clinical use. 
1See appendix 3 for references. 

















(-)3PPP 1 1990 1 n/a n/a n/a n/a 
(+)3PPP 1 1990 1 n/a n/a n/a n/a 
(+)Dinapsoline 1 2002 0 n/a n/a n/a n/a 
(+-)Dinapsoline 1 2002 0 n/a n/a n/a n/a 
(+)-PHNO 11 1986 0.4 38 1.23 0.88 1.59 
18Dinapsoline 1 2002 0 n/a n/a n/a n/a 
5-OH-DPAT 1 1997 0 n/a n/a n/a n/a 
7-OH-DPAT 2 1995 0.5 5 1.26 0.71 1.82 
A68930 1 1997 1 5 0.54 0.16 0.92 
A77636 5 1992 0.6 16 1.5 0.95 2.05 
A86929 5 1996 0.4 10 1.55 0.76 2.34 
ABT-431 2 1996 0 8 0.9 -0.14 1.95 
Alpha-DHEC 1 1995 1 n/a n/a n/a n/a 
Amantadine 1 2008 1 4 -1.35 -2.49 -0.21 
Aplindore 1 2006 1 6 1.86 1.18 2.54 
Apomorphine 123 1975 0.6 89 1.54 1.19 1.9 
AY27110 2 1984 0 8 -0.37 -1.36 0.62 
BAM-1110 1 1998 0 3 6.57 0.75 12.4 
BP897 1 2004 1 n/a n/a n/a n/a 
Bromocriptine 32 1982 0.4 58 0.96 0.73 1.19 
C1-APB 2 1997 0 1 1.49 0.58 2.41 
Cabergoline 11 1994 0.6 13 0.73 -0.24 1.7 
CY208-243 3 1989 0 4 1.29 0.43 2.15 
D145 1 1975 0 n/a n/a n/a n/a 




















Dinapsoline 1 2001 1 9 2.37 1.34 3.41 
Dopamine 4 1988 0.5 3 1.3 -0.23 2.82 
DPPP 1 1986 0 1 0.32 -0.67 1.31 
DU127090 1 2003 0 n/a n/a n/a n/a 
Hexahydrothieno[c]benzo[f]quinoline[f]quinolines 1 1997 0 n/a n/a n/a n/a 
Lergotrile 1 1982 0 n/a n/a n/a n/a 
Lisuride 8 1984 0.1 10 1.5 0.98 2.03 
LY-171555 10 1988 0.7 19 0.48 -0.05 1.01 
N-0498 1 1986 0 n/a n/a n/a n/a 
N-0499 1 1986 0 n/a n/a n/a n/a 
N-0500 1 1986 0 n/a n/a n/a n/a 
N-0923 2 1992 0.5 n/a n/a n/a n/a 
N-0924 1 1994 1 n/a n/a n/a n/a 
N-Ethylnorapomorphine 1 1976 0 n/a n/a n/a n/a 
N-Methylcyclopropylnorapomorphine 1 1976 0 n/a n/a n/a n/a 
NNDipropylA56DTN 1 1990 1 n/a n/a n/a n/a 
N-n-Proplynorapomorphine 1 1976 0 n/a n/a n/a n/a 
Norapomorphine 1 1976 0 n/a n/a n/a n/a 
PD128,907 1 1997 1 n/a n/a n/a n/a 
Pergolide 13 1980 0.5 14 1.01 0.26 1.76 
Piribedil 8 1992 0.8 26 1.07 0.48 1.66 
Pramipexole 7 1992 0.6 14 1.31 0.67 1.96 
Quinelorane 2 2000 1 5 1.22 -0.43 2.86 
Quinpirole 33 1990 0.6 30 1.25 0.8 1.7 
Ropinirole 16 1991 0.7 23 1.85 1.39 2.32 
Rotigotine 4 2007 1.5 10 1.8 1.1 2.51 
RU24213 2 1994 0 6 0.82 0.17 1.48 
RU29717 1 1986 0 n/a n/a n/a n/a 
S31411 1 2004 1 3 0.99 -0.13 2.11 
S32504 4 2001 0.5 23 1 0.33 1.67 
S32601 1 2004 1 2 0.13 -0.95 1.21 
S33084 2 2002 0.5 1 0.72 -0.13 1.57 




















SFK 83959 5 1995 1.2 2 1.3 -0.32 2.93 
SKF 104557 1 2000 1 2 0.1 -2.73 2.93 
SKF 38393 32 1985 0.6 27 0.3 -0.26 0.86 
SKF 75670 1 1995 2 n/a n/a n/a n/a 
SKF 80723 2 1995 1.5 1 3.04 1.42 4.67 
SKF 81297 9 1993 1 17 0.55 0.2 0.9 
SKF 82958 12 1993 0.5 7 1.79 0.87 2.71 
SKF 89124 1 2000 1 4 0.68 -2.54 3.9 
SKF 96990 1 2000 1 3 -0.02 -1.81 1.77 
SKF 97930 1 2000 1 2 0.09 -2.33 2.51 
SLV308 3 2001 0 5 1.14 0.04 2.25 
SLV318 1 2003 0 n/a n/a n/a n/a 
Sumanirole 2 2005 1.5 8 1.7 0.15 3.25 
Talipexole 7 1993 0.4 28 0.86 0.51 1.21 
Terguride 4 1988 0.5 7 0.8 0.22 1.37 
U91356A 2 1992 0 n/a n/a n/a n/a 
 
 
 
 
